{
  "document": "2026 AHA/ASA Guideline for the Early Management of Patients With Acute Ischemic Stroke",
  "source": "Stroke. 2026;57:e00-e00. DOI: 10.1161/STR.0000000000000513",
  "total_trials_found": 199,
  "total_metrics_extracted": 264,
  "recommendation_trial_maps": [
    {
      "recommendation_number": 1,
      "cor": "1",
      "loe": "B-R",
      "summary": "Hospitals treating patients with acute stroke should engage in a multicomponent QI process that involves the continuous monitoring, review, and feedback of stroke quality indicators, benchmarks, and evidence-based practices, in order to increase quality of care, improve patient outcomes, and reduce health care disparities.",
      "reference_numbers": [
        1,
        2,
        3,
        4,
        5,
        6,
        7,
        8
      ],
      "section_number": "2.10"
    },
    {
      "recommendation_number": 2,
      "cor": "1",
      "loe": "B-NR",
      "summary": "Hospitals treating patients with acute stroke should participate in stroke data registries to increase the adherence to quality indicators and guideline recommendations and improve patient outcomes.",
      "reference_numbers": [
        1,
        3,
        7,
        9,
        10,
        11,
        12,
        13,
        14,
        15,
        16,
        17
      ],
      "section_number": "2.10"
    },
    {
      "recommendation_number": 3,
      "cor": "1",
      "loe": "B-NR",
      "summary": "Hospitals treating patients with acute stroke should measure and document baseline stroke severity (eg, NIHSS score) in all acute stroke patients so that risk adjustment models used to compare hospital performance can be sufficiently accurate and reliable.",
      "reference_numbers": [
        18,
        19,
        20,
        21,
        22,
        23,
        24,
        25,
        26,
        27,
        28,
        29
      ],
      "section_number": "2.10"
    },
    {
      "recommendation_number": 1,
      "cor": "1",
      "loe": "B-R",
      "summary": "Educational programs on stroke recognition for all ages to improve stroke preparedness",
      "reference_numbers": [
        1,
        2,
        3,
        4,
        5,
        6,
        7,
        8,
        9,
        10
      ],
      "section_number": "2.1"
    },
    {
      "recommendation_number": 2,
      "cor": "1",
      "loe": "B-NR",
      "summary": "Educational programs should reach diverse communities to reduce knowledge gaps",
      "reference_numbers": [
        1,
        2,
        3,
        4,
        9,
        10,
        11,
        12
      ],
      "section_number": "2.1"
    },
    {
      "recommendation_number": 3,
      "cor": "1",
      "loe": "B-NR",
      "summary": "Educational programs should be sustained over time to improve long-term knowledge",
      "reference_numbers": [
        4,
        7,
        11
      ],
      "section_number": "2.1"
    },
    {
      "recommendation_number": 4,
      "cor": "1",
      "loe": "B-NR",
      "summary": "Targeted stroke education for EMS, physicians, and health care personnel to reduce prehospital delays",
      "reference_numbers": [
        13,
        14,
        15,
        16
      ],
      "section_number": "2.1"
    },
    {
      "recommendation_number": 1,
      "cor": "1",
      "loe": "B-NR",
      "summary": "Establish regional systems of stroke care for access to time-sensitive therapies and rapid transport to EVT centers",
      "reference_numbers": [
        1
      ],
      "section_number": "2.2"
    },
    {
      "recommendation_number": 2,
      "cor": "1",
      "loe": "B-NR",
      "summary": "Develop prehospital triage protocols for rapid stroke identification and transport to appropriate centers",
      "reference_numbers": [
        2,
        3,
        4,
        5,
        6,
        7,
        8,
        9,
        10,
        11,
        12,
        13
      ],
      "section_number": "2.2"
    },
    {
      "recommendation_number": 3,
      "cor": "2a",
      "loe": "B-NR",
      "summary": "Monitoring and feedback on prehospital care quality metrics can reduce delays and increase discharge to home",
      "reference_numbers": [
        14,
        15,
        16
      ],
      "section_number": "2.2"
    },
    {
      "recommendation_number": 1,
      "cor": "2a",
      "loe": "B-NR",
      "summary": "EMS dispatch use of a telephone stroke assessment tool is reasonable for early identification of stroke.",
      "reference_numbers": [
        1,
        2
      ],
      "section_number": "2.3"
    },
    {
      "recommendation_number": 2,
      "cor": "1",
      "loe": "A",
      "summary": "Use of a brief stroke assessment tool by prehospital personnel is recommended to improve early stroke identification.",
      "reference_numbers": [
        3,
        4
      ],
      "section_number": "2.3"
    },
    {
      "recommendation_number": 3,
      "cor": "1",
      "loe": "B-NR",
      "summary": "Prehospital personnel should provide advance notification to the receiving hospital of an inbound suspected stroke.",
      "reference_numbers": [
        5,
        6
      ],
      "section_number": "2.3"
    },
    {
      "recommendation_number": 4,
      "cor": "3: No Benefit",
      "loe": "B-R",
      "summary": "Ambulance-initiated remote ischemic conditioning (RIC) with arm BP cuff inflation is not recommended.",
      "reference_numbers": [
        7
      ],
      "section_number": "2.3"
    },
    {
      "recommendation_number": 5,
      "cor": "3: Harm",
      "loe": "A",
      "summary": "Prehospital initiation of stroke treatment with transdermal glyceryl trinitrate (GTN) is potentially harmful.",
      "reference_numbers": [
        8,
        9,
        10,
        11
      ],
      "section_number": "2.3"
    },
    {
      "recommendation_number": 6,
      "cor": "3: No Benefit",
      "loe": "B-R",
      "summary": "Intensive BP control in the field to a target of 130 to 140 mm Hg systolic does not improve functional outcome.",
      "reference_numbers": [
        12
      ],
      "section_number": "2.3"
    },
    {
      "recommendation_number": 7,
      "cor": "2b",
      "loe": "B-NR",
      "summary": "Usefulness of common adult stroke screening tools in pediatric patients is uncertain; newer pediatric tools' value remains to be determined.",
      "reference_numbers": [
        13,
        14,
        15,
        16
      ],
      "section_number": "2.3"
    },
    {
      "recommendation_number": 1,
      "cor": "1",
      "loe": "B-NR",
      "summary": "EMS should prioritize transport to the closest appropriate facility to reduce time to treatment.",
      "reference_numbers": [
        1,
        2,
        3,
        4,
        5
      ],
      "section_number": "2.4"
    },
    {
      "recommendation_number": 2,
      "cor": "2a",
      "loe": "B-NR",
      "summary": "Direct transport to a TSC can be beneficial for suspected LVO stroke to increase EVT rates and reduce time to treatment.",
      "reference_numbers": [
        6,
        7,
        8
      ],
      "section_number": "2.4"
    },
    {
      "recommendation_number": 3,
      "cor": "2b",
      "loe": "B-NR",
      "summary": "In areas without well-coordinated SSOC and local hospital(s) proficient in thrombolysis delivery and transfer, direct transport of suspected LVO patients to the closest appropriate TSC may be reasonable.",
      "reference_numbers": [
        9
      ],
      "section_number": "2.4"
    },
    {
      "recommendation_number": 4,
      "cor": "3: No Benefit",
      "loe": "B-R",
      "summary": "In areas with well-coordinated SSOC and local hospital(s) proficient in thrombolysis delivery and transfer, direct transport to a distant TSC (eg, 45–60 min) does not improve 3-month clinical outcomes.",
      "reference_numbers": [
        10,
        11,
        12,
        13,
        14
      ],
      "section_number": "2.4"
    },
    {
      "recommendation_number": 5,
      "cor": "1",
      "loe": "B-NR",
      "summary": "Hospitals and EMS should establish agreements and protocols to prioritize interhospital transfer to reduce DIDO times.",
      "reference_numbers": [
        15
      ],
      "section_number": "2.4"
    },
    {
      "recommendation_number": 1,
      "cor": "1",
      "loe": "A",
      "summary": "MSUs recommended for thrombolytic-eligible patients to ensure fastest onset-to-treatment time and improve outcomes",
      "reference_numbers": [
        1,
        2,
        3,
        4,
        5,
        6,
        7
      ],
      "section_number": "2.5"
    },
    {
      "recommendation_number": 2,
      "cor": "1",
      "loe": "A",
      "summary": "MSUs must be equipped to diagnose and treat with IVT",
      "reference_numbers": [
        1,
        2,
        3,
        4,
        5,
        6,
        7
      ],
      "section_number": "2.5"
    },
    {
      "recommendation_number": 3,
      "cor": "1",
      "loe": "B-R",
      "summary": "MSU care with streamlined protocols and neurological expertise is beneficial for emergent evaluation and treatment",
      "reference_numbers": [
        2,
        3,
        4,
        8,
        9,
        10
      ],
      "section_number": "2.5"
    },
    {
      "recommendation_number": 4,
      "cor": "2a",
      "loe": "B-NR",
      "summary": "MSUs can be beneficial for triage of thrombectomy-eligible patients to appropriate facility with prehospital notification",
      "reference_numbers": [
        2,
        3,
        4,
        11,
        12,
        13,
        14,
        15
      ],
      "section_number": "2.5"
    },
    {
      "recommendation_number": 1,
      "cor": "1",
      "loe": "B-NR",
      "summary": "Certification as a stroke specialty hospital by an external credentialing agency is recommended",
      "reference_numbers": [
        1,
        2,
        3,
        4,
        5,
        6,
        7
      ],
      "section_number": "2.6"
    },
    {
      "recommendation_number": 1,
      "cor": "1",
      "loe": "B-NR",
      "summary": "Organized protocol for emergent evaluation of acute neurological deficits in all ages",
      "reference_numbers": [
        1,
        2,
        3,
        4,
        5
      ],
      "section_number": "2.7"
    },
    {
      "recommendation_number": 2,
      "cor": "1",
      "loe": "C-EO",
      "summary": "Suspect acute stroke in pediatric patients with sudden onset and ongoing focal neurological deficits, including first-time seizure",
      "reference_numbers": [],
      "section_number": "2.7"
    },
    {
      "recommendation_number": 3,
      "cor": "1",
      "loe": "B-NR",
      "summary": "Designation of acute stroke team for suspected stroke patients",
      "reference_numbers": [
        3,
        6,
        7
      ],
      "section_number": "2.7"
    },
    {
      "recommendation_number": 4,
      "cor": "1",
      "loe": "A",
      "summary": "Development and education of multidisciplinary stroke teams to increase IVT treatment rates",
      "reference_numbers": [
        8,
        9,
        10,
        11
      ],
      "section_number": "2.7"
    },
    {
      "recommendation_number": 5,
      "cor": "1",
      "loe": "A",
      "summary": "Stroke teams for thrombolytic-eligible and EVT-eligible patients to ensure fastest onset-to-treatment time",
      "reference_numbers": [
        12,
        13,
        14,
        15,
        16,
        17,
        18,
        19
      ],
      "section_number": "2.7"
    },
    {
      "recommendation_number": 1,
      "cor": "1",
      "loe": "B-R",
      "summary": "Prehospital telemedicine for suspected stroke in ambulance to complement paramedic assessment for reperfusion candidate identification",
      "reference_numbers": [
        1,
        2,
        3,
        4
      ],
      "section_number": "2.8"
    },
    {
      "recommendation_number": 2,
      "cor": "1",
      "loe": "B-NR",
      "summary": "Teleradiology for AIS patients in EDs without in-house imaging expertise for timely brain imaging review and IVT decision-making",
      "reference_numbers": [
        5,
        6,
        7
      ],
      "section_number": "2.8"
    },
    {
      "recommendation_number": 3,
      "cor": "1",
      "loe": "B-R",
      "summary": "Telestroke for IVT decision-making and administration in AIS patients in EDs without acute neurological expertise",
      "reference_numbers": [
        8,
        9,
        10,
        11,
        12,
        13,
        14,
        15,
        16,
        17,
        18,
        19,
        20
      ],
      "section_number": "2.8"
    },
    {
      "recommendation_number": 4,
      "cor": "2a",
      "loe": "B-NR",
      "summary": "Telestroke to reduce short-term mortality in AIS patients at hospitals without local stroke expertise",
      "reference_numbers": [
        11,
        16,
        20,
        21,
        22
      ],
      "section_number": "2.8"
    },
    {
      "recommendation_number": 5,
      "cor": "2a",
      "loe": "C-LD",
      "summary": "Telephone consultation with stroke specialist for IVT decision-making and EVT eligibility in AIS patients without in-house stroke expertise or telestroke",
      "reference_numbers": [
        8,
        9,
        10,
        23
      ],
      "section_number": "2.8"
    },
    {
      "recommendation_number": 6,
      "cor": "1",
      "loe": "C-EO",
      "summary": "Support for telemedicine/telestroke resources to ensure 24/7 coverage for AIS patients",
      "reference_numbers": [],
      "section_number": "2.8"
    },
    {
      "recommendation_number": 7,
      "cor": "2b",
      "loe": "B-NR",
      "summary": "Telestroke for triage and interfacility transfer for emergency EVT versus local care in AIS patients at hospitals with telestroke capability",
      "reference_numbers": [
        12,
        14,
        15,
        22,
        24,
        25,
        26,
        27
      ],
      "section_number": "2.8"
    },
    {
      "recommendation_number": 1,
      "cor": "1",
      "loe": "C-EO",
      "summary": "Hospitals should participate in an accountable SSOC that consists of an integrated network of certified hospitals and prehospital EMS systems for optimal acute stroke care.",
      "reference_numbers": [],
      "section_number": "2.9"
    },
    {
      "recommendation_number": 2,
      "cor": "1",
      "loe": "C-EO",
      "summary": "Hospitals without 24/7 thrombectomy should develop interhospital transfer protocols for EVT-eligible patients.",
      "reference_numbers": [],
      "section_number": "2.9"
    },
    {
      "recommendation_number": 3,
      "cor": "1",
      "loe": "B-NR",
      "summary": "PSC hospitals without 24/7 thrombectomy should rapidly perform and interpret vascular imaging to identify LVO eligible for EVT.",
      "reference_numbers": [
        1,
        2,
        3,
        4,
        5,
        6
      ],
      "section_number": "2.9"
    },
    {
      "recommendation_number": 4,
      "cor": "1",
      "loe": "B-NR",
      "summary": "Hospitals should adopt care protocols reflecting current clinical guidelines from professional organizations or agencies.",
      "reference_numbers": [
        7,
        8,
        9,
        10
      ],
      "section_number": "2.9"
    },
    {
      "recommendation_number": 5,
      "cor": "1",
      "loe": "B-R",
      "summary": "Hospitals providing EVT should track key time metrics, care processes, and long-term outcomes.",
      "reference_numbers": [
        1,
        11,
        12,
        13
      ],
      "section_number": "2.9"
    },
    {
      "recommendation_number": 6,
      "cor": "1",
      "loe": "C-EO",
      "summary": "Hospitals providing EVT should credential neurointerventionalists using established standards.",
      "reference_numbers": [],
      "section_number": "2.9"
    },
    {
      "recommendation_number": 7,
      "cor": "2a",
      "loe": "B-NR",
      "summary": "ASRH relying on transfers can consider rapid vascular imaging to identify LVO eligible for EVT.",
      "reference_numbers": [
        3,
        4,
        5,
        6
      ],
      "section_number": "2.9"
    },
    {
      "recommendation_number": 8,
      "cor": "2b",
      "loe": "B-NR",
      "summary": "SSOC may consider developing mobile intervention teams for timely EVT delivery.",
      "reference_numbers": [
        14,
        15,
        16
      ],
      "section_number": "2.9"
    },
    {
      "recommendation_number": 1,
      "cor": "1",
      "loe": "B-NR",
      "summary": "Use of a stroke severity rating scale, preferably NIHSS, is recommended for measuring clinical deficits at baseline and after reperfusion therapies.",
      "reference_numbers": [
        1,
        2
      ],
      "section_number": "3.1"
    },
    {
      "recommendation_number": 2,
      "cor": "1",
      "loe": "B-NR",
      "summary": "Protocols for emergent brain imaging within 25 minutes to facilitate reperfusion interventions",
      "reference_numbers": [
        1,
        2
      ],
      "section_number": "3.2"
    },
    {
      "recommendation_number": 3,
      "cor": "1",
      "loe": "B-NR",
      "summary": "Emergent vascular imaging with CTA/CTP should not be delayed for serum creatinine in LVO",
      "reference_numbers": [
        3,
        4
      ],
      "section_number": "3.2"
    },
    {
      "recommendation_number": 4,
      "cor": "2a",
      "loe": "C-LD",
      "summary": "MRI/MRA for pediatric AIS to identify LVO and differentiate stroke types",
      "reference_numbers": [
        5,
        6,
        7,
        8
      ],
      "section_number": "3.2"
    },
    {
      "recommendation_number": 5,
      "cor": "2a",
      "loe": "C-LD",
      "summary": "CT/CTA for pediatric AIS if MRI/MRA not available within 25 minutes",
      "reference_numbers": [
        5,
        6,
        7,
        8,
        9
      ],
      "section_number": "3.2"
    },
    {
      "recommendation_number": 6,
      "cor": "2a",
      "loe": "B-R",
      "summary": "MRI DWI-FLAIR mismatch for IVT eligibility in wake-up/unknown onset >4.5h",
      "reference_numbers": [
        10,
        11
      ],
      "section_number": "3.2"
    },
    {
      "recommendation_number": 7,
      "cor": "2a",
      "loe": "B-R",
      "summary": "CTP or MR DWI-PWI with automated analysis for IVT eligibility in 4.5-24h window",
      "reference_numbers": [
        12,
        13
      ],
      "section_number": "3.2"
    },
    {
      "recommendation_number": 9,
      "cor": "2a",
      "loe": "A",
      "summary": "Adjunctive CTP, MRI (DWI-FLAIR mismatch), or MR DWI-PWI for EVT evaluation in 6-24h window",
      "reference_numbers": [
        14
      ],
      "section_number": "3.2"
    },
    {
      "recommendation_number": 10,
      "cor": "2b",
      "loe": "B-R",
      "summary": "DTAS for flat-panel head CT vs conventional imaging in LVO with RACE >4 and EVT eligibility",
      "reference_numbers": [
        15,
        16,
        17
      ],
      "section_number": "3.2"
    },
    {
      "recommendation_number": 11,
      "cor": "2b",
      "loe": "B-NR",
      "summary": "DTAS without repeat imaging for emergently transferred LVO patients eligible for EVT",
      "reference_numbers": [
        16,
        18,
        19,
        20
      ],
      "section_number": "3.2"
    },
    {
      "recommendation_number": 1,
      "cor": "1",
      "loe": "C-LD",
      "summary": "Baseline ECG in suspected acute stroke",
      "reference_numbers": [
        1,
        2,
        3,
        4
      ],
      "section_number": "3.3"
    },
    {
      "recommendation_number": 2,
      "cor": "1",
      "loe": "B-NR",
      "summary": "Baseline troponin in suspected acute stroke",
      "reference_numbers": [
        5,
        6,
        7,
        8,
        9
      ],
      "section_number": "3.3"
    },
    {
      "recommendation_number": 1,
      "cor": "3: No Benefit",
      "loe": "A",
      "summary": "Hemodynamic augmentation using hemodilution, high-dose albumin, or chemical vasodilators is not recommended",
      "reference_numbers": [
        1,
        2,
        3
      ],
      "section_number": "4.10"
    },
    {
      "recommendation_number": 2,
      "cor": "3: No Benefit",
      "loe": "B-R",
      "summary": "Mechanical hemodynamic augmentation with counterpulsation devices or sphenopalatine ganglion stimulation is not recommended",
      "reference_numbers": [
        4,
        5,
        6
      ],
      "section_number": "4.10"
    },
    {
      "recommendation_number": 1,
      "cor": "3: No Benefit",
      "loe": "A",
      "summary": "Neuroprotective agents are not recommended in AIS",
      "reference_numbers": [
        1,
        2,
        3,
        4,
        5
      ],
      "section_number": "4.11"
    },
    {
      "recommendation_number": 1,
      "cor": "3: No Benefit",
      "loe": "B-NR",
      "summary": "Emergent carotid endarterectomy (within 48 hours) for high-grade carotid stenosis or occlusion without intracranial occlusion is not beneficial",
      "reference_numbers": [
        1,
        2,
        3
      ],
      "section_number": "4.12"
    },
    {
      "recommendation_number": 1,
      "cor": "1",
      "loe": "C-LD",
      "summary": "Airway support and ventilatory assistance for acute stroke with decreased consciousness or bulbar dysfunction",
      "reference_numbers": [
        1,
        2,
        3
      ],
      "section_number": "4.1"
    },
    {
      "recommendation_number": 2,
      "cor": "1",
      "loe": "C-LD",
      "summary": "Supplemental oxygen for AIS with hypoxia to maintain SpO2 >94%",
      "reference_numbers": [
        4,
        5
      ],
      "section_number": "4.1"
    },
    {
      "recommendation_number": 3,
      "cor": "2b",
      "loe": "B-R",
      "summary": "NBO before EVT for AIS within 6h, NIHSS 10-20, ASPECTS ≥6, anterior circulation LVO",
      "reference_numbers": [
        6,
        7,
        8,
        9
      ],
      "section_number": "4.1"
    },
    {
      "recommendation_number": 4,
      "cor": "2b",
      "loe": "B-NR",
      "summary": "HBO for AIS due to arterial air embolism",
      "reference_numbers": [
        10
      ],
      "section_number": "4.1"
    },
    {
      "recommendation_number": 5,
      "cor": "3: No benefit",
      "loe": "B-R",
      "summary": "Supplemental oxygen not recommended for AIS without hypoxia, ineligible for EVT",
      "reference_numbers": [
        11,
        12,
        13,
        14,
        15,
        16
      ],
      "section_number": "4.1"
    },
    {
      "recommendation_number": 6,
      "cor": "3: No benefit",
      "loe": "B-R",
      "summary": "HBO not recommended for AIS not associated with air embolism",
      "reference_numbers": [
        17
      ],
      "section_number": "4.1"
    },
    {
      "recommendation_number": 1,
      "cor": "3: No Benefit",
      "loe": "B-R",
      "summary": "No benefit of routine 0-degree head positioning compared with 30 degrees for 24 hours in AIS overall",
      "reference_numbers": [
        1,
        2
      ],
      "section_number": "4.2"
    },
    {
      "recommendation_number": 2,
      "cor": "3: No Benefit",
      "loe": "B-R",
      "summary": "No benefit of routine Trendelenburg positioning (−20 degrees) compared with 0- to 30-degree head positioning in AIS with probable large artery atherosclerosis and no reperfusion intervention",
      "reference_numbers": [
        3
      ],
      "section_number": "4.2"
    },
    {
      "recommendation_number": 1,
      "cor": "1",
      "loe": "C-LD",
      "summary": "Correct hypotension and hypovolemia in AIS to maintain systemic perfusion.",
      "reference_numbers": [
        1,
        2,
        3
      ],
      "section_number": "4.3"
    },
    {
      "recommendation_number": 2,
      "cor": "1",
      "loe": "C-EO",
      "summary": "Early treatment of hypertension in AIS when required by comorbid conditions.",
      "reference_numbers": [],
      "section_number": "4.3"
    },
    {
      "recommendation_number": 3,
      "cor": "2b",
      "loe": "C-EO",
      "summary": "Benefit of treating BP ≥220/120 mm Hg within 48-72h in AIS without IVT/EVT or urgent comorbidities is uncertain.",
      "reference_numbers": [],
      "section_number": "4.3"
    },
    {
      "recommendation_number": 4,
      "cor": "3: No Benefit",
      "loe": "A",
      "summary": "Treating BP <220/120 mm Hg within 48-72h in AIS without IVT/EVT or urgent comorbidities is not effective.",
      "reference_numbers": [
        4
      ],
      "section_number": "4.3"
    },
    {
      "recommendation_number": 5,
      "cor": "1",
      "loe": "B-NR",
      "summary": "Lower SBP to <185 mm Hg and DBP <110 mm Hg before IVT in eligible AIS patients.",
      "reference_numbers": [
        5,
        6,
        7,
        8,
        9
      ],
      "section_number": "4.3"
    },
    {
      "recommendation_number": 6,
      "cor": "2a",
      "loe": "B-NR",
      "summary": "Maintain BP ≤185/110 mm Hg before EVT if no IVT.",
      "reference_numbers": [
        10
      ],
      "section_number": "4.3"
    },
    {
      "recommendation_number": 7,
      "cor": "1",
      "loe": "B-R",
      "summary": "Maintain BP <180/105 mm Hg for at least 24h after IVT.",
      "reference_numbers": [
        11,
        12,
        13
      ],
      "section_number": "4.3"
    },
    {
      "recommendation_number": 8,
      "cor": "3: No Benefit",
      "loe": "B-R",
      "summary": "Intensive SBP reduction (<140 mm Hg vs <180 mm Hg) after IVT in mild-moderate AIS is not recommended.",
      "reference_numbers": [
        11
      ],
      "section_number": "4.3"
    },
    {
      "recommendation_number": 9,
      "cor": "2a",
      "loe": "B-NR",
      "summary": "Maintain BP ≤180/105 mm Hg during and for 24h after EVT.",
      "reference_numbers": [
        14,
        15,
        16,
        17
      ],
      "section_number": "4.3"
    },
    {
      "recommendation_number": 10,
      "cor": "3: Harm",
      "loe": "A",
      "summary": "Intensive SBP reduction target of <140 mm Hg for 72h after successful EVT for anterior LVO is harmful.",
      "reference_numbers": [
        18,
        19,
        20,
        21
      ],
      "section_number": "4.3"
    },
    {
      "recommendation_number": 1,
      "cor": "1",
      "loe": "B-R",
      "summary": "Targeting normothermia in AIS patients with hyperthermia is recommended",
      "reference_numbers": [
        1,
        2,
        3
      ],
      "section_number": "4.4"
    },
    {
      "recommendation_number": 2,
      "cor": "1",
      "loe": "C-EO",
      "summary": "Identify and treat sources of hyperthermia in AIS patients",
      "reference_numbers": [],
      "section_number": "4.4"
    },
    {
      "recommendation_number": 3,
      "cor": "3: No Benefit",
      "loe": "B-R",
      "summary": "Induced hypothermia or prophylactic fever prevention is not recommended in AIS patients with normothermia",
      "reference_numbers": [
        4,
        5,
        6,
        7
      ],
      "section_number": "4.4"
    },
    {
      "recommendation_number": 1,
      "cor": "1",
      "loe": "C-LD",
      "summary": "Treat hypoglycemia (blood glucose <60 mg/dL) in AIS",
      "reference_numbers": [
        1,
        2
      ],
      "section_number": "4.5"
    },
    {
      "recommendation_number": 2,
      "cor": "2a",
      "loe": "C-LD",
      "summary": "Treat persistent hyperglycemia to achieve blood glucose 140-180 mg/dL",
      "reference_numbers": [
        1,
        2
      ],
      "section_number": "4.5"
    },
    {
      "recommendation_number": 3,
      "cor": "3: No Benefit",
      "loe": "A",
      "summary": "IV insulin to achieve blood glucose 80-130 mg/dL not recommended",
      "reference_numbers": [
        3,
        4,
        5
      ],
      "section_number": "4.5"
    },
    {
      "recommendation_number": 1,
      "cor": "1",
      "loe": "A",
      "summary": "In adult patients with AIS with disabling deficits, regardless of NIHSS score, and eligible for IVT, faster treatment improves functional outcomes.",
      "reference_numbers": [
        1
      ],
      "section_number": "4.6.1"
    },
    {
      "recommendation_number": 2,
      "cor": "1",
      "loe": "B-NR",
      "summary": "In adult patients with AIS who are eligible for IVT within 4.5 hours of symptom onset, treatment should be initiated as quickly as possible, assuring safe administration and avoiding potential delays associated with additional multimodal neuroimaging.",
      "reference_numbers": [
        2,
        3
      ],
      "section_number": "4.6.1"
    },
    {
      "recommendation_number": 3,
      "cor": "1",
      "loe": "B-NR",
      "summary": "In patients with AIS undergoing IVT, health care professionals should be prepared to treat potential emergent adverse effects, including bleeding complications and angioedema.",
      "reference_numbers": [
        4,
        5,
        6,
        7,
        8,
        9,
        10,
        11,
        12,
        13,
        14,
        15,
        16,
        17,
        18,
        19,
        20
      ],
      "section_number": "4.6.1"
    },
    {
      "recommendation_number": 4,
      "cor": "1",
      "loe": "C-EO",
      "summary": "In patients with AIS eligible for IVT, health care professionals should discuss its potential risks and benefits with competent patients and/or available patient representatives, when feasible, to ensure shared decision-making.",
      "reference_numbers": [],
      "section_number": "4.6.1"
    },
    {
      "recommendation_number": 5,
      "cor": "1",
      "loe": "B-NR",
      "summary": "In patients with suspected ischemic stroke, treating health care professionals should determine blood glucose levels before IVT initiation to assess and urgently treat severe hypoglycemia and hyperglycemia.",
      "reference_numbers": [
        4,
        5,
        6,
        7,
        8,
        9,
        10,
        11,
        12,
        13,
        14,
        15,
        16,
        17,
        18,
        19,
        20
      ],
      "section_number": "4.6.1"
    },
    {
      "recommendation_number": 6,
      "cor": "1",
      "loe": "C-LD",
      "summary": "In patients with suspected ischemic stroke with severe hypoglycemia or hyperglycemia, if symptoms of disabling stroke persist despite correction to normoglycemia, administration of IVT is recommended.",
      "reference_numbers": [],
      "section_number": "4.6.1"
    },
    {
      "recommendation_number": 7,
      "cor": "1",
      "loe": "A",
      "summary": "In patients with AIS who are otherwise eligible for IVT with early ischemic change of mild to moderate extent (other than frank hypodensity attributable to the clinical presentation) on initial brain imaging, IVT is recommended.",
      "reference_numbers": [
        21,
        22
      ],
      "section_number": "4.6.1"
    },
    {
      "recommendation_number": 8,
      "cor": "3: No Benefit",
      "loe": "B-R",
      "summary": "In eligible adult patients with AIS presenting with mild non-disabling stroke deficits within 4.5 hours of symptom onset or last known well, IVT is not recommended.",
      "reference_numbers": [
        23,
        24,
        25,
        26,
        27,
        28,
        29
      ],
      "section_number": "4.6.1"
    },
    {
      "recommendation_number": 9,
      "cor": "1",
      "loe": "B-NR",
      "summary": "In suspected patients with AIS who are taking single or DAPT and are otherwise eligible for IVT, IVT is recommended to improve functional outcomes despite an increase in risk of sICH.",
      "reference_numbers": [
        30
      ],
      "section_number": "4.6.1"
    },
    {
      "recommendation_number": 10,
      "cor": "2a",
      "loe": "B-NR",
      "summary": "In patients with AIS within 4.5 hours of last known well and eligible for IVT, it is reasonable that IVT not be delayed while waiting for hematologic or coagulation testing if there is no reason to suspect an abnormal result.",
      "reference_numbers": [
        31,
        32
      ],
      "section_number": "4.6.1"
    },
    {
      "recommendation_number": 11,
      "cor": "1",
      "loe": "B-NR",
      "summary": "In patients with AIS who are eligible for IVT within 4.5 hours of symptom onset with unknown burden of cerebral microbleeds (CMB), it is recommended that IVT be administered without first obtaining MRI to exclude CMBs.",
      "reference_numbers": [
        33,
        34,
        35,
        36,
        37
      ],
      "section_number": "4.6.1"
    },
    {
      "recommendation_number": 12,
      "cor": "2a",
      "loe": "B-NR",
      "summary": "In patients with AIS within 4.5 hours of last known well and who are eligible for IVT, administration of IVT is reasonable to achieve better functional outcomes if a small number (eg, 1–10) of CMBs was demonstrated on MRI.",
      "reference_numbers": [
        33,
        34,
        35,
        36,
        37
      ],
      "section_number": "4.6.1"
    },
    {
      "recommendation_number": 13,
      "cor": "2b",
      "loe": "B-NR",
      "summary": "In patients with AIS within 4.5 hours of last known well and who are eligible for IVT, if they previously had a high burden (eg, >10) of CMBs demonstrated on MRI, usefulness of IVT is uncertain as it may be associated with an increased risk of sICH.",
      "reference_numbers": [
        33,
        34,
        37
      ],
      "section_number": "4.6.1"
    },
    {
      "recommendation_number": 14,
      "cor": "2b",
      "loe": "C-LD",
      "summary": "In pediatric patients aged 28 days to 18 years with confirmed AIS presenting within 4.5 hours of symptom onset and disabling deficits, IVT with alteplase may be considered as it is safe, but efficacy is uncertain.",
      "reference_numbers": [
        38,
        39,
        40,
        41,
        42
      ],
      "section_number": "4.6.1"
    },
    {
      "recommendation_number": 1,
      "cor": "1",
      "loe": "A",
      "summary": "Tenecteplase 0.25 mg/kg (max 25 mg) or alteplase 0.9 mg/kg within 4.5h for adult AIS eligible for IVT",
      "reference_numbers": [
        1,
        2,
        3,
        4,
        5
      ],
      "section_number": "4.6.2"
    },
    {
      "recommendation_number": 2,
      "cor": "3: No Benefit",
      "loe": "A",
      "summary": "Tenecteplase 0.4 mg/kg within 4.5h for adult AIS eligible for IVT is not recommended",
      "reference_numbers": [
        6,
        7,
        8,
        9
      ],
      "section_number": "4.6.2"
    },
    {
      "recommendation_number": 1,
      "cor": "2a",
      "loe": "B-R",
      "summary": "IVT within 4.5 hours from symptom recognition for unknown onset, MRI-DWI lesion < one-third MCA, no marked FLAIR change",
      "reference_numbers": [
        1
      ],
      "section_number": "4.6.3"
    },
    {
      "recommendation_number": 2,
      "cor": "2a",
      "loe": "B-R",
      "summary": "IVT 4.5–9 hours from last known well OR within 9 hours from midpoint of sleep (wake-up stroke), salvageable penumbra on perfusion imaging",
      "reference_numbers": [
        2,
        3
      ],
      "section_number": "4.6.3"
    },
    {
      "recommendation_number": 3,
      "cor": "2b",
      "loe": "B-R",
      "summary": "IVT 4.5 to 24 hours from symptom onset or last known well, LVO, salvageable penumbra, cannot receive EVT",
      "reference_numbers": [
        2,
        3,
        4,
        5
      ],
      "section_number": "4.6.3"
    },
    {
      "recommendation_number": 1,
      "cor": "2b",
      "loe": "B-R",
      "summary": "IV reteplase within 4.5h, not undergoing EVT, may be considered",
      "reference_numbers": [
        1,
        2
      ],
      "section_number": "4.6.4"
    },
    {
      "recommendation_number": 2,
      "cor": "2b",
      "loe": "B-R",
      "summary": "IV mutant prourokinase within 4.5h, not undergoing EVT, may be considered",
      "reference_numbers": [
        3,
        4
      ],
      "section_number": "4.6.4"
    },
    {
      "recommendation_number": 3,
      "cor": "3: No Benefit",
      "loe": "A",
      "summary": "IV desmoteplase within 3-9h not recommended",
      "reference_numbers": [
        5,
        6,
        7,
        8
      ],
      "section_number": "4.6.4"
    },
    {
      "recommendation_number": 4,
      "cor": "3: No Benefit",
      "loe": "B-R",
      "summary": "IV mutant prourokinase + low-dose alteplase within 4.5h not recommended",
      "reference_numbers": [
        9,
        10
      ],
      "section_number": "4.6.4"
    },
    {
      "recommendation_number": 5,
      "cor": "3: No Benefit",
      "loe": "B-R",
      "summary": "IV urokinase within 6h not beneficial",
      "reference_numbers": [
        8
      ],
      "section_number": "4.6.4"
    },
    {
      "recommendation_number": 6,
      "cor": "3: Harm",
      "loe": "A",
      "summary": "IV streptokinase within 6h should not be administered",
      "reference_numbers": [
        8
      ],
      "section_number": "4.6.4"
    },
    {
      "recommendation_number": 7,
      "cor": "3: No Benefit",
      "loe": "A",
      "summary": "Sonothrombolysis adjunct to IVT not recommended",
      "reference_numbers": [
        11,
        12
      ],
      "section_number": "4.6.4"
    },
    {
      "recommendation_number": 1,
      "cor": "2a",
      "loe": "B-NR",
      "summary": "IVT for AIS with known sickle cell disease in adults",
      "reference_numbers": [
        1
      ],
      "section_number": "4.6.5"
    },
    {
      "recommendation_number": 2,
      "cor": "2b",
      "loe": "C-LD",
      "summary": "IVT for acute nonarteritic CRAO with disabling visual loss within 4.5 hours in adults",
      "reference_numbers": [
        2,
        3,
        4,
        5,
        6
      ],
      "section_number": "4.6.5"
    },
    {
      "recommendation_number": 1,
      "cor": "1",
      "loe": "A",
      "summary": "IVT is safe and recommended in AIS patients eligible for both IVT and EVT",
      "reference_numbers": [
        1,
        2
      ],
      "section_number": "4.7.1"
    },
    {
      "recommendation_number": 2,
      "cor": "1",
      "loe": "A",
      "summary": "IVT should be administered as rapidly as possible without delay for EVT",
      "reference_numbers": [
        3
      ],
      "section_number": "4.7.1"
    },
    {
      "recommendation_number": 1,
      "cor": "1",
      "loe": "A",
      "summary": "EVT for mRS 0-1, ASPECTS 3-10, 0-6h",
      "reference_numbers": [
        1,
        2,
        3,
        4,
        5,
        6,
        7,
        8,
        9,
        10,
        11
      ],
      "section_number": "4.7.2"
    },
    {
      "recommendation_number": 2,
      "cor": "1",
      "loe": "A",
      "summary": "EVT for mRS 0-1, ASPECTS ≥6, 6-24h",
      "reference_numbers": [
        12,
        13,
        14
      ],
      "section_number": "4.7.2"
    },
    {
      "recommendation_number": 3,
      "cor": "1",
      "loe": "A",
      "summary": "EVT for mRS 0-1, ASPECTS 3-5, age <80, 6-24h, no mass effect",
      "reference_numbers": [
        7,
        8
      ],
      "section_number": "4.7.2"
    },
    {
      "recommendation_number": 4,
      "cor": "2a",
      "loe": "B-R",
      "summary": "EVT for mRS 0-1, ASPECTS 0-2, age <80, 0-6h, no mass effect",
      "reference_numbers": [
        8,
        10,
        11
      ],
      "section_number": "4.7.2"
    },
    {
      "recommendation_number": 5,
      "cor": "2a",
      "loe": "B-NR",
      "summary": "EVT for mRS 2, ASPECTS ≥6, 0-6h",
      "reference_numbers": [
        15,
        16
      ],
      "section_number": "4.7.2"
    },
    {
      "recommendation_number": 6,
      "cor": "2b",
      "loe": "B-NR",
      "summary": "EVT for mRS 3-4, ASPECTS ≥6, 0-6h",
      "reference_numbers": [
        17,
        18,
        19,
        20
      ],
      "section_number": "4.7.2"
    },
    {
      "recommendation_number": 7,
      "cor": "2a",
      "loe": "B-NR",
      "summary": "EVT for dominant proximal M2, mRS 0-1, ASPECTS ≥6, 0-6h",
      "reference_numbers": [
        21,
        22,
        23
      ],
      "section_number": "4.7.2"
    },
    {
      "recommendation_number": 8,
      "cor": "3: No Benefit",
      "loe": "A",
      "summary": "No EVT for nondominant M2/distal/ACA/PCA, 0-6h",
      "reference_numbers": [
        23,
        24
      ],
      "section_number": "4.7.2"
    },
    {
      "recommendation_number": 1,
      "cor": "1",
      "loe": "A",
      "summary": "EVT for basilar occlusion, mRS 0-1, NIHSS ≥10, PC-ASPECTS ≥6, within 24h",
      "reference_numbers": [
        1,
        2
      ],
      "section_number": "4.7.3"
    },
    {
      "recommendation_number": 2,
      "cor": "2b",
      "loe": "B-R",
      "summary": "EVT for basilar occlusion, mRS 0-1, NIHSS 6-9, PC-ASPECTS ≥6, within 24h",
      "reference_numbers": [
        3,
        4,
        5
      ],
      "section_number": "4.7.3"
    },
    {
      "recommendation_number": 1,
      "cor": "1",
      "loe": "A",
      "summary": "EVT with stent retrievers, contact aspiration, or combination techniques is recommended for LVO",
      "reference_numbers": [
        1,
        2,
        3,
        4
      ],
      "section_number": "4.7.4"
    },
    {
      "recommendation_number": 2,
      "cor": "1",
      "loe": "A",
      "summary": "Reperfusion to extended TICI grade 2b/2c/3 as early as possible is recommended",
      "reference_numbers": [
        1,
        5,
        6
      ],
      "section_number": "4.7.4"
    },
    {
      "recommendation_number": 3,
      "cor": "1",
      "loe": "B-R",
      "summary": "General anesthesia or procedural sedation are recommended to facilitate EVT",
      "reference_numbers": [
        7,
        8,
        9
      ],
      "section_number": "4.7.4"
    },
    {
      "recommendation_number": 4,
      "cor": "2b",
      "loe": "B-R",
      "summary": "Use of a proximal balloon to guide catheters remains uncertain",
      "reference_numbers": [
        10,
        11,
        12
      ],
      "section_number": "4.7.4"
    },
    {
      "recommendation_number": 5,
      "cor": "3: No Benefit",
      "loe": "A",
      "summary": "EVT with stent retrievers is of no benefit for medium/distal anterior, middle (nondominant/codominant M2, M3), or posterior cerebral arteries",
      "reference_numbers": [
        13,
        14
      ],
      "section_number": "4.7.4"
    },
    {
      "recommendation_number": 6,
      "cor": "2b",
      "loe": "B-NR",
      "summary": "Acute treatment of both tandem extracranial-intracranial anterior circulation occlusions, including emergent extracranial stenting, may be reasonable",
      "reference_numbers": [
        5,
        15,
        16,
        17,
        18
      ],
      "section_number": "4.7.4"
    },
    {
      "recommendation_number": 7,
      "cor": "2b",
      "loe": "B-NR",
      "summary": "Rescue intracranial balloon angioplasty and/or stenting in failed EVT remains uncertain",
      "reference_numbers": [
        19,
        20,
        21
      ],
      "section_number": "4.7.4"
    },
    {
      "recommendation_number": 8,
      "cor": "2b",
      "loe": "B-R",
      "summary": "Adjunctive intraarterial thrombolytics after EVT may be reasonable",
      "reference_numbers": [
        22,
        23,
        24,
        25
      ],
      "section_number": "4.7.4"
    },
    {
      "recommendation_number": 9,
      "cor": "3: No Benefit",
      "loe": "B-R",
      "summary": "Preoperative tirofiban before EVT is not useful for LVO",
      "reference_numbers": [
        26,
        27
      ],
      "section_number": "4.7.4"
    },
    {
      "recommendation_number": 1,
      "cor": "2a",
      "loe": "B-NR",
      "summary": "EVT for pediatric patients ≥6 years, LVO, within 6 hours from symptom onset",
      "reference_numbers": [
        1,
        2,
        3,
        4
      ],
      "section_number": "4.7.5"
    },
    {
      "recommendation_number": 2,
      "cor": "2a",
      "loe": "B-NR",
      "summary": "EVT for pediatric patients ≥6 years, LVO, 6 to 24 hours from symptom onset, potentially salvageable brain tissue",
      "reference_numbers": [
        1,
        2,
        3
      ],
      "section_number": "4.7.5"
    },
    {
      "recommendation_number": 3,
      "cor": "2b",
      "loe": "B-NR",
      "summary": "EVT for pediatric patients aged 28 days to 6 years, LVO, within 24 hours from symptom onset, potentially salvageable brain tissue",
      "reference_numbers": [
        1,
        2,
        3
      ],
      "section_number": "4.7.5"
    },
    {
      "recommendation_number": 1,
      "cor": "1",
      "loe": "A",
      "summary": "Aspirin recommended within 48 hours after AIS onset",
      "reference_numbers": [
        1,
        2,
        3
      ],
      "section_number": "4.8"
    },
    {
      "recommendation_number": 3,
      "cor": "2b",
      "loe": "B-R",
      "summary": "IV tirofiban efficacy not well established in AIS",
      "reference_numbers": [
        4,
        5
      ],
      "section_number": "4.8"
    },
    {
      "recommendation_number": 4,
      "cor": "3: Harm",
      "loe": "B-R",
      "summary": "IV abciximab not recommended in AIS due to bleeding",
      "reference_numbers": [
        6,
        7
      ],
      "section_number": "4.8"
    },
    {
      "recommendation_number": 5,
      "cor": "1",
      "loe": "A",
      "summary": "Antiplatelet preferred over anticoagulation for noncardioembolic AIS/TIA",
      "reference_numbers": [
        8,
        9
      ],
      "section_number": "4.8"
    },
    {
      "recommendation_number": 7,
      "cor": "2a",
      "loe": "B-R",
      "summary": "Antiplatelet or anticoagulant for ≥3 months in AIS with extracranial carotid/vertebral dissection",
      "reference_numbers": [
        10,
        11,
        12
      ],
      "section_number": "4.8"
    },
    {
      "recommendation_number": 8,
      "cor": "2b",
      "loe": "B-NR",
      "summary": "Effectiveness of changing/increasing aspirin in noncardioembolic stroke/TIA unclear",
      "reference_numbers": [
        13,
        14
      ],
      "section_number": "4.8"
    },
    {
      "recommendation_number": 9,
      "cor": "3: No Benefit",
      "loe": "B-R",
      "summary": "Ticagrelor not recommended over aspirin for minor noncardioembolic AIS/high-risk TIA",
      "reference_numbers": [
        15
      ],
      "section_number": "4.8"
    },
    {
      "recommendation_number": 10,
      "cor": "3: Harm",
      "loe": "B-R",
      "summary": "Triple antiplatelet therapy not recommended for noncardioembolic ischemic stroke",
      "reference_numbers": [
        16
      ],
      "section_number": "4.8"
    },
    {
      "recommendation_number": 11,
      "cor": "3: Harm",
      "loe": "B-NR",
      "summary": "Adding antiplatelet to anticoagulation in ischemic stroke with AF (no CAD/stent) is harmful",
      "reference_numbers": [
        17,
        18
      ],
      "section_number": "4.8"
    },
    {
      "recommendation_number": 12,
      "cor": "1",
      "loe": "A",
      "summary": "DAPT (aspirin + clopidogrel) for minor AIS/high-risk TIA (NIHSS ≤3, ABCD2 ≥4) within 24h, 21 days, then SAPT",
      "reference_numbers": [
        19,
        20,
        21,
        22,
        23,
        24,
        25
      ],
      "section_number": "4.8"
    },
    {
      "recommendation_number": 13,
      "cor": "2b",
      "loe": "B-R",
      "summary": "DAPT (ticagrelor + aspirin) for 30 days may be considered for recent (<24h) minor AIS/high-risk TIA (NIHSS ≤5, ABCD2 ≥6, ≥50% stenosis)",
      "reference_numbers": [
        26
      ],
      "section_number": "4.8"
    },
    {
      "recommendation_number": 14,
      "cor": "2a",
      "loe": "B-R",
      "summary": "DAPT (clopidogrel + aspirin) for 21 days then SAPT for minor AIS/high-risk TIA (NIHSS ≤5 or 4-5 within 24h, ABCD2 ≥4, ≥50% stenosis) within 24-72h or NIHSS 4-5 within 24h",
      "reference_numbers": [
        27
      ],
      "section_number": "4.8"
    },
    {
      "recommendation_number": 15,
      "cor": "2b",
      "loe": "B-R",
      "summary": "DAPT (ticagrelor + aspirin) for 21 days (then ticagrelor alone) may be reasonable for minor AIS/high-risk TIA (NIHSS ≤3, ABCD2 ≥4, CYP2C19 LOF allele) within 24h",
      "reference_numbers": [
        28
      ],
      "section_number": "4.8"
    },
    {
      "recommendation_number": 18,
      "cor": "3: No Benefit",
      "loe": "B-R",
      "summary": "IV eptifibatide not recommended adjunctively with IVT within 3h of AIS onset",
      "reference_numbers": [
        29,
        30
      ],
      "section_number": "4.8"
    },
    {
      "recommendation_number": 1,
      "cor": "2a",
      "loe": "A",
      "summary": "Early oral anticoagulation poststroke in selected AIS with AF is reasonable",
      "reference_numbers": [
        1,
        2,
        3
      ],
      "section_number": "4.9"
    },
    {
      "recommendation_number": 2,
      "cor": "2b",
      "loe": "B-NR",
      "summary": "Urgent anticoagulation in AIS with ipsilateral, high-grade ICA stenosis: benefit not well established",
      "reference_numbers": [
        4,
        5
      ],
      "section_number": "4.9"
    },
    {
      "recommendation_number": 3,
      "cor": "2b",
      "loe": "C-LD",
      "summary": "Short-term anticoagulation in AIS with ipsilateral, nonocclusive, extracranial intraluminal thrombus: safety/efficacy not well established",
      "reference_numbers": [
        6,
        7,
        8
      ],
      "section_number": "4.9"
    },
    {
      "recommendation_number": 4,
      "cor": "2b",
      "loe": "C-LD",
      "summary": "Anticoagulation in AIS with HT may be considered depending on scenario/indication",
      "reference_numbers": [
        9,
        10,
        11
      ],
      "section_number": "4.9"
    },
    {
      "recommendation_number": 5,
      "cor": "3: No Benefit",
      "loe": "A",
      "summary": "Argatroban as adjunct to IVT in AIS is not effective for long-term functional outcomes",
      "reference_numbers": [
        12,
        13,
        14,
        15
      ],
      "section_number": "4.9"
    },
    {
      "recommendation_number": 6,
      "cor": "3: No Benefit",
      "loe": "A",
      "summary": "Early anticoagulation (within 48 hours of stroke onset) in AIS is not recommended",
      "reference_numbers": [
        4,
        16,
        17,
        18,
        19,
        20,
        21,
        22,
        23,
        24
      ],
      "section_number": "4.9"
    },
    {
      "recommendation_number": 1,
      "cor": "1",
      "loe": "B-R",
      "summary": "Stroke unit care for AIS, all ages",
      "reference_numbers": [
        1,
        2,
        3,
        4,
        5,
        6,
        7,
        8,
        9,
        10,
        11,
        12,
        13,
        14,
        15,
        16
      ],
      "section_number": "5.1"
    },
    {
      "recommendation_number": 1,
      "cor": "1",
      "loe": "C-EO",
      "summary": "Bedside swallow screening prior to liquid or food intake is recommended to screen for aspiration risk.",
      "reference_numbers": [],
      "section_number": "5.2"
    },
    {
      "recommendation_number": 2,
      "cor": "2a",
      "loe": "C-LD",
      "summary": "Dysphagia screening by speech pathologists or other trained health care professionals is reasonable.",
      "reference_numbers": [
        1
      ],
      "section_number": "5.2"
    },
    {
      "recommendation_number": 3,
      "cor": "2a",
      "loe": "B-NR",
      "summary": "Endoscopic examination of swallowing function is reasonable for patients unable to participate in bedside screening.",
      "reference_numbers": [
        2,
        3,
        4
      ],
      "section_number": "5.2"
    },
    {
      "recommendation_number": 4,
      "cor": "2b",
      "loe": "B-NR",
      "summary": "Oral hygiene protocol may be reasonable to reduce pneumonia risk.",
      "reference_numbers": [
        5,
        6
      ],
      "section_number": "5.2"
    },
    {
      "recommendation_number": 5,
      "cor": "2a",
      "loe": "B-R",
      "summary": "Pharyngeal electrical stimulation (PES) can be beneficial to reduce dysphagia severity and aspiration risk.",
      "reference_numbers": [
        7,
        8,
        9
      ],
      "section_number": "5.2"
    },
    {
      "recommendation_number": 6,
      "cor": "2a",
      "loe": "B-R",
      "summary": "PES after ventilator weaning can be beneficial for severe stroke patients with dysphagia requiring tracheotomy and mechanical ventilation.",
      "reference_numbers": [
        7,
        9,
        10,
        11
      ],
      "section_number": "5.2"
    },
    {
      "recommendation_number": 1,
      "cor": "1",
      "loe": "B-R",
      "summary": "Enteral diet should be started within 7 days of admission after AIS",
      "reference_numbers": [
        1,
        2,
        3,
        4,
        5,
        6
      ],
      "section_number": "5.3"
    },
    {
      "recommendation_number": 2,
      "cor": "1",
      "loe": "B-NR",
      "summary": "Nutritional screening is recommended early, preferably within 48 hours of admission, using a validated tool",
      "reference_numbers": [
        2,
        3,
        4,
        5,
        6,
        7,
        8,
        9
      ],
      "section_number": "5.3"
    },
    {
      "recommendation_number": 3,
      "cor": "2a",
      "loe": "B-NR",
      "summary": "For AIS with dysphagia, nasogastric tubes are reasonable within first 7 days; percutaneous gastrostomy for >2–3 weeks inability to swallow",
      "reference_numbers": [
        1
      ],
      "section_number": "5.3"
    },
    {
      "recommendation_number": 1,
      "cor": "1",
      "loe": "B-R",
      "summary": "IPC in addition to routine care is recommended over routine care alone to reduce the risk of DVT in AIS patients with impaired mobility and no contraindications to IPC.",
      "reference_numbers": [
        1,
        2
      ],
      "section_number": "5.4"
    },
    {
      "recommendation_number": 2,
      "cor": "2a",
      "loe": "B-R",
      "summary": "Prophylactic-dose subcutaneous heparin (UFH or LMWH) is reasonable to reduce the risk of VTE in AIS patients with impaired mobility.",
      "reference_numbers": [
        3
      ],
      "section_number": "5.4"
    },
    {
      "recommendation_number": 3,
      "cor": "2b",
      "loe": "A",
      "summary": "Benefit of prophylactic-dose subcutaneous heparin (UFH or LMWH) over no prophylactic-dose heparin is not well established to increase overall survival in AIS patients with impaired mobility.",
      "reference_numbers": [
        2
      ],
      "section_number": "5.4"
    },
    {
      "recommendation_number": 4,
      "cor": "2b",
      "loe": "B-R",
      "summary": "Benefit of prophylactic-dose LMWH over prophylactic-dose UFH to prevent DVT is uncertain in AIS patients with impaired mobility selected for prophylactic anticoagulation.",
      "reference_numbers": [
        4,
        5,
        6
      ],
      "section_number": "5.4"
    },
    {
      "recommendation_number": 5,
      "cor": "3: Harm",
      "loe": "B-R",
      "summary": "Elastic compression stockings cause harm, including skin breakdown, ulceration, and tissue necrosis, compared with usual care in AIS patients with impaired mobility.",
      "reference_numbers": [
        7,
        8,
        9
      ],
      "section_number": "5.4"
    },
    {
      "recommendation_number": 1,
      "cor": "1",
      "loe": "B-NR",
      "summary": "Structured depression inventory screening for poststroke depression in AIS patients",
      "reference_numbers": [
        1,
        2,
        3,
        4
      ],
      "section_number": "5.5"
    },
    {
      "recommendation_number": 2,
      "cor": "1",
      "loe": "B-R",
      "summary": "Antidepressants and/or nonpharmacological interventions for patients with PSD",
      "reference_numbers": [
        5,
        6,
        7,
        8,
        9,
        10,
        11,
        12,
        13,
        14,
        15,
        16,
        17
      ],
      "section_number": "5.5"
    },
    {
      "recommendation_number": 1,
      "cor": "2a",
      "loe": "C-EO",
      "summary": "Referral to palliative care resources is reasonable for select patients with AIS and their families.",
      "reference_numbers": [],
      "section_number": "5.6"
    },
    {
      "recommendation_number": 2,
      "cor": "3: No Benefit",
      "loe": "A",
      "summary": "Routine use of prophylactic antibiotics has not been shown to be beneficial in improving functional outcomes in patients with AIS.",
      "reference_numbers": [
        1,
        2,
        3,
        4,
        5
      ],
      "section_number": "5.6"
    },
    {
      "recommendation_number": 3,
      "cor": "3: Harm",
      "loe": "C-LD",
      "summary": "Routine placement of indwelling bladder catheters should not be performed in patients with AIS due to risk of catheter-associated UTIs.",
      "reference_numbers": [
        6
      ],
      "section_number": "5.6"
    },
    {
      "recommendation_number": 1,
      "cor": "1",
      "loe": "A",
      "summary": "In-hospital, formal, interdisciplinary assessment and provision of rehabilitation is recommended to improve functional recovery.",
      "reference_numbers": [
        1
      ],
      "section_number": "5.7"
    },
    {
      "recommendation_number": 2,
      "cor": "3: No Benefit",
      "loe": "A",
      "summary": "SSRIs are not effective for improving motor recovery or functional status.",
      "reference_numbers": [
        2,
        3,
        4,
        5
      ],
      "section_number": "5.7"
    },
    {
      "recommendation_number": 3,
      "cor": "3: Harm",
      "loe": "B-R",
      "summary": "High-dose, very early mobilization within 24 hours of stroke onset is not recommended and may be harmful.",
      "reference_numbers": [
        6,
        7,
        8
      ],
      "section_number": "5.7"
    },
    {
      "recommendation_number": 1,
      "cor": "1",
      "loe": "C-EO",
      "summary": "Early discussion of care options and outcomes for large cerebral/cerebellar infarctions at high risk for brain swelling/herniation",
      "reference_numbers": [],
      "section_number": "6.1"
    },
    {
      "recommendation_number": 2,
      "cor": "1",
      "loe": "C-EO",
      "summary": "Close monitoring for neurological worsening after large cerebral/cerebellar infarctions",
      "reference_numbers": [],
      "section_number": "6.1"
    },
    {
      "recommendation_number": 3,
      "cor": "1",
      "loe": "C-LD",
      "summary": "Early transfer to institution with neurosurgical/critical care expertise for large cerebral/cerebellar infarctions at increased risk for malignant brain swelling",
      "reference_numbers": [
        1
      ],
      "section_number": "6.1"
    },
    {
      "recommendation_number": 1,
      "cor": "2a",
      "loe": "C-LD",
      "summary": "Osmotic therapy as bridge to surgery for large cerebral/cerebellar infarctions with neurological decline from brain swelling",
      "reference_numbers": [],
      "section_number": "6.2"
    },
    {
      "recommendation_number": 2,
      "cor": "3",
      "loe": "B-R",
      "summary": "IV glibenclamide not recommended for large hemispheric infarction age 18-70",
      "reference_numbers": [
        1
      ],
      "section_number": "6.2"
    },
    {
      "recommendation_number": 3,
      "cor": "3",
      "loe": "C-LD",
      "summary": "Hypothermia, barbiturates, corticosteroids should not be used for brain swelling in large infarctions",
      "reference_numbers": [],
      "section_number": "6.2"
    },
    {
      "recommendation_number": 1,
      "cor": "2a",
      "loe": "B-NR",
      "summary": "Decompressive hemicraniectomy for large territorial cerebral infarctions at high risk for brain swelling and herniation, with decreased level of consciousness",
      "reference_numbers": [
        1
      ],
      "section_number": "6.3"
    },
    {
      "recommendation_number": 2,
      "cor": "1",
      "loe": "A",
      "summary": "Decompressive craniectomy with dural expansion for unilateral MCA infarctions in patients ≤60 years, within 48 hours from brain swelling, with neurological deterioration despite medical therapy",
      "reference_numbers": [
        2,
        3,
        4,
        5,
        6
      ],
      "section_number": "6.3"
    },
    {
      "recommendation_number": 3,
      "cor": "2b",
      "loe": "B-R",
      "summary": "Decompressive craniectomy with dural expansion for unilateral MCA infarctions in patients >60 years, within 48 hours from brain swelling, with neurological deterioration despite medical therapy",
      "reference_numbers": [
        3,
        7,
        8,
        9
      ],
      "section_number": "6.3"
    },
    {
      "recommendation_number": 4,
      "cor": "2b",
      "loe": "B-NR",
      "summary": "Early decompressive craniectomy within 48 hours for AIS patients who received IV tPA and develop malignant cerebral edema despite medical therapy",
      "reference_numbers": [
        10,
        11
      ],
      "section_number": "6.3"
    },
    {
      "recommendation_number": 1,
      "cor": "1",
      "loe": "C-LD",
      "summary": "Ventriculostomy for cerebellar infarction with obstructive hydrocephalus",
      "reference_numbers": [
        1,
        2,
        3
      ],
      "section_number": "6.4"
    },
    {
      "recommendation_number": 2,
      "cor": "1",
      "loe": "B-NR",
      "summary": "Decompressive suboccipital craniectomy with dural expansion for cerebellar infarction with neurological deterioration from brainstem compression or volumes ≥35 mL",
      "reference_numbers": [
        1,
        2,
        3,
        4,
        5,
        6,
        7
      ],
      "section_number": "6.4"
    },
    {
      "recommendation_number": 1,
      "cor": "1",
      "loe": "C-LD",
      "summary": "Antiseizure medication recommended for unprovoked seizure after AIS in adults based on specific patient characteristics",
      "reference_numbers": [],
      "section_number": "6.5"
    },
    {
      "recommendation_number": 2,
      "cor": "3: No Benefit",
      "loe": "C-LD",
      "summary": "Prophylactic antiseizure medication not recommended in adults with AIS",
      "reference_numbers": [
        1,
        2
      ],
      "section_number": "6.5"
    }
  ],
  "trials": {
    "ABESTT-II": {
      "trial_name": "AbESTT-II",
      "full_name": null,
      "category": "Antiplatelet therapy",
      "sections_referenced": [
        "4.8"
      ],
      "metrics": [
        {
          "metric_type": "percentage",
          "value": 33,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": "0.944",
          "outcome": "favorable clinical outcomes at 3 months",
          "population_subgroup": null,
          "comparison": "placebo vs abciximab",
          "raw_text": "There was no increase in favorable clinical outcomes at 3 months (33% placebo versus 32% abciximab; P=0.944)"
        },
        {
          "metric_type": "percentage",
          "value": 5.5,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": "0.002",
          "outcome": "sICH or fatal ICH within 5 days",
          "population_subgroup": null,
          "comparison": "abciximab vs placebo",
          "raw_text": "significant increase in sICH or fatal ICH, within 5 days of enrollment (5.5% versus 0.5%; P=0.002)"
        }
      ],
      "metric_count": 2
    },
    "ACT": {
      "trial_name": "AcT",
      "full_name": null,
      "category": "IVT alternative agents",
      "sections_referenced": [
        "4.3",
        "4.6.2"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "ADRS": {
      "trial_name": "ADRS",
      "full_name": "Aphasia Depression Rating Scale",
      "category": "Other",
      "sections_referenced": [
        "5.5"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "AHA COMPREHENSIVE REVIEW": {
      "trial_name": "AHA comprehensive review",
      "full_name": null,
      "category": "Prehospital/systems of care",
      "sections_referenced": [
        "2.7"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "AHA GET WITH THE GUIDELINES (GWTG)-STROKE REGISTRY": {
      "trial_name": "AHA Get With the Guidelines (GWTG)-Stroke registry",
      "full_name": null,
      "category": "Prehospital/systems of care",
      "sections_referenced": [
        "2.7"
      ],
      "metrics": [
        {
          "metric_type": "OR",
          "value": 0.96,
          "ci_95_lower": 0.95,
          "ci_95_upper": 0.98,
          "p_value": "<0.001",
          "outcome": "in-hospital mortality",
          "population_subgroup": null,
          "comparison": "per 15-minute earlier treatment",
          "raw_text": "reduced in-hospital mortality (OR, 0.96 [95% CI, 0.95–0.98]; P<0.001)"
        },
        {
          "metric_type": "OR",
          "value": 0.96,
          "ci_95_lower": 0.95,
          "ci_95_upper": 0.98,
          "p_value": "<0.001",
          "outcome": "lower rates of sICH",
          "population_subgroup": null,
          "comparison": "per 15-minute earlier treatment",
          "raw_text": "lower rates of sICH (OR, 0.96 [95% CI, 0.95–0.98]; P<0.001)"
        },
        {
          "metric_type": "OR",
          "value": 1.04,
          "ci_95_lower": 1.03,
          "ci_95_upper": 1.05,
          "p_value": "<0.001",
          "outcome": "increased independent ambulation at discharge",
          "population_subgroup": null,
          "comparison": "per 15-minute earlier treatment",
          "raw_text": "increased independent ambulation at discharge (OR, 1.04 [95% CI, 1.03–1.05]; P<0.001)"
        },
        {
          "metric_type": "OR",
          "value": 1.03,
          "ci_95_lower": 1.02,
          "ci_95_upper": 1.04,
          "p_value": "<0.001",
          "outcome": "higher rates of discharge to home",
          "population_subgroup": null,
          "comparison": "per 15-minute earlier treatment",
          "raw_text": "higher rates of discharge to home (OR, 1.03 [95% CI, 1.02–1.04]; P<0.001)"
        }
      ],
      "metric_count": 4
    },
    "AHA/ASA SECONDARY PREVENTION GUIDELINES": {
      "trial_name": "AHA/ASA secondary prevention guidelines",
      "full_name": null,
      "category": "Other",
      "sections_referenced": [
        "4.12"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "AMETIS": {
      "trial_name": "AMETIS",
      "full_name": null,
      "category": "EVT technique",
      "sections_referenced": [
        "4.7.4"
      ],
      "metrics": [
        {
          "metric_type": null,
          "value": null,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "90-day functional outcomes and major procedural complications",
          "population_subgroup": null,
          "comparison": "general anesthesia vs procedural sedation",
          "raw_text": "AMETIS randomized 273 thrombectomy patients to general anesthesia versus procedural sedation and found comparable 90-day functional outcomes and major procedural complications."
        }
      ],
      "metric_count": 1
    },
    "ANGEL-ASPECT": {
      "trial_name": "ANGEL-ASPECT",
      "full_name": "Endovascular Treatment for AIS in Asia",
      "category": "EVT large core",
      "sections_referenced": [
        "3.2",
        "4.3",
        "4.7.2"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "ANGEL-REBOOT": {
      "trial_name": "ANGEL-REBOOT",
      "full_name": null,
      "category": "EVT technique",
      "sections_referenced": [
        "4.7.4"
      ],
      "metrics": [
        {
          "metric_type": "n",
          "value": 348,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "patients underwent EVT with TICI 0 to 2a revascularization",
          "population_subgroup": null,
          "comparison": null,
          "raw_text": "ANGEL-REBOOT RCT in China failed to show superiority of rescue balloon angioplasty or stenting in 348 patients who underwent EVT with TICI 0 to 2a revascularization"
        }
      ],
      "metric_count": 1
    },
    "ANGIOCAT": {
      "trial_name": "ANGIOCAT",
      "full_name": null,
      "category": "Imaging",
      "sections_referenced": [
        "3.2"
      ],
      "metrics": [
        {
          "metric_type": "door-to-groin puncture time",
          "value": 18,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": "<0.001",
          "outcome": "workflow speed",
          "population_subgroup": null,
          "comparison": "DTAS vs conventional workflow",
          "raw_text": "door-to-groin puncture,18 versus 42 minutes; P<0.001"
        },
        {
          "metric_type": "door-to-reperfusion time",
          "value": 57,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": "<0.001",
          "outcome": "workflow speed",
          "population_subgroup": null,
          "comparison": "DTAS vs conventional workflow",
          "raw_text": "door to reperfusion, 57 versus 84 minutes; P<0.001"
        },
        {
          "metric_type": "cOR",
          "value": 2.2,
          "ci_95_lower": 1.2,
          "ci_95_upper": 4.1,
          "p_value": 0.009,
          "outcome": "good outcomes (ordinal mRS)",
          "population_subgroup": null,
          "comparison": "DTAS vs conventional workflow",
          "raw_text": "ordinal mRS: cOR, 2.2 [95% CI, 1.2–4.1]; P=0.009"
        }
      ],
      "metric_count": 3
    },
    "APTOLL": {
      "trial_name": "ApTOLL",
      "full_name": null,
      "category": "Neuroprotective Agents",
      "sections_referenced": [
        "4.11"
      ],
      "metrics": [
        {
          "metric_type": null,
          "value": null,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "safety",
          "population_subgroup": null,
          "comparison": "ApTOLL vs placebo",
          "raw_text": "Anti-inflammatory therapies, including ApTOLL and stem cell therapy, were reported as safe but have not been studied in pivotal trials"
        }
      ],
      "metric_count": 1
    },
    "ARAIS": {
      "trial_name": "ARAIS",
      "full_name": null,
      "category": "Anticoagulation",
      "sections_referenced": [
        "4.9"
      ],
      "metrics": [
        {
          "metric_type": "percentage",
          "value": 63.8,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "mRS score of 0 to 1 at 90 days",
          "population_subgroup": "argatroban group",
          "comparison": "argatroban vs placebo",
          "raw_text": "63.8% of participants in the argatroban group and 64.9% of participants in the placebo group had an mRS score of 0 to 1 at 90 days"
        }
      ],
      "metric_count": 1
    },
    "ARAMIS": {
      "trial_name": "ARAMIS",
      "full_name": null,
      "category": "IVT standard window",
      "sections_referenced": [
        "4.6.1"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "ARTIS": {
      "trial_name": "ARTIS",
      "full_name": null,
      "category": "Antiplatelet therapy",
      "sections_referenced": [
        "4.8"
      ],
      "metrics": [
        {
          "metric_type": "risk ratio",
          "value": 2.78,
          "ci_95_lower": 1.01,
          "ci_95_upper": 7.63,
          "p_value": 0.04,
          "outcome": "symptomatic intracranial hemorrhage (sICH)",
          "population_subgroup": null,
          "comparison": "IV aspirin + alteplase vs standard treatment",
          "raw_text": "sICH was higher in the aspirin arm (4.3% versus 1.6% with standard treatment; risk ratio, 2.78 [95% CI, 1.01–7.63]; P=0.04)"
        }
      ],
      "metric_count": 1
    },
    "ARTSS-2": {
      "trial_name": "ARTSS-2",
      "full_name": "Argatroban With Recombinant Tissue Plasminogen Activator for Acute Stroke",
      "category": "Anticoagulation",
      "sections_referenced": [
        "4.9"
      ],
      "metrics": [
        {
          "metric_type": "percentage",
          "value": 10,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "sICH",
          "population_subgroup": "placebo",
          "comparison": "argatroban vs placebo",
          "raw_text": "There was no difference in the proportion of participants with sICH among the placebo (10%), low-dose argatroban (13%), or high-dose argatroban (7%) arms."
        }
      ],
      "metric_count": 1
    },
    "ASTER": {
      "trial_name": "ASTER",
      "full_name": null,
      "category": "EVT technique",
      "sections_referenced": [
        "4.7.4"
      ],
      "metrics": [
        {
          "metric_type": null,
          "value": null,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "revascularization results",
          "population_subgroup": null,
          "comparison": "first-line aspiration vs stent retrievers",
          "raw_text": "In the ASTER RCT, first-line aspiration did not show increased revascularization results compared with stent retrievers in anterior circulation thrombectomy of 381 patients."
        }
      ],
      "metric_count": 1
    },
    "ASTER 2": {
      "trial_name": "ASTER 2",
      "full_name": null,
      "category": "EVT technique",
      "sections_referenced": [
        "4.7.4"
      ],
      "metrics": [
        {
          "metric_type": null,
          "value": null,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": null,
          "population_subgroup": null,
          "comparison": "combination of contact aspiration and stent retriever vs stent retriever alone",
          "raw_text": "In ASTER 2, a combination of contact aspiration and stent retriever did not show superiority to stent retriever alone in an RCT of 408 patients."
        }
      ],
      "metric_count": 1
    },
    "ATTENTION": {
      "trial_name": "ATTENTION",
      "full_name": null,
      "category": "EVT posterior circulation",
      "sections_referenced": [
        "3.2",
        "4.7.3"
      ],
      "metrics": [
        {
          "metric_type": "percentage",
          "value": 46,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "90-day functional outcome",
          "population_subgroup": null,
          "comparison": "EVT vs medical management",
          "raw_text": "the study showed a 2-fold statistically significant benefit in 90-day functional outcome for the thrombectomy group compared with the medical group (46% and 23%)"
        },
        {
          "metric_type": "percentage",
          "value": 5,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "sICH rate",
          "population_subgroup": null,
          "comparison": "EVT vs medical management",
          "raw_text": "Although the sICH rate was 5% in the EVT group and 0% in the medical group, this trend did not reach statistical significance."
        }
      ],
      "metric_count": 2
    },
    "ATTENTION-IA": {
      "trial_name": "ATTENTION-IA",
      "full_name": null,
      "category": "EVT technique",
      "sections_referenced": [
        "4.7.4"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "ATTEST-2": {
      "trial_name": "ATTEST-2",
      "full_name": null,
      "category": "IVT alternative agents",
      "sections_referenced": [
        "4.6.2"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "AURORA": {
      "trial_name": "AURORA",
      "full_name": null,
      "category": "EVT extended window",
      "sections_referenced": [
        "4.7.2"
      ],
      "metrics": [
        {
          "metric_type": "adjusted cOR",
          "value": 2.54,
          "ci_95_lower": 1.83,
          "ci_95_upper": 3.54,
          "p_value": "<0.0001",
          "outcome": "reduced disability at 90 days",
          "population_subgroup": null,
          "comparison": "EVT vs medical management",
          "raw_text": "The AURORA study showed reduced disability at 90 days (adjusted cOR, 2.54 [95% CI, 1.83–3.54]; P<0.0001) in favor of EVT in the extended time window of 6 to 24 hours."
        }
      ],
      "metric_count": 1
    },
    "AUSCR": {
      "trial_name": "AusCR",
      "full_name": null,
      "category": "Prehospital/systems of care",
      "sections_referenced": [
        "2.10"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "AUSTRIAN STROKE REGISTRY STUDY": {
      "trial_name": "Austrian Stroke Registry study",
      "full_name": null,
      "category": "IVT standard window",
      "sections_referenced": [
        "4.6.5"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "AVC II": {
      "trial_name": "AVC II",
      "full_name": null,
      "category": "Prehospital/systems of care",
      "sections_referenced": [
        "2.7"
      ],
      "metrics": [
        {
          "metric_type": "aOR",
          "value": 1.39,
          "ci_95_lower": 1.01,
          "ci_95_upper": 2.02,
          "p_value": null,
          "outcome": "increasing thrombolytic rates",
          "population_subgroup": null,
          "comparison": "intervention vs control groups",
          "raw_text": "adjusted OR, 1.39 [95% CI, 1.01–2.02]"
        }
      ],
      "metric_count": 1
    },
    "AVERT": {
      "trial_name": "AVERT",
      "full_name": "A Very Early Rehabilitation Trial",
      "category": "Rehabilitation",
      "sections_referenced": [
        "5.7"
      ],
      "metrics": [
        {
          "metric_type": null,
          "value": null,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "functional benefit",
          "population_subgroup": "very early (<24 hours after stroke onset) mobilization",
          "comparison": "very early mobilization vs standard care",
          "raw_text": "very early (<24 hours after stroke onset) mobilization has not been shown to provide functional benefit, and high doses resulted in worse outcomes in 1 RCT.8"
        },
        {
          "metric_type": "percentage",
          "value": 46,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "favorable outcome at 3 months (mRS 0-2)",
          "population_subgroup": "high-dose, very early mobilization group",
          "comparison": "high-dose, very early mobilization vs usual care",
          "raw_text": "patients in the high-dose, very early mobilization group had less favorable outcomes (46% versus 50%; adjusted OR, 0.73 [95% CI, 0.59–0.90]; P=0.004) than those in the usual care group"
        },
        {
          "metric_type": "aOR",
          "value": 0.73,
          "ci_95_lower": 0.59,
          "ci_95_upper": 0.9,
          "p_value": 0.004,
          "outcome": "favorable outcome at 3 months (mRS 0-2)",
          "population_subgroup": null,
          "comparison": "high-dose, very early mobilization vs usual care",
          "raw_text": "adjusted OR, 0.73 [95% CI, 0.59–0.90]; P=0.004"
        },
        {
          "metric_type": "percentage",
          "value": 8,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "death",
          "population_subgroup": "very early mobilization group",
          "comparison": "high-dose, very early mobilization vs usual care",
          "raw_text": "8% versus 7% of patients died in the very early mobilization group"
        },
        {
          "metric_type": "percentage",
          "value": 19,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "nonfatal serious adverse event",
          "population_subgroup": "very early mobilization group",
          "comparison": "high-dose, very early mobilization vs usual care",
          "raw_text": "19% versus 20% had a nonfatal serious adverse event with high-dose, very early mobilization"
        },
        {
          "metric_type": "time window",
          "value": 24,
          "unit": "hours",
          "outcome": "High-dose, very early mobilization within 24 hours of stroke onset",
          "raw_text": "within 24 hours of stroke onset",
          "source": "footnote"
        }
      ],
      "metric_count": 6
    },
    "B-PROUD": {
      "trial_name": "B_PROUD",
      "full_name": "Berlin Pre-hospital Or Usual Delivery of stroke care",
      "category": "Prehospital/systems of care",
      "sections_referenced": [
        "2.5"
      ],
      "metrics": [
        {
          "metric_type": "improved functional outcomes",
          "value": null,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "functional outcomes",
          "population_subgroup": "patients treated in MSUs",
          "comparison": "MSU management vs conventional EMS care",
          "raw_text": "The B_PROUD (Berlin Pre-hospital Or Usual Delivery of stroke care) trial demonstrated improved functional outcomes for patients treated in MSUs and increased rates and faster administration of thrombolytics."
        }
      ],
      "metric_count": 1
    },
    "BAOCHE": {
      "trial_name": "BAOCHE",
      "full_name": null,
      "category": "EVT posterior circulation",
      "sections_referenced": [
        "3.2",
        "4.7.3"
      ],
      "metrics": [
        {
          "metric_type": "percentage",
          "value": 46,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "mRS score of 0 to 3",
          "population_subgroup": null,
          "comparison": "EVT vs medical management",
          "raw_text": "an mRS score of 0 to 3 was achieved in 46% of the EVT group, as opposed to 24% in the medical management group, which reached statistical significance."
        },
        {
          "metric_type": "percentage",
          "value": 100,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "trial defined good outcome (mRS score, 0–3)",
          "population_subgroup": "NIHSS 6-9, EVT group (n=6)",
          "comparison": "EVT vs medical management",
          "raw_text": "All patients treated with EVT reached the trial defined good outcome (mRS score, 0–3), while only 6 of the 11 managed medically got these results."
        },
        {
          "metric_type": "percentage",
          "value": 46,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "mRS of 0–3",
          "population_subgroup": "PC-ASPECTS score ≥6 without pons-midbrain index ≥3",
          "comparison": "EVT vs medical management",
          "raw_text": "EVT showed favorable outcomes that reached statistical significance, over the medical management group (mRS of 0–3 was achieved in 46% of the EVT group, as opposed to 24% in the medical management group)."
        }
      ],
      "metric_count": 3
    },
    "BASICS": {
      "trial_name": "BASICS",
      "full_name": null,
      "category": "EVT posterior circulation",
      "sections_referenced": [
        "4.7.3"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "BEST": {
      "trial_name": "BEST",
      "full_name": null,
      "category": "EVT posterior circulation",
      "sections_referenced": [
        "4.7.3"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "BEST-MSU": {
      "trial_name": "BEST-MSU",
      "full_name": "Benefits of Stroke Treatment Using a Mobile Stroke Unit",
      "category": "Prehospital/systems of care",
      "sections_referenced": [
        "2.5"
      ],
      "metrics": [
        {
          "metric_type": "significantly faster thrombolysis",
          "value": null,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "thrombolysis time",
          "population_subgroup": "patients eligible for thrombolytics",
          "comparison": "MSU management vs conventional EMS care",
          "raw_text": "the BEST-MSU (Benefits of Stroke Treatment Using a Mobile Stroke Unit) trial, which demonstrated significantly faster thrombolysis and improved clinical outcomes for patients eligible for thrombolytics."
        }
      ],
      "metric_count": 1
    },
    "CADISS": {
      "trial_name": "CADISS",
      "full_name": "Cervical Artery Dissection in Stroke Study",
      "category": "Antiplatelet therapy",
      "sections_referenced": [
        "4.8"
      ],
      "metrics": [
        {
          "metric_type": "percentage",
          "value": 2.4,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "recurrent stroke rate at 1 year",
          "population_subgroup": null,
          "comparison": "antiplatelet vs anticoagulation",
          "raw_text": "The recurrent stroke rate at 1 year was low at 6 (2.4%), with 4 in the antiplatelet group and 2 in the anticoagulation group."
        }
      ],
      "metric_count": 1
    },
    "CAST": {
      "trial_name": "CAST",
      "full_name": "Chinese Acute Stroke Trial",
      "category": "Antiplatelet therapy",
      "sections_referenced": [
        "4.8"
      ],
      "metrics": [
        {
          "metric_type": "percentage",
          "value": 5.3,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": "0.03",
          "outcome": "combined in-hospital death or nonfatal stroke at 4 weeks",
          "population_subgroup": null,
          "comparison": "aspirin vs placebo",
          "raw_text": "Aspirin was associated with a reduction in combined in-hospital death or nonfatal stroke at 4 weeks (5.3% versus 5.9%; P=0.03)"
        }
      ],
      "metric_count": 1
    },
    "CHABILIS-T II": {
      "trial_name": "CHABILIS-T II",
      "full_name": null,
      "category": "IVT extended window",
      "sections_referenced": [
        "4.6.3"
      ],
      "metrics": [
        {
          "metric_type": "aOR",
          "value": 2.5,
          "ci_95_lower": 1.4,
          "ci_95_upper": 4.4,
          "p_value": 0.002,
          "outcome": "recanalization",
          "population_subgroup": null,
          "comparison": "tenecteplase vs placebo",
          "raw_text": "There was significant improvement in recanalization (aOR, 2.5 [95% CI, 1.4–4.4]; P=0.002)"
        }
      ],
      "metric_count": 1
    },
    "CHANCE": {
      "trial_name": "CHANCE",
      "full_name": "Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular Events",
      "category": "Antiplatelet therapy",
      "sections_referenced": [
        "4.8"
      ],
      "metrics": [
        {
          "metric_type": "HR",
          "value": 0.68,
          "ci_95_lower": 0.57,
          "ci_95_upper": 0.81,
          "p_value": "<0.001",
          "outcome": "recurrent stroke (ischemic or hemorrhagic) at 90 days",
          "population_subgroup": null,
          "comparison": "DAPT (clopidogrel plus aspirin) vs aspirin alone",
          "raw_text": "DAPT was associated with a decreased rate of recurrent stroke (ischemic or hemorrhagic) at 90 days over aspirin (8.2% versus 7%; HR, 0.68 [95% CI, 0.570.81]; P<0.001)"
        },
        {
          "metric_type": "percentage",
          "value": 0.3,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": "0.73",
          "outcome": "moderate-severe hemorrhage",
          "population_subgroup": null,
          "comparison": "DAPT vs aspirin alone",
          "raw_text": "with an identical rate of moderate-severe hemorrhage in both groups (0.3%; P=0.73)"
        },
        {
          "metric_type": "absolute risk difference",
          "value": 1.7,
          "ci_95_lower": 0.03,
          "ci_95_upper": 3.42,
          "p_value": null,
          "outcome": "poor outcome at 90 days",
          "population_subgroup": null,
          "comparison": "DAPT vs aspirin alone",
          "raw_text": "DAPT was associated with improved 90-day functional outcome (absolute reduction of poor outcome, 1.70% [95% CI, 0.03–3.42]) compared with aspirin alone"
        },
        {
          "metric_type": "HR",
          "value": 0.64,
          "ci_95_lower": 0.52,
          "ci_95_upper": 0.79,
          "p_value": "<0.001",
          "outcome": "1-week risk of new ischemic stroke",
          "population_subgroup": null,
          "comparison": "DAPT vs aspirin alone",
          "raw_text": "DAPT reduced the 1-week risk of new ischemic stroke by 35% (HR, 0.64 [95% CI, 0.52–0.79]; P<0.001)"
        }
      ],
      "metric_count": 4
    },
    "CHANCE 2": {
      "trial_name": "CHANCE 2",
      "full_name": null,
      "category": "Antiplatelet therapy",
      "sections_referenced": [
        "4.8"
      ],
      "metrics": [
        {
          "metric_type": "HR",
          "value": 0.77,
          "ci_95_lower": 0.64,
          "ci_95_upper": 0.94,
          "p_value": "0.008",
          "outcome": "recurrent stroke within 90 days",
          "population_subgroup": "CYP2C19 loss-of-function allele (clopidogrel nonresponders)",
          "comparison": "DAPT (ticagrelor plus aspirin) vs DAPT (clopidogrel plus aspirin)",
          "raw_text": "CHANCE 2 demonstrated that the DAPT regimen with ticagrelor plus aspirin was superior to the DAPT combination of clopidogrel plus aspirin in decreasing the risk of recurrent stroke within 90 days (6.0% versus 7.6%; HR, 0.77 [95% CI, 0.64–0.94]; P=0.008)"
        },
        {
          "metric_type": "HR",
          "value": 2.18,
          "ci_95_lower": 1.66,
          "ci_95_upper": 2.85,
          "p_value": null,
          "outcome": "total bleeding events",
          "population_subgroup": null,
          "comparison": "ticagrelor vs clopidogrel (both with aspirin)",
          "raw_text": "Ticagrelor was associated with more total bleeding events than clopidogrel (5.3% versus 2.5%; HR, 2.18 [95% CI, 1.66–2.85])"
        },
        {
          "metric_type": "HR",
          "value": 0.82,
          "ci_95_lower": 0.34,
          "ci_95_upper": 1.98,
          "p_value": null,
          "outcome": "severe or moderate bleeding",
          "population_subgroup": null,
          "comparison": "ticagrelor vs clopidogrel (both with aspirin)",
          "raw_text": "the risk of severe or moderate bleeding did not differ between the 2 treatment groups (0.3% versus 0.3%; HR, 0.82 [95% CI, 0.34–1.98])"
        }
      ],
      "metric_count": 3
    },
    "CHARM": {
      "trial_name": "CHARM",
      "full_name": "IV glibenclamide for cerebral edema after large hemispheric stroke",
      "category": "Complications management",
      "sections_referenced": [
        "6.2"
      ],
      "metrics": [
        {
          "metric_type": "cOR",
          "value": 1.17,
          "ci_95_lower": 0.8,
          "ci_95_upper": 1.71,
          "p_value": 0.42,
          "outcome": "mRS score at 90 days (shift analysis)",
          "population_subgroup": null,
          "comparison": "IV glibenclamide vs placebo",
          "raw_text": "The trial showed that IV glibenclamide did not improve mRS score at 90 days using shift analysis (cOR, 1.17 [95% CI, 0.80–1.71]; P=0.42)"
        },
        {
          "metric_type": "HR",
          "value": 1.2,
          "ci_95_lower": 0.85,
          "ci_95_upper": 1.7,
          "p_value": 0.3,
          "outcome": "90-day mortality",
          "population_subgroup": null,
          "comparison": "IV glibenclamide vs placebo",
          "raw_text": "or 90-day mortality (hazard ratio, 1.20 [95% CI, 0.85–1.70]; P=0.30)"
        },
        {
          "metric_type": "age_range",
          "value": "18 to 70",
          "unit": "years",
          "outcome": "Age range for population in which IV glibenclamide was studied",
          "raw_text": "Age: 18 to 70; large hemispheric infarction",
          "source": "footnote"
        }
      ],
      "metric_count": 3
    },
    "CHOICE": {
      "trial_name": "CHOICE",
      "full_name": null,
      "category": "EVT technique",
      "sections_referenced": [
        "4.7.4"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "CLEAR STROKE": {
      "trial_name": "CLEAR stroke",
      "full_name": null,
      "category": "Antiplatelet therapy",
      "sections_referenced": [
        "4.8"
      ],
      "metrics": [
        {
          "metric_type": "percentage",
          "value": 1.4,
          "ci_95_lower": 0,
          "ci_95_upper": 4.3,
          "p_value": null,
          "outcome": "symptomatic intracranial hemorrhage (sICH)",
          "population_subgroup": "combination tPA + eptifibatide",
          "comparison": "tPA + eptifibatide vs tPA only",
          "raw_text": "1 sICH (1.4% [95% CI, 0–4.3]) versus 2 sICH (8.0% [95% CI, 0–19.2]) in the tPA only arm (P=0.17)"
        }
      ],
      "metric_count": 1
    },
    "CLOTBUST-ER": {
      "trial_name": "CLOTBUST-ER",
      "full_name": "Combined Lysis of Thrombus With Ultrasound and Systemic Tissue Plasminogen Activator [tPA] for Emergent Revascularization in AIS",
      "category": "IVT alternative agents",
      "sections_referenced": [
        "4.6.4"
      ],
      "metrics": [
        {
          "metric_type": null,
          "value": null,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "neurological improvement, death, and SAEs",
          "population_subgroup": null,
          "comparison": "sonothrombolysis vs sham ultrasound",
          "raw_text": "Compared with the control arm, the neurological improvement, death, and SAEs in the intervention arm were not statistically different."
        }
      ],
      "metric_count": 1
    },
    "CLOTS 1": {
      "trial_name": "CLOTS 1",
      "full_name": null,
      "category": "Anticoagulation",
      "sections_referenced": [
        "5.4"
      ],
      "metrics": [
        {
          "metric_type": "percentage",
          "value": 10,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "DVT in the popliteal or femoral veins",
          "population_subgroup": "GPCs group",
          "comparison": "GPCs vs usual care",
          "raw_text": "10% of patients randomized to GPCs developed a primary endpoint compared with 10.5% of patients randomized to usual care only"
        },
        {
          "metric_type": "percentage",
          "value": 5,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "skin breaks, skin ulceration, skin blistering, and skin necrosis",
          "population_subgroup": "GPCs group",
          "comparison": "GPCs vs usual care",
          "raw_text": "Skin breaks, skin ulceration, skin blistering, and skin necrosis occurred more commonly in those randomized to GPCs (5%) than those randomized to usual care only (1%)"
        }
      ],
      "metric_count": 2
    },
    "CLOTS 2": {
      "trial_name": "CLOTS 2",
      "full_name": null,
      "category": "Anticoagulation",
      "sections_referenced": [
        "5.4"
      ],
      "metrics": [
        {
          "metric_type": "percentage",
          "value": 6.3,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "DVT in the popliteal or femoral veins",
          "population_subgroup": "thigh-length GPCs group",
          "comparison": "thigh-length GPCs vs below-knee GPCs",
          "raw_text": "6.3% of patients with thigh-length GPCs developed a primary end point compared with 8.8% of those with below-knee GPCs"
        },
        {
          "metric_type": "percentage",
          "value": 3.9,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "skin complications",
          "population_subgroup": "thigh-length GPCs group",
          "comparison": "thigh-length GPCs vs below-knee GPCs",
          "raw_text": "skin complications occurred in 3.9% of patients randomized to thigh-length GPCs compared with 2.9% of those with below-knee GPCs"
        }
      ],
      "metric_count": 2
    },
    "CLOTS-3": {
      "trial_name": "CLOTS-3",
      "full_name": "Clots in Legs Or sTockings after Stroke",
      "category": "Complications management",
      "sections_referenced": [
        "5.4"
      ],
      "metrics": [
        {
          "metric_type": "percentage",
          "value": 8.5,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "primary endpoint (proximal DVT or symptomatic DVT within 30 days)",
          "population_subgroup": "IPC group",
          "comparison": "IPC vs no IPC",
          "raw_text": "The primary endpoint was seen in 8.5% of patients randomized to IPC and 12.1% of patients randomized to no IPC"
        },
        {
          "metric_type": "absolute risk difference",
          "value": -3.6,
          "ci_95_lower": -5.8,
          "ci_95_upper": -1.4,
          "p_value": null,
          "outcome": "primary endpoint (proximal DVT or symptomatic DVT within 30 days)",
          "population_subgroup": null,
          "comparison": "IPC vs no IPC",
          "raw_text": "risk difference, –3.6 [95% CI, –1.4 to –5.8]"
        },
        {
          "metric_type": "percentage",
          "value": 11,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "death during treatment period",
          "population_subgroup": "IPC group",
          "comparison": "IPC vs no IPC",
          "raw_text": "11% of those randomized to IPC died compared with 13% of those randomized to no IPC (P=0.057)"
        },
        {
          "metric_type": "percentage",
          "value": 3,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "skin breakdown",
          "population_subgroup": "IPC group",
          "comparison": "IPC vs no IPC",
          "raw_text": "3% in IPC group versus 1% in control group; P=0.002"
        }
      ],
      "metric_count": 4
    },
    "COCHRANE REVIEW META-ANALYSIS OF 8 ORAL ANTICOAGULANT THERAPY TRIALS": {
      "trial_name": "Cochrane review meta-analysis of 8 oral anticoagulant therapy trials",
      "full_name": null,
      "category": "Antiplatelet therapy",
      "sections_referenced": [
        "4.8"
      ],
      "metrics": [
        {
          "metric_type": "RR",
          "value": 0.8,
          "ci_95_lower": 0.56,
          "ci_95_upper": 1.14,
          "p_value": null,
          "outcome": "benefit of oral anticoagulation (medium intensity) over antiplatelet therapy",
          "population_subgroup": "medium intensity (INR 2.0–3.6)",
          "comparison": "oral anticoagulation vs antiplatelet therapy",
          "raw_text": "medium intensity: risk ratio, 0.80 [95% CI, 0.56–1.14]"
        },
        {
          "metric_type": "RR",
          "value": 1.02,
          "ci_95_lower": 0.49,
          "ci_95_upper": 2.13,
          "p_value": null,
          "outcome": "benefit of oral anticoagulation (high intensity) over antiplatelet therapy",
          "population_subgroup": "high intensity (INR 3.0–4.5)",
          "comparison": "oral anticoagulation vs antiplatelet therapy",
          "raw_text": "high intensity: risk ratio, 1.02 [95% CI, 0.49–2.13]"
        },
        {
          "metric_type": "RR",
          "value": 1.93,
          "ci_95_lower": 1.27,
          "ci_95_upper": 2.94,
          "p_value": null,
          "outcome": "risk of bleeding complications (medium intensity)",
          "population_subgroup": "medium intensity (INR 2.0–3.6)",
          "comparison": "oral anticoagulation vs antiplatelet therapy",
          "raw_text": "medium-intensity and high-intensity anticoagulation were associated with a significantly higher risk of bleeding complications (medium intensity: risk ratio, 1.93 [95% CI, 1.27–2.94])"
        },
        {
          "metric_type": "RR",
          "value": 9.0,
          "ci_95_lower": 3.9,
          "ci_95_upper": 21,
          "p_value": null,
          "outcome": "risk of bleeding complications (high intensity)",
          "population_subgroup": "high intensity (INR 3.0–4.5)",
          "comparison": "oral anticoagulation vs antiplatelet therapy",
          "raw_text": "high intensity: risk ratio, 9.0 [95% CI, 3.9–21]"
        }
      ],
      "metric_count": 4
    },
    "COMPASS": {
      "trial_name": "COMPASS",
      "full_name": null,
      "category": "EVT technique",
      "sections_referenced": [
        "4.7.4"
      ],
      "metrics": [
        {
          "metric_type": null,
          "value": null,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "functional outcomes in 90 days",
          "population_subgroup": null,
          "comparison": "aspiration vs stent retrievers",
          "raw_text": "In COMPASS, 270 patients at 15 sites were randomized to aspiration versus stent retrievers and reached similar functional outcomes in 90 days."
        }
      ],
      "metric_count": 1
    },
    "COVERDELL ACUTE STROKE REGISTRY": {
      "trial_name": "Coverdell Acute Stroke Registry",
      "full_name": null,
      "category": "Other",
      "sections_referenced": [
        "2.10"
      ],
      "metrics": [
        {
          "metric_type": null,
          "value": 50579,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "risk of death after the first week of admission",
          "population_subgroup": "patients cared for at nonparticipating centers",
          "comparison": "nonparticipating centers vs participating hospitals",
          "raw_text": "Another comparison study of 50579 patients, including 56% treated in centers participating in the Coverdell Acute Stroke Registry, found that patients cared for at nonparticipating centers had a higher risk of death after the first week of admission compared with patients cared for at participating hospitals.17"
        }
      ],
      "metric_count": 1
    },
    "DAWN": {
      "trial_name": "DAWN",
      "full_name": "DWI or CTP Assessment with Clinical Mismatch in the Triage of Wake-Up and Late Presenting Strokes Undergoing Neurointervention with Trevo",
      "category": "EVT extended window",
      "sections_referenced": [
        "2.9",
        "3.2",
        "4.3",
        "4.7.2",
        "4.7.4"
      ],
      "metrics": [
        {
          "metric_type": "NNT",
          "value": 2.8,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "functional independence",
          "population_subgroup": null,
          "comparison": "EVT vs medical management",
          "raw_text": "NNT achieving functional independence of 2.8 in DAWN"
        },
        {
          "metric_type": null,
          "value": null,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "functional outcome",
          "population_subgroup": "extended time window of 6 to 24 hours",
          "comparison": "balloon-guided catheters vs control",
          "raw_text": "subgroup analysis in DAWN showed no benefit in the extended time window of 6 to 24 hours"
        }
      ],
      "metric_count": 2
    },
    "DECIMAL": {
      "trial_name": "DECIMAL",
      "full_name": "Decompressive Craniectomy in Malignant Middle Cerebral Artery Infarction",
      "category": "Complications management",
      "sections_referenced": [
        "6.3"
      ],
      "metrics": [
        {
          "metric_type": "absolute risk reduction",
          "value": 50,
          "ci_95_lower": 34,
          "ci_95_upper": 66,
          "p_value": null,
          "outcome": "mortality at 12 months",
          "population_subgroup": "patients <60 years of age",
          "comparison": "decompressive craniectomy vs medical management",
          "raw_text": "an absolute risk reduction in mortality of 50% (95% CI, 34–66) at 12 months"
        },
        {
          "metric_type": "percentage",
          "value": 43,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "moderate disability or better (mRS score, 2 or 3) at 12 months",
          "population_subgroup": "surgical group",
          "comparison": "decompressive craniectomy vs medical management",
          "raw_text": "At 12 months, moderate disability or better (mRS score, 2 or 3) was achieved in 43% (22/51) of the surgical group"
        },
        {
          "metric_type": "percentage",
          "value": 55,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "moderate disability or better (mRS score, 2 or 3) at 12 months",
          "population_subgroup": "surgical survivors",
          "comparison": "decompressive craniectomy vs medical management",
          "raw_text": "55% (22/40) of survivors"
        },
        {
          "metric_type": "percentage",
          "value": 21,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "moderate disability or better (mRS score, 2 or 3) at 12 months",
          "population_subgroup": "total medical group",
          "comparison": "decompressive craniectomy vs medical management",
          "raw_text": "21% of the total medical group"
        },
        {
          "metric_type": "percentage",
          "value": 75,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "moderate disability or better (mRS score, 2 or 3) at 12 months",
          "population_subgroup": "medical survivors",
          "comparison": "decompressive craniectomy vs medical management",
          "raw_text": "75% of the medical survivors"
        }
      ],
      "metric_count": 5
    },
    "DEFUSE-3": {
      "trial_name": "DEFUSE-3",
      "full_name": "Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3",
      "category": "EVT extended window",
      "sections_referenced": [
        "2.9",
        "3.2",
        "4.7.2"
      ],
      "metrics": [
        {
          "metric_type": "NNT",
          "value": 3.6,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "functional independence",
          "population_subgroup": null,
          "comparison": "EVT vs medical management",
          "raw_text": "the NNT achieving functional independence of ... 3.6 in DEFUSE-3"
        },
        {
          "metric_type": "NNT",
          "value": 3.6,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "functional independence",
          "population_subgroup": null,
          "comparison": "EVT vs medical management",
          "raw_text": "NNT of 3.6 in DEFUSE 3"
        }
      ],
      "metric_count": 2
    },
    "DESTINY": {
      "trial_name": "DESTINY",
      "full_name": "Decompressive Surgery for the Treatment of Malignant Infarction of the Middle Cerebral Artery",
      "category": "Complications management",
      "sections_referenced": [
        "6.3"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "DESTINY II": {
      "trial_name": "DESTINY II",
      "full_name": null,
      "category": "Complications management",
      "sections_referenced": [
        "6.3"
      ],
      "metrics": [
        {
          "metric_type": "percentage",
          "value": 76,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "mortality",
          "population_subgroup": "age >60",
          "comparison": "nonsurgical group",
          "raw_text": "76% in the nonsurgical group versus 42% in the surgical group in DESTINY II"
        },
        {
          "metric_type": "percentage",
          "value": 6,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "moderate disability (mRS 3) at 12 months",
          "population_subgroup": "total surgical group",
          "comparison": "surgical group",
          "raw_text": "At 12 months, moderate disability (mRS score, 3) was achieved in 6% of the total surgical group"
        },
        {
          "metric_type": "percentage",
          "value": 11,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "moderate disability (mRS 3) at 12 months",
          "population_subgroup": "surgical survivors",
          "comparison": "surgical group",
          "raw_text": "11% of survivors"
        },
        {
          "metric_type": "percentage",
          "value": 5,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "moderate disability (mRS 3) at 12 months",
          "population_subgroup": "total medical group",
          "comparison": "medical group",
          "raw_text": "5% of the total medical group"
        },
        {
          "metric_type": "percentage",
          "value": 20,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "moderate disability (mRS 3) at 12 months",
          "population_subgroup": "medical survivors",
          "comparison": "medical group",
          "raw_text": "20% of the medical survivors"
        },
        {
          "metric_type": "percentage",
          "value": 0,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "independence (mRS ≤2) at 12 months",
          "population_subgroup": "all survivors",
          "comparison": "surgical vs medical",
          "raw_text": "independence (mRS score, ≤2) was not achieved by any survivors in either group"
        }
      ],
      "metric_count": 6
    },
    "DEVT": {
      "trial_name": "DEVT",
      "full_name": "Direct Endovascular Thrombectomy Versus Combined Intravenous Thrombolysis and Endovascular Thrombectomy for Patients With Acute Large Vessel Occlusion (DEVT): A Randomized Clinical Trial",
      "category": "EVT vs combined IVT+EVT",
      "sections_referenced": [
        "2.9",
        "4.7.1"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "DIAS-3": {
      "trial_name": "DIAS-3",
      "full_name": null,
      "category": "IVT alternative agents",
      "sections_referenced": [
        "4.6.4"
      ],
      "metrics": [
        {
          "metric_type": "OR",
          "value": 1.33,
          "ci_95_lower": 0.95,
          "ci_95_upper": 1.85,
          "p_value": "0.096",
          "outcome": "functional independence (mRS 0 to 2 at 90 days)",
          "population_subgroup": null,
          "comparison": "desmoteplase vs placebo",
          "raw_text": "no significant difference in the odds of functional independence defined as mRS 0 to 2 at 90 days with desmoteplase versus placebo (OR, 1.33 [95% CI, 0.95–1.85]; P=0.096)"
        },
        {
          "metric_type": "OR",
          "value": 1.59,
          "ci_95_lower": 1.08,
          "ci_95_upper": 2.35,
          "p_value": "0.019",
          "outcome": "vessel recanalization",
          "population_subgroup": null,
          "comparison": "desmoteplase vs placebo",
          "raw_text": "desmoteplase was safe and was associated with increased odds of vessel recanalization (OR, 1.59 [95% CI, 1.08–2.35]; P=0.019)"
        }
      ],
      "metric_count": 2
    },
    "DIAS-4": {
      "trial_name": "DIAS-4",
      "full_name": null,
      "category": "IVT alternative agents",
      "sections_referenced": [
        "4.6.4"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "DIAS-J": {
      "trial_name": "DIAS-J",
      "full_name": null,
      "category": "IVT alternative agents",
      "sections_referenced": [
        "4.6.4"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "DIRECT-MT": {
      "trial_name": "DIRECT-MT",
      "full_name": "Direct Intraarterial Thrombectomy in Order to Revascularize Acute Ischemic Stroke Patients With Large Vessel Occlusion Efficiently in Chinese Tertiary Hospitals: A Multicenter Randomized Clinical Trial",
      "category": "EVT vs combined IVT+EVT",
      "sections_referenced": [
        "2.9",
        "4.7.1",
        "4.7.4"
      ],
      "metrics": [
        {
          "metric_type": null,
          "value": null,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "90-day functional outcomes",
          "population_subgroup": null,
          "comparison": "general anesthesia vs procedural sedation",
          "raw_text": "In DIRECT-MT, a subgroup analysis of 636 patients showed comparable 90-day functional outcomes between the 2 groups."
        }
      ],
      "metric_count": 1
    },
    "DIRECT-TNK": {
      "trial_name": "DIRECT-TNK",
      "full_name": "Randomization to Endovascular Treatment Alone or Preceded by Systemic Thrombolysis With Tenecteplase in Ischemic Stroke",
      "category": "EVT vs combined IVT+EVT",
      "sections_referenced": [
        "4.7.1"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "DISTAL": {
      "trial_name": "DISTAL",
      "full_name": null,
      "category": "EVT M2/medium vessel",
      "sections_referenced": [
        "4.7.2",
        "4.7.4"
      ],
      "metrics": [
        {
          "metric_type": "percentage",
          "value": 65,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "received IVT",
          "population_subgroup": null,
          "comparison": null,
          "raw_text": "Both allowed treatment with IVT, with 65% receiving this treatment in DISTAL and 58% in ESCAPE-MeVO."
        },
        {
          "metric_type": "median",
          "value": 6,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "presentation NIHSS",
          "population_subgroup": null,
          "comparison": null,
          "raw_text": "Presentation NIHSS values were generally low, with median values of 6 and 7."
        },
        {
          "metric_type": "percentage",
          "value": 35,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "90-day mRS 0-1",
          "population_subgroup": null,
          "comparison": "EVT vs medical management",
          "raw_text": "Both trials failed to demonstrate improved outcomes with endovascular therapy relative to medical management for 90-day mRS scores 0 to 1 (EVT versus medical management: 35% vs 38%, DISTAL; 42% versus 43%, ESCAPE-MeVO)."
        }
      ],
      "metric_count": 3
    },
    "DSM": {
      "trial_name": "DSM",
      "full_name": "Diagnostic and Statistical Manual of Mental Disorders",
      "category": "Other",
      "sections_referenced": [
        "5.5"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "ECASS-4": {
      "trial_name": "ECASS-4",
      "full_name": "European Cooperative Acute Stroke Study 4",
      "category": "IVT extended window",
      "sections_referenced": [
        "3.2",
        "4.6.3"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "ECASS-III": {
      "trial_name": "ECASS-III",
      "full_name": "European Cooperative Acute Stroke Study III",
      "category": "IVT standard window",
      "sections_referenced": [
        "3.2",
        "4.6.1",
        "4.6.3"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "ELAN": {
      "trial_name": "ELAN",
      "full_name": "Early versus Late Initiation of Direct Oral Anticoagulants in Post-Ischemic Stroke Patients with Atrial Fibrillation",
      "category": "Anticoagulation",
      "sections_referenced": [
        "4.9"
      ],
      "metrics": [
        {
          "metric_type": "absolute risk difference",
          "value": -1.18,
          "ci_95_lower": -2.84,
          "ci_95_upper": 0.47,
          "p_value": null,
          "outcome": "recurrent AIS, systemic embolism, major bleeding, sICH, or vascular death",
          "population_subgroup": null,
          "comparison": "early anticoagulation vs later anticoagulation",
          "raw_text": "led to a numerical (but not statistically significant) reduction in recurrent AIS, systemic embolism, major bleeding, sICH, or vascular death (risk difference, –1.18 [95% CI, –2.84 to 0.47])"
        }
      ],
      "metric_count": 1
    },
    "ENCHANTED": {
      "trial_name": "ENCHANTED",
      "full_name": null,
      "category": "Blood pressure management",
      "sections_referenced": [
        "4.3",
        "6.3"
      ],
      "metrics": [
        {
          "metric_type": null,
          "value": null,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "patient outcome or mortality",
          "population_subgroup": null,
          "comparison": "IV tPA at different dosages",
          "raw_text": "administration of IV tPA at different dosages did not affect patient outcome or mortality"
        }
      ],
      "metric_count": 1
    },
    "EPITHET": {
      "trial_name": "EPITHET",
      "full_name": "Echoplanar Imaging Thrombolytic Evaluation Trial",
      "category": "IVT extended window",
      "sections_referenced": [
        "3.2",
        "4.6.3"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "ESCAPE": {
      "trial_name": "ESCAPE",
      "full_name": "Endovascular Treatment for Small Core and Proximal Occlusion Ischemic Stroke",
      "category": "EVT standard window",
      "sections_referenced": [
        "2.9",
        "3.2",
        "4.7.1",
        "4.7.2"
      ],
      "metrics": [
        {
          "metric_type": "median",
          "value": 241,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "time from onset to recanalization (minutes)",
          "population_subgroup": null,
          "comparison": null,
          "raw_text": "median time from onset to recanalization of 359 minutes, as compared with 241 minutes in the ESCAPE trial"
        }
      ],
      "metric_count": 1
    },
    "ESCAPE-MEVO": {
      "trial_name": "ESCAPE-MeVO",
      "full_name": "Efficacy and safety of EVT for patients with ischemic stroke and symptomatic acute medium vessel intracranial occlusions",
      "category": "EVT M2/medium vessel",
      "sections_referenced": [
        "4.7.2",
        "4.7.4"
      ],
      "metrics": [
        {
          "metric_type": "RR",
          "value": 0.9,
          "ci_95_lower": 0.6,
          "ci_95_upper": 1.33,
          "p_value": null,
          "outcome": null,
          "population_subgroup": "proximal M2 MCA",
          "comparison": "EVT vs medical management",
          "raw_text": "For proximal M2 MCA, the risk ratio was 0.9 (95% CI, 0.6–1.33)"
        },
        {
          "metric_type": "median",
          "value": 8,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "NIHSS score at presentation",
          "population_subgroup": null,
          "comparison": null,
          "raw_text": "median NIHSS score of 8, compared with the median NIHSS score of 15 in the patients included in the previous meta-analysis"
        },
        {
          "metric_type": "median",
          "value": 359,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "time from onset to recanalization (minutes)",
          "population_subgroup": null,
          "comparison": null,
          "raw_text": "median time from onset to recanalization of 359 minutes, as compared with 241 minutes in the ESCAPE trial"
        },
        {
          "metric_type": "percentage",
          "value": 58,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "received IVT",
          "population_subgroup": null,
          "comparison": null,
          "raw_text": "Both allowed treatment with IVT, with 65% receiving this treatment in DISTAL and 58% in ESCAPE-MeVO."
        },
        {
          "metric_type": "median",
          "value": 7,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "presentation NIHSS",
          "population_subgroup": null,
          "comparison": null,
          "raw_text": "Presentation NIHSS values were generally low, with median values of 6 and 7."
        },
        {
          "metric_type": "percentage",
          "value": 42,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "90-day mRS 0-1",
          "population_subgroup": null,
          "comparison": "EVT vs medical management",
          "raw_text": "Both trials failed to demonstrate improved outcomes with endovascular therapy relative to medical management for 90-day mRS scores 0 to 1 (EVT versus medical management: 35% vs 38%, DISTAL; 42% versus 43%, ESCAPE-MeVO)."
        },
        {
          "metric_type": "HR",
          "value": 1.82,
          "ci_95_lower": 1.06,
          "ci_95_upper": 3.12,
          "p_value": null,
          "outcome": "mortality",
          "population_subgroup": "stent-retriever first pass",
          "comparison": "EVT vs medical management",
          "raw_text": "ESCAPE-MeVO using stent-retrievers for first pass suggested harm with EVT, as mortality was significantly greater (HR, 1.82 [95% CI, 1.06–3.12])"
        }
      ],
      "metric_count": 7
    },
    "ESCAPE-NA1": {
      "trial_name": "ESCAPE-NA1",
      "full_name": null,
      "category": "Neuroprotective Agents",
      "sections_referenced": [
        "4.11"
      ],
      "metrics": [
        {
          "metric_type": null,
          "value": null,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "primary outcome",
          "population_subgroup": null,
          "comparison": "nerinetide vs placebo",
          "raw_text": "In a phase 3 trial, there was no difference in the primary outcome, although subgroup analysis showed potential for an effect in selected patients"
        }
      ],
      "metric_count": 1
    },
    "EXIT-BT": {
      "trial_name": "EXIT-BT",
      "full_name": null,
      "category": "IVT extended window",
      "sections_referenced": [
        "4.6.3"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "EXTEND": {
      "trial_name": "EXTEND",
      "full_name": "Extending the Time for Thrombolysis in Emergency Neurological Deficits",
      "category": "IVT extended window",
      "sections_referenced": [
        "3.2",
        "4.6.3"
      ],
      "metrics": [
        {
          "metric_type": "percentage",
          "value": 35.4,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "mRS 0-1 at 90 days",
          "population_subgroup": null,
          "comparison": "alteplase vs placebo",
          "raw_text": "improvement in mRS score 0 to 1 at 90 days (35.4% versus 29.5%; adjusted risk ratio, 1.44 [95% CI, 1.01–2.06]; P=0.04)"
        },
        {
          "metric_type": "aRR",
          "value": 1.44,
          "ci_95_lower": 1.01,
          "ci_95_upper": 2.06,
          "p_value": 0.04,
          "outcome": "mRS 0-1 at 90 days",
          "population_subgroup": null,
          "comparison": "alteplase vs placebo",
          "raw_text": "adjusted risk ratio, 1.44 [95% CI, 1.01–2.06]; P=0.04"
        },
        {
          "metric_type": "percentage",
          "value": 6.2,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "sICH",
          "population_subgroup": null,
          "comparison": "alteplase vs placebo",
          "raw_text": "increased risk of sICH (6.2% versus 0.9%; adjusted risk ratio, 7.22 [95% CI, 0.97–53.5]; P=0.05)"
        },
        {
          "metric_type": "aRR",
          "value": 7.22,
          "ci_95_lower": 0.97,
          "ci_95_upper": 53.5,
          "p_value": 0.05,
          "outcome": "sICH",
          "population_subgroup": null,
          "comparison": "alteplase vs placebo",
          "raw_text": "adjusted risk ratio, 7.22 [95% CI, 0.97–53.5]; P=0.05"
        },
        {
          "metric_type": "time window",
          "value": [
            4.5,
            9
          ],
          "unit": "hours",
          "outcome": "IVT 4.5–9 hours from last known well",
          "raw_text": "4.5–9 hours from last known well",
          "source": "footnote"
        },
        {
          "metric_type": "time window",
          "value": [
            4.5,
            24
          ],
          "unit": "hours",
          "outcome": "IVT 4.5 to 24 hours from symptom onset or last known well",
          "raw_text": "4.5 to 24 hours from symptom onset or last known well",
          "source": "footnote"
        }
      ],
      "metric_count": 6
    },
    "EXTEND-IA": {
      "trial_name": "EXTEND-IA",
      "full_name": "Extending the Time for Thrombolysis in Emergency Neurological Deficits–Intra-Arterial",
      "category": "EVT standard window",
      "sections_referenced": [
        "2.9",
        "3.2",
        "4.3",
        "4.6.2",
        "4.7.1"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "FOOD": {
      "trial_name": "FOOD",
      "full_name": null,
      "category": "Other",
      "sections_referenced": [
        "5.3"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "FOOD 1": {
      "trial_name": "FOOD 1",
      "full_name": "Feed Or Ordinary Diet",
      "category": "Other",
      "sections_referenced": [
        "5.3"
      ],
      "metrics": [
        {
          "metric_type": null,
          "value": null,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "primary outcomes (mRS <3; all-cause death)",
          "population_subgroup": "patients without swallowing dysfunction",
          "comparison": "nutritional supplements + normal diet vs normal diet alone",
          "raw_text": "The FOOD 1 trial1 showed that the addition of nutritional supplements alongside a normal hospital diet offers no additional benefit to patients without dysphagia."
        },
        {
          "metric_type": null,
          "value": null,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "primary outcomes (mRS <3; all-cause death)",
          "population_subgroup": "patients without swallowing dysfunction",
          "comparison": "nutritional supplements vs no supplements",
          "raw_text": "The study found no difference in primary outcomes (mRS <3; all-cause death) between use of supplements versus no supplements in these patients."
        }
      ],
      "metric_count": 2
    },
    "FOOD 2": {
      "trial_name": "FOOD 2",
      "full_name": "Feed Or Ordinary Diet",
      "category": "Other",
      "sections_referenced": [
        "5.3"
      ],
      "metrics": [
        {
          "metric_type": "absolute risk reduction",
          "value": null,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": 0.09,
          "outcome": "death",
          "population_subgroup": "patients with dysphagia who require tube feeding",
          "comparison": "early enteral feeding (within 7 days) vs withholding nutrition for at least 7 days",
          "raw_text": "FOOD 21 trial demonstrated a trend toward improved outcomes with institution of early nutrition within the first 7 days of hospitalization for patients requiring tube feedings."
        },
        {
          "metric_type": "absolute risk reduction",
          "value": null,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": 0.09,
          "outcome": "death",
          "population_subgroup": "patients with dysphagia who require tube feeding",
          "comparison": "early enteral feeding (within 7 days) vs withholding nutrition for at least 7 days",
          "raw_text": "finding a trend (P=0.09) in the absolute risk reduction of death when enteral feeding was commenced within 7 days of admission in patients with dysphagia who require tube feeding."
        }
      ],
      "metric_count": 2
    },
    "FOOD 3": {
      "trial_name": "FOOD 3",
      "full_name": "Feed Or Ordinary Diet",
      "category": "Other",
      "sections_referenced": [
        "5.3"
      ],
      "metrics": [
        {
          "metric_type": "absolute risk",
          "value": null,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "death and/or poor outcome",
          "population_subgroup": null,
          "comparison": "early percutaneous gastrostomy tube placement vs nasogastric feeding tube placement",
          "raw_text": "The FOOD 31 trial showed that early percutaneous gastrostomy tube insertion was not beneficial compared with nasogastric tube management."
        },
        {
          "metric_type": "absolute risk",
          "value": null,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "death and/or poor outcome",
          "population_subgroup": null,
          "comparison": "early percutaneous gastrostomy tube placement vs nasogastric feeding tube placement",
          "raw_text": "FOOD 3 found an increased absolute risk for death and/or poor outcome in patients with early percutaneous gastrostomy tube placement compared with nasogastric feeding tube placement."
        }
      ],
      "metric_count": 2
    },
    "GARFIELD-AF REGISTRY": {
      "trial_name": "GARFIELD-AF registry",
      "full_name": null,
      "category": "Antiplatelet therapy",
      "sections_referenced": [
        "4.8"
      ],
      "metrics": [
        {
          "metric_type": "aHR",
          "value": 1.49,
          "ci_95_lower": 1.01,
          "ci_95_upper": 2.2,
          "p_value": null,
          "outcome": "incidence rates of stroke",
          "population_subgroup": null,
          "comparison": "anticoagulation plus antiplatelet therapy vs anticoagulation monotherapy",
          "raw_text": "patients treated with anticoagulation plus antiplatelet therapy had significantly higher incidence rates of stroke (adjusted HR, 1.49 [95% CI, 1.01–2.20])"
        },
        {
          "metric_type": "aHR",
          "value": 1.41,
          "ci_95_lower": 1.17,
          "ci_95_upper": 1.7,
          "p_value": null,
          "outcome": "any bleeding event",
          "population_subgroup": null,
          "comparison": "anticoagulation plus antiplatelet therapy vs anticoagulation monotherapy",
          "raw_text": "any bleeding event (adjusted HR, 1.41 [95% CI, 1.17–1.70])"
        }
      ],
      "metric_count": 2
    },
    "GWDG": {
      "trial_name": "GWDG",
      "full_name": null,
      "category": "Prehospital/systems of care",
      "sections_referenced": [
        "2.10"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "GWTG": {
      "trial_name": "GWTG",
      "full_name": "Get With The Guidelines-Stroke registry",
      "category": "IVT standard window",
      "sections_referenced": [
        "4.6.5"
      ],
      "metrics": [
        {
          "metric_type": null,
          "value": null,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "safety or outcomes after IV alteplase",
          "population_subgroup": "patients with sickle cell disease vs those without",
          "comparison": "IV alteplase in sickle cell disease vs non-sickle cell disease",
          "raw_text": "A GWTG observational study of patients with sickle cell disease compared with those without demonstrated no dif­ference in safety or outcomes after IV alteplase."
        },
        {
          "metric_type": null,
          "value": null,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "complications or discharge outcome after treatment with IV alteplase",
          "population_subgroup": "sickle cell disease vs matched controls",
          "comparison": "IV alteplase in sickle cell disease vs matched controls",
          "raw_text": "A case-control analysis using the population from the AHA GWTG-Stroke registry, including 832 adult cases with sickle cell disease and 3328 age-, sex-, and race-matched controls without sickle cell disease with similar severity of neurological deficits at presentation, showed that sickle cell disease was not associated with worsened complications or dis­charge outcome after treatment with IV alteplase."
        }
      ],
      "metric_count": 2
    },
    "GWTG-STROKE": {
      "trial_name": "GWTG-Stroke",
      "full_name": "Get With The Guidelines-Stroke",
      "category": "Other",
      "sections_referenced": [
        "2.10"
      ],
      "metrics": [
        {
          "metric_type": null,
          "value": 732,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "greater reductions in mortality at 30 days and 1 year and higher rates of discharge to home",
          "population_subgroup": "patients treated at registry hospitals",
          "comparison": "registry hospitals vs nonparticipating hospitals",
          "raw_text": "A comparison study of 732 hospitals that were matched according to whether they participated in the GWTG-Stroke registry or not found that patients treated at registry hospitals had greater reductions in mortality at 30 days and 1 year and higher rates of discharge to home compared with patients treated at nonparticipating hospitals.7"
        }
      ],
      "metric_count": 1
    },
    "HAMLET": {
      "trial_name": "HAMLET",
      "full_name": "Hemicraniectomy after Middle Cerebral Artery Infarction with Life-threatening Edema Trial",
      "category": "Complications management",
      "sections_referenced": [
        "6.3"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "HEADDFIRST": {
      "trial_name": "HeADDFIRST",
      "full_name": "Hemicraniectomy and Durotomy Upon Deterioration From Infarction-Related Swelling Trial",
      "category": "Complications management",
      "sections_referenced": [
        "6.3"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "HEADPOST": {
      "trial_name": "HeadPoST",
      "full_name": "International Head Positioning in acute Stroke Trial",
      "category": "Other",
      "sections_referenced": [
        "4.1",
        "4.2"
      ],
      "metrics": [
        {
          "metric_type": "aOR",
          "value": 1.19,
          "ci_95_lower": 0.95,
          "ci_95_upper": 1.48,
          "p_value": null,
          "outcome": "death or dependency",
          "population_subgroup": "SpO2 <93% vs SpO2 ≥93%",
          "comparison": "hypoxia vs non-hypoxia",
          "raw_text": "patients with hypoxia (SpO2 <93%) did not have a significantly higher odds of death or dependency (55.6% versus 40.0%; aOR, 1.19 [95% CI, 0.95–1.48])"
        },
        {
          "metric_type": "aOR",
          "value": 1.34,
          "ci_95_lower": 1.07,
          "ci_95_upper": 1.38,
          "p_value": null,
          "outcome": "serious adverse events (SAEs)",
          "population_subgroup": null,
          "comparison": "per unit decrease in SpO2",
          "raw_text": "there was a significant association of SpO2 and SAEs, with a decrease in SAEs as SpO2 increased (aOR, 1.34 [95% CI, 1.07–1.38])"
        },
        {
          "metric_type": null,
          "value": null,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "distribution of mRS scores at 90 days",
          "population_subgroup": null,
          "comparison": "flat-head (0 degrees) vs elevated head (≥30 degrees) position",
          "raw_text": "The distribution of mRS scores at 90 days did not differ between the groups."
        },
        {
          "metric_type": null,
          "value": null,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "pneumonia rates",
          "population_subgroup": null,
          "comparison": "flat-head (0 degrees) vs elevated head (≥30 degrees) position",
          "raw_text": "rates of pneumonia did not differ between the 2 groups"
        }
      ],
      "metric_count": 4
    },
    "HEMMI": {
      "trial_name": "HeMMI",
      "full_name": "Hemicraniectomy for Malignant Middle cerebral Artery Infarction",
      "category": "Complications management",
      "sections_referenced": [
        "6.3"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "HERMES": {
      "trial_name": "HERMES",
      "full_name": "Highly Effective Reperfusion Evaluated in Multiple Endovascular Stroke Trials",
      "category": "EVT standard window",
      "sections_referenced": [
        "3.2",
        "4.7.1",
        "4.7.2",
        "4.7.4"
      ],
      "metrics": [
        {
          "metric_type": "cOR",
          "value": 2.95,
          "ci_95_lower": 1.38,
          "ci_95_upper": 6.32,
          "p_value": null,
          "outcome": "emergent revascularization with EVT benefit over medical management in tandem occlusions",
          "population_subgroup": "tandem occlusions",
          "comparison": "EVT vs medical management",
          "raw_text": "emergent revascularization with EVT demonstrated a significant benefit over medical management in this subgroup (cOR, 2.95 [95% CI, 1.38–6.32])"
        },
        {
          "metric_type": "cOR",
          "value": 2.79,
          "ci_95_lower": 1.96,
          "ci_95_upper": 3.98,
          "p_value": null,
          "outcome": "better disability outcomes at 90 days (mRS score distribution)",
          "population_subgroup": "3 hours from symptom onset to expected arterial puncture",
          "comparison": "EVT vs control",
          "raw_text": "At 3 hours, the cOR was 2.79 (95% CI, 1.96–3.98), with an absolute risk difference (ARD) of 39.2% for lower disability scores."
        },
        {
          "metric_type": "cOR",
          "value": 1.98,
          "ci_95_lower": 1.3,
          "ci_95_upper": 3.0,
          "p_value": null,
          "outcome": "better disability outcomes at 90 days (mRS score distribution)",
          "population_subgroup": "6 hours from symptom onset to expected arterial puncture",
          "comparison": "EVT vs control",
          "raw_text": "At 6 hours, the cOR was 1.98 (95% CI, 1.30–3.00), and the ARD was 30.2%"
        },
        {
          "metric_type": "cOR",
          "value": 1.57,
          "ci_95_lower": 0.86,
          "ci_95_upper": 2.88,
          "p_value": null,
          "outcome": "better disability outcomes at 90 days (mRS score distribution)",
          "population_subgroup": "8 hours from symptom onset to expected arterial puncture",
          "comparison": "EVT vs control",
          "raw_text": "At 8 hours, the cOR was 1.57 (95% CI, 0.86–2.88), with an ARD of 15.7%."
        },
        {
          "metric_type": "cOR",
          "value": 0.84,
          "ci_95_lower": 0.76,
          "ci_95_upper": 0.93,
          "p_value": null,
          "outcome": "less favorable degree of disability",
          "population_subgroup": "patients who achieved substantial reperfusion with EVT; per 1-hour delay to reperfusion",
          "comparison": "per hour delay",
          "raw_text": "each 1-hour delay to reperfusion was associated with a less favorable degree of disability (cOR, 0.84 [95% CI, 0.76–0.93]; ARD, −6.7%)"
        },
        {
          "metric_type": "OR",
          "value": 0.81,
          "ci_95_lower": 0.71,
          "ci_95_upper": 0.92,
          "p_value": null,
          "outcome": "less functional independence",
          "population_subgroup": "patients who achieved substantial reperfusion with EVT; per 1-hour delay to reperfusion",
          "comparison": "per hour delay",
          "raw_text": "less functional independence (OR, 0.81 [95% CI, 0.71–0.92]; ARD, −5.2% [95% CI, −8.3 to −2.1])"
        },
        {
          "metric_type": "OR",
          "value": 1.12,
          "ci_95_lower": 0.93,
          "ci_95_upper": 1.34,
          "p_value": null,
          "outcome": "mortality",
          "population_subgroup": "patients who achieved substantial reperfusion with EVT; per 1-hour delay to reperfusion",
          "comparison": "per hour delay",
          "raw_text": "no change in mortality (OR, 1.12 [95% CI, 0.93–1.34]; ARD, 1.5% [95% CI, −0.9 to 4.2])"
        },
        {
          "metric_type": "cOR",
          "value": 3.68,
          "ci_95_lower": 1.95,
          "ci_95_upper": 6.92,
          "p_value": null,
          "outcome": "favorable effect of EVT over standard care",
          "population_subgroup": "patients ≥80 years of age",
          "comparison": "EVT vs standard care",
          "raw_text": "The HERMES pooled patient-level analysis indicated a favorable effect of EVT over standard care, even in patients ≥80 years of age (cOR, 3.68 [95% CI, 1.95–6.92])"
        },
        {
          "metric_type": "cOR",
          "value": 2.08,
          "ci_95_lower": 1.22,
          "ci_95_upper": 3.55,
          "p_value": null,
          "outcome": "significant benefit from EVT",
          "population_subgroup": "prestroke mRS 1-2",
          "comparison": "EVT vs conservative management",
          "raw_text": "A subsequent HERMES meta-analysis pooled data from 7 RCTs (n=1764), including 199 participants with a prestroke mRS score of 1 to 2, demonstrated a significant benefit from EVT in this subgroup (cOR, 2.08 [95% CI; 1.22–3.55])"
        },
        {
          "metric_type": "aOR",
          "value": 2.39,
          "ci_95_lower": 1.08,
          "ci_95_upper": 5.28,
          "p_value": 0.03,
          "outcome": "90-day mRS score of 0 to 2",
          "population_subgroup": "M2 occlusions",
          "comparison": "EVT vs control",
          "raw_text": "EVT was favorable in patients with M2 occlusions (adjusted OR, 2.39 [95% CI, 1.08–5.28]; P=0.03) for a 90-day mRS score of 0 to 2 (58.2% EVT versus 39.7% control)"
        },
        {
          "metric_type": "percentage",
          "value": 58.2,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "90-day mRS score of 0 to 2",
          "population_subgroup": "M2 occlusions",
          "comparison": "EVT",
          "raw_text": "58.2% EVT versus 39.7% control"
        },
        {
          "metric_type": "percentage",
          "value": 71,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "successful reperfusion to mTICI grade 2b/3",
          "population_subgroup": null,
          "comparison": null,
          "raw_text": "In the HERMES collaboration, 402 of 570 patients (71%) were successfully reperfused to mTICI grade 2b/3."
        },
        {
          "metric_type": "RR",
          "value": 1.81,
          "ci_95_lower": 0.96,
          "ci_95_upper": 3.4,
          "p_value": null,
          "outcome": "benefit for EVT in tandem occlusion",
          "population_subgroup": "tandem occlusion",
          "comparison": "EVT vs medical management",
          "raw_text": "In the HERMES meta-analysis, 122 of 1254 patients (risk ratio, 1.81 [95% CI, 0.96–3.4])"
        }
      ],
      "metric_count": 13
    },
    "HOPES-2": {
      "trial_name": "HOPES-2",
      "full_name": "Hospitalized Stroke Patients 90-day Outcomes trial",
      "category": "Other",
      "sections_referenced": [
        "4.2"
      ],
      "metrics": [
        {
          "metric_type": "OR",
          "value": 2.05,
          "ci_95_lower": 0.87,
          "ci_95_upper": 4.82,
          "p_value": 0.09,
          "outcome": "mRS score, 0–2 at 90 days",
          "population_subgroup": null,
          "comparison": "head-down (–20 degrees, Trendelenburg) vs 0- to 30-degree head positioning",
          "raw_text": "The primary outcome (mRS score, 0–2) at 90 days was not improved in the head-down position (OR, 2.05 [95% CI, 0.87–4.82]; P=0.09)."
        },
        {
          "metric_type": "OR",
          "value": -0.15,
          "ci_95_lower": -0.25,
          "ci_95_upper": -0.05,
          "p_value": 0.004,
          "outcome": "change from baseline NIHSS score to day 12",
          "population_subgroup": null,
          "comparison": "head-down (–20 degrees, Trendelenburg) vs 0- to 30-degree head positioning",
          "raw_text": "change from baseline NIHSS score to day 12 (OR, –0.15 [95% CI, –0.25 to –0.05]; P=0.004)"
        },
        {
          "metric_type": "OR",
          "value": 2.66,
          "ci_95_lower": 1.1,
          "ci_95_upper": 6.44,
          "p_value": 0.03,
          "outcome": "mRS score 0 to 1 at 90 days",
          "population_subgroup": null,
          "comparison": "head-down (–20 degrees, Trendelenburg) vs 0- to 30-degree head positioning",
          "raw_text": "mRS score 0 to 1 at 90 days (OR, 2.66 [95% CI, 1.10–6.44]; P=0.03)"
        },
        {
          "metric_type": "OR",
          "value": 2.7,
          "ci_95_lower": 1.17,
          "ci_95_upper": 5.72,
          "p_value": 0.01,
          "outcome": "90-day ordinal-shift analysis",
          "population_subgroup": null,
          "comparison": "head-down (–20 degrees, Trendelenburg) vs 0- to 30-degree head positioning",
          "raw_text": "90-day ordinal-shift analysis (OR, 2.7 [95% CI, 1.17–5.72]; P=0.01)"
        },
        {
          "metric_type": null,
          "value": null,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "complication rates and mortality",
          "population_subgroup": null,
          "comparison": "head-down (–20 degrees, Trendelenburg) vs 0- to 30-degree head positioning",
          "raw_text": "There was no difference in complication rates and mortality between the groups."
        }
      ],
      "metric_count": 5
    },
    "IMPROVE": {
      "trial_name": "IMPROVE",
      "full_name": "Initiative to Maximize Progress in Optimized Vascular Events",
      "category": "Prehospital/systems of care",
      "sections_referenced": [
        "2.2"
      ],
      "metrics": [
        {
          "metric_type": null,
          "value": null,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "improving the delivery of thrombolytic treatment at both spoke and hub sites in the network",
          "population_subgroup": null,
          "comparison": null,
          "raw_text": "the IMPROVE (Initiative to Maximize Progress in Optimized Vascular Events) Stroke Care program, which aimed to improve a regional system of care within comprehensive stroke net­works, including a QI program, was successful at improving the delivery of thrombolytic treatment at both spoke and hub sites in the network and identi­fied opportunities for continuous QI."
        }
      ],
      "metric_count": 1
    },
    "INDIVIDUAL PATIENT DATA META-ANALYSIS OF CADISS AND TREAT-CAD": {
      "trial_name": "individual patient data meta-analysis of CADISS and TREAT-CAD",
      "full_name": null,
      "category": "Antiplatelet therapy",
      "sections_referenced": [
        "4.8"
      ],
      "metrics": [
        {
          "metric_type": "OR",
          "value": 0.33,
          "ci_95_lower": 0.08,
          "ci_95_upper": 1.05,
          "p_value": 0.06,
          "outcome": "primary endpoints",
          "population_subgroup": null,
          "comparison": "anticoagulation vs antiplatelet",
          "raw_text": "fewer primary endpoints in the anticoagulation group versus the antiplatelet group (1.4% versus 4.4%; OR, 0.33 [95% CI, 0.08–1.05]; P=0.06)"
        },
        {
          "metric_type": "OR",
          "value": 0.14,
          "ci_95_lower": 0.02,
          "ci_95_upper": 0.61,
          "p_value": 0.01,
          "outcome": "ischemic stroke",
          "population_subgroup": null,
          "comparison": "anticoagulation vs antiplatelet",
          "raw_text": "anticoagulation was associated with fewer ischemic strokes (0.5% versus 4.0%; OR, 0.14 [95% CI, 0.02–0.61]; P=0.01)"
        }
      ],
      "metric_count": 2
    },
    "INSPIRES": {
      "trial_name": "INSPIRES",
      "full_name": null,
      "category": "Antiplatelet therapy",
      "sections_referenced": [
        "4.8"
      ],
      "metrics": [
        {
          "metric_type": "HR",
          "value": 0.79,
          "ci_95_lower": 0.66,
          "ci_95_upper": 0.94,
          "p_value": "0.008",
          "outcome": "recurrent stroke at 90 days",
          "population_subgroup": "mild AIS or high-risk TIA of presumed atherosclerotic cause",
          "comparison": "DAPT (clopidogrel and aspirin) vs aspirin alone",
          "raw_text": "combined clopidogrel and aspirin therapy initiated within 72 hours after stroke onset was associated with a lower risk of recurrent stroke at 90 days than aspirin alone (7.3% versus 9.2%; HR, 0.79 [95% CI, 0.66–0.94]; P=0.008)"
        },
        {
          "metric_type": "HR",
          "value": 2.08,
          "ci_95_lower": 1.07,
          "ci_95_upper": 4.04,
          "p_value": "0.03",
          "outcome": "moderate-to-severe bleeding",
          "population_subgroup": null,
          "comparison": "DAPT vs aspirin alone",
          "raw_text": "was also associated with a higher risk of moderate-to-severe bleeding (0.9% versus 0.4%; HR, 2.08 [95% CI, 1.07–4.04]; P=0.03)"
        }
      ],
      "metric_count": 2
    },
    "INSTINCT": {
      "trial_name": "INSTINCT",
      "full_name": "INcreasing Stroke Treatment through Interactive behavioral Change Tactics",
      "category": "Prehospital/systems of care",
      "sections_referenced": [
        "2.7"
      ],
      "metrics": [
        {
          "metric_type": "percentage",
          "value": 1.0,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "alteplase use before intervention",
          "population_subgroup": null,
          "comparison": "before vs after intervention in intervention group hospitals",
          "raw_text": "alteplase use increased from 1.00% before intervention to 2.62% after intervention within the intervention group hospitals without safety concerns"
        }
      ],
      "metric_count": 1
    },
    "IST": {
      "trial_name": "IST",
      "full_name": "International Stroke Trial",
      "category": "Antiplatelet therapy",
      "sections_referenced": [
        "4.8"
      ],
      "metrics": [
        {
          "metric_type": "percentage",
          "value": 2.8,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": "<0.001",
          "outcome": "recurrent ischemic strokes within 14 days",
          "population_subgroup": null,
          "comparison": "aspirin vs control",
          "raw_text": "The aspirin group had significantly fewer recurrent ischemic strokes within 14 days (2.8% versus 3.9%; P<0.001)"
        },
        {
          "metric_type": "percentage",
          "value": 0.9,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "hemorrhagic strokes",
          "population_subgroup": null,
          "comparison": "aspirin vs control",
          "raw_text": "no difference in hemorrhagic strokes (0.9% versus 0.8%)"
        },
        {
          "metric_type": "percentage",
          "value": 11.3,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": "<0.05",
          "outcome": "death or recurrent stroke",
          "population_subgroup": null,
          "comparison": "aspirin vs control",
          "raw_text": "a significant reduction in death or recurrent stroke (11.3% versus 12.4%; P<0.05)"
        }
      ],
      "metric_count": 3
    },
    "LACI-2": {
      "trial_name": "LACI-2",
      "full_name": null,
      "category": "Other",
      "sections_referenced": [
        "4.10"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "LASTE": {
      "trial_name": "LASTE",
      "full_name": null,
      "category": "EVT large core",
      "sections_referenced": [
        "3.2",
        "4.7.2"
      ],
      "metrics": [
        {
          "metric_type": "percentage",
          "value": 13.3,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "functional independence at 90 days",
          "population_subgroup": "ASPECTS 0-2",
          "comparison": "EVT vs medical treatment",
          "raw_text": "In the population studied in LASTE, 13.3% achieved functional independence at 90 days after EVT, while only 7.5% did in the medical treatment group."
        }
      ],
      "metric_count": 1
    },
    "LI": {
      "trial_name": "Li",
      "full_name": null,
      "category": "Other",
      "sections_referenced": [
        "6.3"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "MEINEL ET AL": {
      "trial_name": "Meinel et al",
      "full_name": null,
      "category": "IVT standard window",
      "sections_referenced": [
        "4.6.5"
      ],
      "metrics": [
        {
          "metric_type": "risk",
          "value": "lower",
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "sICH",
          "population_subgroup": "DOAC-exposed group",
          "comparison": "DOAC-exposed vs unexposed patients receiving IVT",
          "raw_text": "the investigators found that patients from the DOAC-exposed group exhibited a lower risk of sICH than patients in the unexposed group"
        }
      ],
      "metric_count": 1
    },
    "META-ANALYSIS (2019 AIS GUIDELINE UPDATE)": {
      "trial_name": "meta-analysis (2019 AIS guideline update)",
      "full_name": null,
      "category": "Other",
      "sections_referenced": [
        "4.12"
      ],
      "metrics": [
        {
          "metric_type": "OR",
          "value": 1.57,
          "ci_95_lower": 1.3,
          "ci_95_upper": 1.9,
          "p_value": null,
          "outcome": "30-day stroke",
          "population_subgroup": null,
          "comparison": "carotid endarterectomy within 2 days vs days 3–14",
          "raw_text": "higher rates of 30-day stroke (OR, 1.57 [95% CI, 1.3–1.9])"
        },
        {
          "metric_type": "OR",
          "value": 5.19,
          "ci_95_lower": 4.1,
          "ci_95_upper": 6.6,
          "p_value": null,
          "outcome": "30-day death",
          "population_subgroup": null,
          "comparison": "carotid endarterectomy within 2 days vs days 3–14",
          "raw_text": "and death (OR, 5.19 [95% CI, 4.1–6.6])"
        }
      ],
      "metric_count": 2
    },
    "META-ANALYSIS (8 EXTENDED WINDOW THROMBOLYSIS PHASE 2 AND 3 TRIALS)": {
      "trial_name": "meta-analysis (8 extended window thrombolysis phase 2 and 3 trials)",
      "full_name": null,
      "category": "IVT extended window",
      "sections_referenced": [
        "4.6.3"
      ],
      "metrics": [
        {
          "metric_type": "OR",
          "value": 1.43,
          "ci_95_lower": 1.17,
          "ci_95_upper": 1.75,
          "p_value": null,
          "outcome": "excellent (mRS 0–1 at 90 days) outcome",
          "population_subgroup": null,
          "comparison": "IVT vs control",
          "raw_text": "IVT was associated with greater odds of excellent (mRS 0–1 at 90 days) outcome (OR, 1.43 [95% CI, 1.17–1.75])"
        },
        {
          "metric_type": "OR",
          "value": 4.25,
          "ci_95_lower": 1.67,
          "ci_95_upper": 10.84,
          "p_value": null,
          "outcome": "symptomatic hemorrhage",
          "population_subgroup": null,
          "comparison": "IVT vs control",
          "raw_text": "despite an increase in symptomatic hemorrhage (OR, 4.25 [95% CI, 1.67–10.84])"
        }
      ],
      "metric_count": 2
    },
    "META-ANALYSIS (EPITHET, ECASS-4, EXTEND)": {
      "trial_name": "meta-analysis (EPITHET, ECASS-4, EXTEND)",
      "full_name": null,
      "category": "IVT extended window",
      "sections_referenced": [
        "4.6.3"
      ],
      "metrics": [
        {
          "metric_type": "aOR",
          "value": 1.86,
          "ci_95_lower": 1.15,
          "ci_95_upper": 2.99,
          "p_value": 0.011,
          "outcome": "excellent functional outcomes (mRS 0–1 at 90 days)",
          "population_subgroup": ">4.5- to 9-hour window with salvageable ischemic penumbra on MR DWI-PWI or CTP imaging",
          "comparison": "IV alteplase vs placebo",
          "raw_text": "confirmed the benefit of IV alteplase with excellent functional outcomes (mRS score 0–1) at 90 days (adjusted OR, 1.86 [95% CI, 1.15–2.99]; P=0.011)"
        },
        {
          "metric_type": "aOR",
          "value": 9.7,
          "ci_95_lower": 1.23,
          "ci_95_upper": 76.55,
          "p_value": 0.031,
          "outcome": "symptomatic intracranial hemorrhage (sICH)",
          "population_subgroup": ">4.5- to 9-hour window with salvageable ischemic penumbra on MR DWI-PWI or CTP imaging",
          "comparison": "IV alteplase vs placebo",
          "raw_text": "despite an increase risk of sICH (adjusted OR, 9.7 [95% CI, 1.23–76.55]; P=0.031)"
        }
      ],
      "metric_count": 2
    },
    "META-ANALYSIS OF BEST, BASICS, ATTENTION, AND BAOCHE": {
      "trial_name": "Meta-analysis of BEST, BASICS, ATTENTION, and BAOCHE",
      "full_name": null,
      "category": "EVT posterior circulation",
      "sections_referenced": [
        "4.7.3"
      ],
      "metrics": [
        {
          "metric_type": "median",
          "value": 20,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "NIHSS",
          "population_subgroup": null,
          "comparison": null,
          "raw_text": "A meta-analysis of the 4 RCTs (BEST, BASICS, ATTENTION, and BAOCHE) showed the median NIHSS of ~20"
        }
      ],
      "metric_count": 1
    },
    "MOST": {
      "trial_name": "MOST",
      "full_name": "Multi-Arm Optimization of Stroke Thrombolysis",
      "category": "Antiplatelet therapy",
      "sections_referenced": [
        "4.8",
        "4.9"
      ],
      "metrics": [
        {
          "metric_type": "mean (SD)",
          "value": 5.2,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "utility-weighted mRS score at 90 days",
          "population_subgroup": "argatroban",
          "comparison": "argatroban vs eptifibatide vs placebo (all adjunctive to IVT)",
          "raw_text": "90 day mean [±SD] utility-weighted mRS scores were 5.2±3.7 with argatroban, 6.3±3.2 with eptifibatide, and 6.8±3.0 with placebo"
        },
        {
          "metric_type": "percentage",
          "value": 24,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "90-day mortality",
          "population_subgroup": "argatroban",
          "comparison": "argatroban vs eptifibatide vs placebo (all adjunctive to IVT)",
          "raw_text": "increased 90-day mortality (argatroban 24%, eptifibatide 12%, placebo 8%)"
        },
        {
          "metric_type": "mean",
          "value": 5.2,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "utility-weighed mRS score at 90 days",
          "population_subgroup": "argatroban-treated participants",
          "comparison": "argatroban vs placebo",
          "raw_text": "At 90 days, the mean utility-weighed mRS score was 5.2 in argatroban-treated participants and 6.8 in placebo-treated participants."
        },
        {
          "metric_type": "percentage",
          "value": 4,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "sICH",
          "population_subgroup": "argatroban group",
          "comparison": "argatroban vs placebo",
          "raw_text": "The proportion of participants with sICH was 4% in the argatroban group and 2% in the placebo group."
        }
      ],
      "metric_count": 4
    },
    "MR ASAP": {
      "trial_name": "MR ASAP",
      "full_name": null,
      "category": "Other",
      "sections_referenced": [
        "2.3"
      ],
      "metrics": [
        {
          "metric_type": "aOR",
          "value": 0.97,
          "ci_95_lower": 0.65,
          "ci_95_upper": 1.47,
          "p_value": null,
          "outcome": "mRS at 90 days",
          "population_subgroup": null,
          "comparison": "transdermal GTN vs standard care",
          "raw_text": "The primary outcome, mRS at 90 days, showed no sig­nificant difference between groups (adjusted com­mon odds ratio [OR], 0.97 [95% CI, 0.65–1.47])."
        },
        {
          "metric_type": "percentage",
          "value": 34,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "7-day mortality rate",
          "population_subgroup": "ICH",
          "comparison": "GTN vs standard care",
          "raw_text": "in patients with ICH, the GTN group had a higher 7-day mortality rate (34% versus 10%)"
        }
      ],
      "metric_count": 2
    },
    "MR CLEAN": {
      "trial_name": "MR CLEAN",
      "full_name": "Multicenter Randomized Clinical trial of Endovascular treatment for Acute ischemic stroke in the Netherlands",
      "category": "EVT standard window",
      "sections_referenced": [
        "2.9",
        "3.2",
        "4.3",
        "4.7.1",
        "4.7.2"
      ],
      "metrics": [
        {
          "metric_type": "count",
          "value": 45,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "enrolled patients with prestroke mRS score ≥2",
          "population_subgroup": "prestroke mRS ≥2",
          "comparison": null,
          "raw_text": "only MR CLEAN6 enrolled patients with a prestroke mRS score of ≥2 (n=45)"
        }
      ],
      "metric_count": 1
    },
    "MR CLEAN-NO IV": {
      "trial_name": "MR CLEAN-NO IV",
      "full_name": "Multicenter Randomized Clinical trial of Endovascular treatment for Acute ischemic stroke in the Netherlands – No Intravenous",
      "category": "EVT vs combined IVT+EVT",
      "sections_referenced": [
        "2.9"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "MR-CLEAN REGISTRY": {
      "trial_name": "MR-CLEAN Registry",
      "full_name": null,
      "category": "EVT M2/medium vessel",
      "sections_referenced": [
        "4.7.2"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "NATIONWIDE COHORT STUDY": {
      "trial_name": "nationwide cohort study",
      "full_name": null,
      "category": "IVT standard window",
      "sections_referenced": [
        "4.6.5"
      ],
      "metrics": [
        {
          "metric_type": "risk",
          "value": "not associated",
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "sICH",
          "population_subgroup": "patients with recent DOAC exposure",
          "comparison": "recent DOAC exposure vs no recent DOAC exposure among patients selected for IVT",
          "raw_text": "a nationwide cohort study7 found that, among patients selected for IVT in routine clinical practice, exposure to a DOAC within the 7 days preceding stroke onset was not associated with an elevated risk of sICH"
        },
        {
          "metric_type": "percentage",
          "value": 9.6,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "patients with recent DOAC exposure selected for IVT",
          "population_subgroup": "patients with recent DOAC exposure presenting with ischemic stroke within 3.5 hours",
          "comparison": "selected for IVT vs total with recent DOAC exposure",
          "raw_text": "Of 22 977 patients with recent DOAC exposure who pre­sented with ischemic stroke within 3.5 hours of time last known well ... only approximately 2207 were selected for IVT"
        },
        {
          "metric_type": "percentage",
          "value": 1.1,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "patients known to have taken a DOAC within 48 hours selected for IVT",
          "population_subgroup": "patients with recent DOAC exposure presenting with ischemic stroke within 3.5 hours",
          "comparison": "selected for IVT vs total with recent DOAC exposure",
          "raw_text": "of whom only 25 were known to have taken a DOAC within 48 hours of time last known well"
        }
      ],
      "metric_count": 3
    },
    "NCT05039697": {
      "trial_name": "NCT05039697",
      "full_name": null,
      "category": "Other",
      "sections_referenced": [
        "4.1"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "NCT05965687": {
      "trial_name": "NCT05965687",
      "full_name": null,
      "category": "Other",
      "sections_referenced": [
        "4.1"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "NCT06224426": {
      "trial_name": "NCT06224426",
      "full_name": null,
      "category": "Other",
      "sections_referenced": [
        "4.1"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "NINDS RT-PA": {
      "trial_name": "NINDS rt-PA",
      "full_name": "National Institute of Neurological Disorders and Stroke Recombinant Tissue-Type Plasminogen Activator trials",
      "category": "IVT standard window",
      "sections_referenced": [
        "3.2"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "NINDS RT-PA TRIAL": {
      "trial_name": "NINDS rt-PA trial",
      "full_name": "National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study",
      "category": "IVT standard window",
      "sections_referenced": [
        "4.6.1"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "NINDS TPA": {
      "trial_name": "NINDS tPA",
      "full_name": null,
      "category": "IVT standard window",
      "sections_referenced": [
        "4.6.3"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "NINDS TPA STUDY": {
      "trial_name": "NINDS tPA Study",
      "full_name": "National Institute of Neurological Disorders and Stroke Tissue Plasminogen Activator Study",
      "category": "IVT standard window",
      "sections_referenced": [
        "4.6.1"
      ],
      "metrics": [
        {
          "metric_type": "percent",
          "value": null,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "early ischemic changes did not modify treatment effect",
          "population_subgroup": null,
          "comparison": "IVT vs placebo",
          "raw_text": "Early ischemic changes of mild to moderate extent on CT scan did not modify the treatment effect of IVT in the NINDS tPA trial and therefore should not be considered a contraindication.21,22"
        },
        {
          "metric_type": "n",
          "value": 16,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "patients with ASPECTS 0 to 2",
          "population_subgroup": "ASPECTS 0 to 2",
          "comparison": null,
          "raw_text": "A large extent of hypodensity, such as ASPECTS 0 to 2, was rare (n=16) in the NINDS tPA Study."
        }
      ],
      "metric_count": 2
    },
    "NOR-SASS": {
      "trial_name": "NOR-SASS",
      "full_name": "Norwegian Sonothrombolysis in Acute Stroke Study",
      "category": "IVT alternative agents",
      "sections_referenced": [
        "4.6.4"
      ],
      "metrics": [
        {
          "metric_type": null,
          "value": null,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "neurological improvement at 24 hours and functional outcome at 90 days",
          "population_subgroup": null,
          "comparison": "sonothrombolysis vs sham",
          "raw_text": "Neurological improvement at 24 hours and functional outcome at 90 days were not statistically significantly different in the 2 groups, nor were the rates of sICH."
        }
      ],
      "metric_count": 1
    },
    "NOR-TEST 2": {
      "trial_name": "NOR-TEST 2",
      "full_name": "Norwegian Tenecteplase Stroke Trial 2",
      "category": "IVT alternative agents",
      "sections_referenced": [
        "4.6.2"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "OPENS-2": {
      "trial_name": "OPENS-2",
      "full_name": "Normobaric Hyperoxia Combined With Reperfusion for AIS",
      "category": "Other",
      "sections_referenced": [
        "4.1"
      ],
      "metrics": [
        {
          "metric_type": "median",
          "value": 2,
          "ci_95_lower": 1,
          "ci_95_upper": 4,
          "p_value": null,
          "outcome": "mRS score at 90 days",
          "population_subgroup": "NBO group",
          "comparison": "NBO vs sham NBO",
          "raw_text": "The median mRS score for the NBO group was 2 (IQR, 1–4) and was 3 (IQR, 1–4) in the sham NBO group"
        },
        {
          "metric_type": "cOR",
          "value": 1.65,
          "ci_95_lower": 1.09,
          "ci_95_upper": 2.5,
          "p_value": 0.018,
          "outcome": "ordinal mRS at 90 days",
          "population_subgroup": null,
          "comparison": "NBO vs sham NBO",
          "raw_text": "adjusted cOR, 1.65 [95% CI, 1.09–2.50]; P=0.018"
        }
      ],
      "metric_count": 2
    },
    "OPTIMAL-BP": {
      "trial_name": "OPTIMAL-BP",
      "full_name": null,
      "category": "Blood pressure management",
      "sections_referenced": [
        "4.3"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "OPTIMAS": {
      "trial_name": "OPTIMAS",
      "full_name": "Optimal Timing of Anticoagulation After AIS with Atrial Fibrillation",
      "category": "Anticoagulation",
      "sections_referenced": [
        "4.9"
      ],
      "metrics": [
        {
          "metric_type": "noninferiority",
          "value": null,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "primary outcome",
          "population_subgroup": null,
          "comparison": "early DOAC therapy vs delayed DOAC therapy",
          "raw_text": "Early DOAC therapy was noninferior to delayed DOAC therapy."
        }
      ],
      "metric_count": 1
    },
    "OPTIMIST": {
      "trial_name": "OPTIMIST",
      "full_name": "Optimal Post Tpa-Iv Monitoring in Ischemic Stroke",
      "category": "IVT standard window",
      "sections_referenced": [
        "4.6.1"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "OPTIMIST MAIN": {
      "trial_name": "OPTIMIST MAIN",
      "full_name": null,
      "category": "IVT standard window",
      "sections_referenced": [
        "4.6.1"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "ORIGINAL": {
      "trial_name": "ORIGINAL",
      "full_name": null,
      "category": "IVT alternative agents",
      "sections_referenced": [
        "4.6.2"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "PASS": {
      "trial_name": "PASS",
      "full_name": "Preventive Antibiotics in Stroke Study",
      "category": "Complications management",
      "sections_referenced": [
        "5.6"
      ],
      "metrics": [
        {
          "metric_type": "adjusted cOR",
          "value": 0.95,
          "ci_95_lower": 0.82,
          "ci_95_upper": 1.09,
          "p_value": 0.46,
          "outcome": "distribution of functional outcome scores on the mRS score at 3 months",
          "population_subgroup": null,
          "comparison": "preventive antimicrobial therapy vs standard care",
          "raw_text": "PASS (Preventive Antibiotics in Stroke Study) trial showed no difference in the primary endpoint of distribution of functional outcome scores on the mRS score at 3 months (adjusted cOR, 0.95 [95% CI, 0.82–1.09]; P=0.46)"
        },
        {
          "metric_type": "OR",
          "value": 0.57,
          "ci_95_lower": 0.38,
          "ci_95_upper": 0.85,
          "p_value": 0.005,
          "outcome": "incidence of infection",
          "population_subgroup": null,
          "comparison": "preventive antimicrobial therapy vs standard care",
          "raw_text": "despite an overall reduction in the incidence of infection (OR, 0.57 [95% CI, 0.38–0.85]; P=0.005)"
        },
        {
          "metric_type": "OR",
          "value": 0.34,
          "ci_95_lower": 0.26,
          "ci_95_upper": 0.46,
          "p_value": "<0.001",
          "outcome": "number of UTIs",
          "population_subgroup": null,
          "comparison": "preventive antimicrobial therapy vs standard care",
          "raw_text": "including reducing the number of UTIs (OR, 0.34 [95% CI, 0.26–0.46]; P<0.001)"
        },
        {
          "metric_type": "OR",
          "value": 0.91,
          "ci_95_lower": 0.73,
          "ci_95_upper": 1.13,
          "p_value": 0.385,
          "outcome": "rate of poststroke pneumonia",
          "population_subgroup": null,
          "comparison": "preventive antimicrobial therapy vs standard care",
          "raw_text": "but no significant decrease in the rate of poststroke pneumonia (OR, 0.91 [95% CI, 0.73–1.13]; P=0.385)"
        }
      ],
      "metric_count": 4
    },
    "PEDNIHSS": {
      "trial_name": "PedNIHSS",
      "full_name": null,
      "category": "Imaging",
      "sections_referenced": [
        "2.10"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "PICASSO": {
      "trial_name": "PICASSO",
      "full_name": null,
      "category": "Other",
      "sections_referenced": [
        "4.7.4"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "POINT": {
      "trial_name": "POINT",
      "full_name": "Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke",
      "category": "Antiplatelet therapy",
      "sections_referenced": [
        "4.8"
      ],
      "metrics": [
        {
          "metric_type": "HR",
          "value": 0.75,
          "ci_95_lower": 0.59,
          "ci_95_upper": 0.95,
          "p_value": "0.02",
          "outcome": "composite primary endpoint (ischemic stroke, MI, or vascular death) within 90 days",
          "population_subgroup": null,
          "comparison": "DAPT (clopidogrel plus aspirin) vs aspirin alone",
          "raw_text": "DAPT resulted in fewer ischemic events (5% versus 6.5%; HR, 0.75 [95% CI, 0.59–0.95]; P=0.02)"
        },
        {
          "metric_type": "HR",
          "value": 2.32,
          "ci_95_lower": 1.1,
          "ci_95_upper": 4.87,
          "p_value": "0.02",
          "outcome": "major hemorrhages",
          "population_subgroup": null,
          "comparison": "DAPT vs aspirin alone",
          "raw_text": "but more major hemorrhages (0.9% versus 0.4%; HR, 2.32 [95% CI, 1.10–4.87]; P=0.02)"
        },
        {
          "metric_type": "OR",
          "value": 0.97,
          "ci_95_lower": 0.82,
          "ci_95_upper": 1.14,
          "p_value": "0.69",
          "outcome": "disability at 90 days",
          "population_subgroup": null,
          "comparison": "DAPT vs aspirin alone",
          "raw_text": "no significant difference in disability at 90 days seen in POINT (14.3% versus 14.7%; OR, 0.97 [95% CI, 0.82–1.14]; P=0.69)"
        },
        {
          "metric_type": "HR",
          "value": 0.65,
          "ci_95_lower": 0.5,
          "ci_95_upper": 0.85,
          "p_value": "0.0015",
          "outcome": "ischemic events 0–21 days",
          "population_subgroup": null,
          "comparison": "DAPT vs aspirin alone",
          "raw_text": "DAPT versus aspirin 0–21 days HR, 0.65 [95% CI, 0.50–0.85]; P=0.0015"
        },
        {
          "metric_type": "HR",
          "value": 1.38,
          "ci_95_lower": 0.81,
          "ci_95_upper": 2.35,
          "p_value": "0.24",
          "outcome": "ischemic events 22–90 days",
          "population_subgroup": null,
          "comparison": "DAPT vs aspirin alone",
          "raw_text": "versus 22–90 days HR, 1.38 [95% CI, 0.81–2.35]; P=0.24"
        }
      ],
      "metric_count": 5
    },
    "POOLED ANALYSIS OF SPORTIF III AND SPORTIF IV": {
      "trial_name": "pooled analysis of SPORTIF III and SPORTIF IV",
      "full_name": null,
      "category": "Antiplatelet therapy",
      "sections_referenced": [
        "4.8"
      ],
      "metrics": [
        {
          "metric_type": "percentage",
          "value": 1.5,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "major bleeding",
          "population_subgroup": "warfarin",
          "comparison": "warfarin vs warfarin plus aspirin",
          "raw_text": "higher rates of major bleeding in either anticoagulant arm (1.5%/year with warfarin versus 4.95%/year with warfarin plus aspirin; P=0.004)"
        },
        {
          "metric_type": "percentage",
          "value": 2.35,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "major bleeding",
          "population_subgroup": "ximelagatran",
          "comparison": "ximelagatran vs ximelagatran plus aspirin",
          "raw_text": "and 2.35%/year with ximelagatran and 5.09%/year versus ximelagatran plus aspirin; P=0.046"
        }
      ],
      "metric_count": 2
    },
    "POSITIVE": {
      "trial_name": "POSITIVE",
      "full_name": "Perfusion imaging selection of ischemic stroke patients for endovascular therapy",
      "category": "Imaging",
      "sections_referenced": [
        "4.7.2"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "POST-TNK": {
      "trial_name": "POST-TNK",
      "full_name": null,
      "category": "EVT technique",
      "sections_referenced": [
        "4.7.4"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "POST-UK": {
      "trial_name": "POST-UK",
      "full_name": null,
      "category": "EVT technique",
      "sections_referenced": [
        "4.7.4"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "PRACTISE": {
      "trial_name": "PRACTISE",
      "full_name": "PRomoting ACute Thrombolysis in Ischemic StrokE",
      "category": "Prehospital/systems of care",
      "sections_referenced": [
        "2.7"
      ],
      "metrics": [
        {
          "metric_type": "percentage",
          "value": 13.1,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "patients with acute stroke treated with IVT",
          "population_subgroup": null,
          "comparison": "intervention hospitals vs control hospitals",
          "raw_text": "intervention hospitals treated 13.1% of all patients with acute stroke versus 12.2% at control hospitals"
        },
        {
          "metric_type": "aOR",
          "value": 1.25,
          "ci_95_lower": 0.93,
          "ci_95_upper": 1.68,
          "p_value": null,
          "outcome": "IVT use",
          "population_subgroup": null,
          "comparison": "intervention hospitals vs control hospitals",
          "raw_text": "adjusted OR, 1.25 [95% CI, 0.93–1.68]"
        }
      ],
      "metric_count": 2
    },
    "PRECIOUS": {
      "trial_name": "PRECIOUS",
      "full_name": "Prevention of infections and fever to improve outcome in older patients with acute stroke",
      "category": "Complications management",
      "sections_referenced": [
        "5.6"
      ],
      "metrics": [
        {
          "metric_type": "adjusted cOR",
          "value": 0.99,
          "ci_95_lower": 0.77,
          "ci_95_upper": 1.27,
          "p_value": 0.93,
          "outcome": "functional outcome of mRS score at 90 days",
          "population_subgroup": null,
          "comparison": "prophylactic ceftriaxone vs standard care",
          "raw_text": "PRECIOUS (Prevention of infections and fever to improve outcome in older patients with acute stroke) trial also did not show benefit of prophylactic ceftriaxone on functional outcome of mRS score at 90 days (adjusted cOR, 0.99 [95% CI, 0.77–1.27]; P=0.93)"
        }
      ],
      "metric_count": 1
    },
    "PRESTO": {
      "trial_name": "PRESTO",
      "full_name": "Prehospital Triage of Patients with Suspected Stroke Symptoms",
      "category": "Prehospital/systems of care",
      "sections_referenced": [
        "2.3"
      ],
      "metrics": [
        {
          "metric_type": "AUC",
          "value": null,
          "ci_95_lower": 0.72,
          "ci_95_upper": 0.83,
          "p_value": null,
          "outcome": "accuracy of 8 prehospital stroke scales for detecting aLVO stroke",
          "population_subgroup": null,
          "comparison": null,
          "raw_text": "The area under the receiver operating characteristic curve (AUC) ranged from 0.72 to 0.83."
        }
      ],
      "metric_count": 1
    },
    "PREVAIL": {
      "trial_name": "PREVAIL",
      "full_name": "Prevention of VTE After AIS With LMWH Enoxaparin",
      "category": "Anticoagulation",
      "sections_referenced": [
        "5.4"
      ],
      "metrics": [
        {
          "metric_type": "percentage",
          "value": 10,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": 0.0001,
          "outcome": "primary endpoint (composite of DVT or PE)",
          "population_subgroup": "enoxaparin group",
          "comparison": "enoxaparin vs UFH",
          "raw_text": "The rate of the primary endpoint was 10% in those patients randomized to enoxaparin compared with 18% in those randomized to UFH (P=0.0001)"
        },
        {
          "metric_type": "percentage",
          "value": 1,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "extracranial hemorrhage",
          "population_subgroup": "enoxaparin group",
          "comparison": "enoxaparin vs UFH",
          "raw_text": "the rate of extracranial hemorrhage was 1% in those treated with enoxaparin and 0% in those treated with UFH"
        }
      ],
      "metric_count": 2
    },
    "PRISMS": {
      "trial_name": "PRISMS",
      "full_name": "A Study of Intravenous Thrombolysis With Alteplase in Acute Ischemic Stroke Patients With Minor Non-disabling Symptoms",
      "category": "IVT standard window",
      "sections_referenced": [
        "4.6.1"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "PROST": {
      "trial_name": "PROST",
      "full_name": "Prourokinase in the Treatment of AIS Within 4.5 hours of Stroke Onset",
      "category": "IVT alternative agents",
      "sections_referenced": [
        "4.6.4"
      ],
      "metrics": [
        {
          "metric_type": "percentage",
          "value": 65.2,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "mRS score 0–1 at 90 days",
          "population_subgroup": null,
          "comparison": "prourokinase vs alteplase",
          "raw_text": "no significant difference in the primary outcome (mRS score 0–1 at 90 days) (65.2% versus 64.3%)"
        },
        {
          "metric_type": "percentage",
          "value": 1.5,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "sICH",
          "population_subgroup": null,
          "comparison": "prourokinase vs alteplase",
          "raw_text": "no significant difference in ... sICH (1.5% versus 1.8%)"
        },
        {
          "metric_type": "percentage",
          "value": 25.8,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": "<0.001",
          "outcome": "systemic bleeding within 90 days",
          "population_subgroup": null,
          "comparison": "prourokinase vs alteplase",
          "raw_text": "a lower risk of systemic bleeding within 90 days with prourokinase (25.8% versus 42.2%; P<0.001)"
        }
      ],
      "metric_count": 3
    },
    "PROST-2": {
      "trial_name": "PROST-2",
      "full_name": null,
      "category": "IVT alternative agents",
      "sections_referenced": [
        "4.6.4"
      ],
      "metrics": [
        {
          "metric_type": "percentage",
          "value": 72.0,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": "<0.0001",
          "outcome": "mRS score at 90 days, 0–1",
          "population_subgroup": null,
          "comparison": "prourokinase vs alteplase",
          "raw_text": "Noninferiority was found in the primary outcome (mRS score at 90 days, 0–1) (72.0% versus 68.7%; P<0.0001)"
        },
        {
          "metric_type": "percentage",
          "value": 0.3,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": "0.021",
          "outcome": "sICH",
          "population_subgroup": null,
          "comparison": "prourokinase vs alteplase",
          "raw_text": "a lower risk of sICH (0.3% versus 1.0%; P=0.021)"
        },
        {
          "metric_type": "percentage",
          "value": 0.5,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": "0.0072",
          "outcome": "major bleeding at 7 days",
          "population_subgroup": null,
          "comparison": "prourokinase vs alteplase",
          "raw_text": "major bleeding at 7 days (0.5% versus 2.1%; P=0.0072) with prourokinase"
        }
      ],
      "metric_count": 3
    },
    "PROTECT": {
      "trial_name": "PROTECT",
      "full_name": "Prophylaxis of Thromboembolic Events by Certoparin",
      "category": "Anticoagulation",
      "sections_referenced": [
        "5.4"
      ],
      "metrics": [
        {
          "metric_type": "percentage",
          "value": 7.0,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": 0.0011,
          "outcome": "primary endpoint (composite of proximal DVT, PE, or death related to VTE)",
          "population_subgroup": "certoparin group",
          "comparison": "certoparin vs UFH",
          "raw_text": "7.0% of patients in the certoparin group and 9.7% of patients in the UFH group developed a primary endpoint (P=0.0011)"
        }
      ],
      "metric_count": 1
    },
    "PROTECT-MT": {
      "trial_name": "PROTECT-MT",
      "full_name": null,
      "category": "EVT technique",
      "sections_referenced": [
        "4.7.4"
      ],
      "metrics": [
        {
          "metric_type": null,
          "value": null,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "functional outcomes",
          "population_subgroup": null,
          "comparison": "balloon-guided catheters vs control",
          "raw_text": "a placebo double-blind RCT, PROTECT-MT in China, showed worse functional outcomes with balloon-guided catheters in 329 patients."
        }
      ],
      "metric_count": 1
    },
    "RACECAT": {
      "trial_name": "RACECAT",
      "full_name": "Direct Transfer to an Endovascular Center Compared to Transfer to the Closest Stroke Center in Acute Stroke Patients with Suspected Large Vessel Occlusion",
      "category": "Prehospital/systems of care",
      "sections_referenced": [
        "2.4",
        "2.9"
      ],
      "metrics": [
        {
          "metric_type": "median",
          "value": 3,
          "ci_95_lower": 2,
          "ci_95_upper": 5,
          "p_value": null,
          "outcome": "mRS score at 90 days",
          "population_subgroup": null,
          "comparison": "direct to TSC vs local non-TSC",
          "raw_text": "The primary outcome was shift-analysis of the median mRS score at 90 days and was not different between the 2 groups (3, interquartile range [IQR], 2–5 versus 3 [IQR, 2–5])"
        },
        {
          "metric_type": "percentage",
          "value": 47.5,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "received IV tPA",
          "population_subgroup": null,
          "comparison": "direct to TSC vs local non-TSC",
          "raw_text": "significantly lower odds of receiving IV tPA in patients directly transported to TSCs (47.5% versus 60.4%)"
        },
        {
          "metric_type": "percentage",
          "value": 48.8,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "received thrombectomy",
          "population_subgroup": null,
          "comparison": "direct to TSC vs local non-TSC",
          "raw_text": "higher odds of receiving thrombectomy (48.8% versus 39.4%)"
        },
        {
          "metric_type": "percentage",
          "value": 27.3,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "mortality at 90 days",
          "population_subgroup": null,
          "comparison": "direct to TSC vs local non-TSC",
          "raw_text": "Mortality at 90 days was similar between groups (27.3% versus 27.2%)"
        },
        {
          "metric_type": "median",
          "value": 33,
          "ci_95_lower": 25,
          "ci_95_upper": 48,
          "p_value": null,
          "outcome": "DTN time (minutes)",
          "population_subgroup": "local stroke centers",
          "comparison": null,
          "raw_text": "Local stroke centers had median (IQR) DTN times of 33 (25–48) minutes"
        },
        {
          "metric_type": "median",
          "value": 78,
          "ci_95_lower": 63,
          "ci_95_upper": 97,
          "p_value": null,
          "outcome": "DIDO time (minutes)",
          "population_subgroup": "local stroke centers",
          "comparison": null,
          "raw_text": "DIDO times of 78 (63–97) minutes"
        },
        {
          "metric_type": "percentage",
          "value": 43.4,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "mRS 0-2 at 90 days",
          "population_subgroup": null,
          "comparison": "direct to EVT center vs drip-and-ship",
          "raw_text": "RACECAT found no significant difference in 90-day mRS 0-2 (43.4% vs 44.2%)"
        }
      ],
      "metric_count": 7
    },
    "RAISE": {
      "trial_name": "RAISE",
      "full_name": null,
      "category": "IVT alternative agents",
      "sections_referenced": [
        "4.6.4"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "RAPIDO": {
      "trial_name": "RAPIDO",
      "full_name": "Rostro caido, Alteración del equilibrio, Pérdida de fuerza, Impedimento visual, Dificuldad para hablar, Obtenga ayuda rapido",
      "category": "Prehospital/systems of care",
      "sections_referenced": [
        "2.1"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "READAPT": {
      "trial_name": "READAPT",
      "full_name": null,
      "category": "Antiplatelet therapy",
      "sections_referenced": [
        "4.8"
      ],
      "metrics": [
        {
          "metric_type": "percentage",
          "value": 32.2,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "late (>24 hours) DAPT initiation",
          "population_subgroup": "patients with minor AIS or high-risk TIA treated with DAPT",
          "comparison": null,
          "raw_text": "32.2% had late (>24 hours) DAPT initiation"
        },
        {
          "metric_type": "percentage",
          "value": 63.2,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "did not receive loading doses of clopidogrel",
          "population_subgroup": "patients with minor AIS or high-risk TIA treated with DAPT",
          "comparison": null,
          "raw_text": "63.2% patients did not receive loading doses of clopidogrel"
        },
        {
          "metric_type": "percentage",
          "value": 7.8,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "met the DAPT RCT inclusion/exclusion criteria",
          "population_subgroup": "patients with minor AIS or high-risk TIA treated with DAPT",
          "comparison": null,
          "raw_text": "only 7.8% met the DAPT RCT inclusion/exclusion criteria"
        }
      ],
      "metric_count": 3
    },
    "REGARDS": {
      "trial_name": "REGARDS",
      "full_name": "Reasons for Geographic and Racial Differences in Stroke",
      "category": "Other",
      "sections_referenced": [
        "2.10"
      ],
      "metrics": [
        {
          "metric_type": null,
          "value": 207,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "better quality care",
          "population_subgroup": "patients with incident stroke admitted to registry hospital",
          "comparison": "hospital participating in a stroke registry vs nonparticipating hospital",
          "raw_text": "an analysis of the Reasons for Geographic and Racial Differences in Stroke (REGARDS) population-based cohort found that 207 patients with incident stroke who were admitted to a hospital that participated in a stroke registry received better quality care than 339 patients admitted to a nonparticipating hospital.13"
        }
      ],
      "metric_count": 1
    },
    "RES-Q": {
      "trial_name": "RES-Q",
      "full_name": null,
      "category": "Prehospital/systems of care",
      "sections_referenced": [
        "2.10"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "RESCUE ICAS": {
      "trial_name": "RESCUE ICAS",
      "full_name": null,
      "category": "EVT technique",
      "sections_referenced": [
        "4.7.4"
      ],
      "metrics": [
        {
          "metric_type": "percentage",
          "value": 42.2,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "functional independence at 90 days",
          "population_subgroup": "stenting group",
          "comparison": "stenting vs no stenting",
          "raw_text": "functional independence at 90 days was significantly higher in the stenting group (42.2% versus 28.4%)"
        }
      ],
      "metric_count": 1
    },
    "RESCUE LIMIT": {
      "trial_name": "RESCUE LIMIT",
      "full_name": null,
      "category": "EVT large core",
      "sections_referenced": [
        "3.2"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "RESCUE-BT": {
      "trial_name": "RESCUE-BT",
      "full_name": null,
      "category": "EVT technique",
      "sections_referenced": [
        "4.7.4"
      ],
      "metrics": [
        {
          "metric_type": null,
          "value": null,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "functional benefit in 90 days",
          "population_subgroup": "LVO prior to EVT",
          "comparison": "IV preoperative tirofiban vs placebo",
          "raw_text": "RESCUE-BT, administration of IV preoperative tirofiban versus placebo in the setting of LVO prior to EVT showed no functional benefit in 90 days."
        }
      ],
      "metric_count": 1
    },
    "RESILIENT": {
      "trial_name": "RESILIENT",
      "full_name": null,
      "category": "EVT standard window",
      "sections_referenced": [
        "4.7.2"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "RESIST": {
      "trial_name": "RESIST",
      "full_name": "Remote Ischemic Conditioning in Patients With Acute Stroke Trial",
      "category": "Blood pressure management",
      "sections_referenced": [
        "2.3"
      ],
      "metrics": [
        {
          "metric_type": null,
          "value": null,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "functional outcome (mRS score shift at 90 days)",
          "population_subgroup": null,
          "comparison": "RIC vs sham cuff",
          "raw_text": "RIC treatment was not significantly associated with improved outcomes or differences in serious adverse events (SAEs), and this held for secondary endpoints assessing outcomes by stroke subtype and use of reperfusion therapy."
        }
      ],
      "metric_count": 1
    },
    "REVASCAT": {
      "trial_name": "REVASCAT",
      "full_name": "Randomized Trial of Revascularization with Solitaire FR Device versus Best Medical Therapy in the Treatment of Acute Stroke Due to Anterior Circulation Large Vessel Occlusion Presenting within Eight Hours of Symptom Onset",
      "category": "EVT standard window",
      "sections_referenced": [
        "2.9",
        "3.2",
        "4.3",
        "4.7.1",
        "4.7.2"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "REVISION": {
      "trial_name": "REVISION",
      "full_name": "Early Reperfusion Therapy With Intravenous Alteplase for Recovery of VISION in Acute Central Retinal Artery Occlusion",
      "category": "IVT standard window",
      "sections_referenced": [
        "4.6.5"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "RIC": {
      "trial_name": "RIC",
      "full_name": null,
      "category": "Neuroprotective Agents",
      "sections_referenced": [
        "4.11"
      ],
      "metrics": [
        {
          "metric_type": null,
          "value": null,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "efficacy",
          "population_subgroup": null,
          "comparison": "RIC vs control",
          "raw_text": "RIC has shown conflicting results in 2 separate clinical trials"
        }
      ],
      "metric_count": 1
    },
    "RIGHT-2": {
      "trial_name": "RIGHT-2",
      "full_name": null,
      "category": "Blood pressure management",
      "sections_referenced": [
        "2.3"
      ],
      "metrics": [
        {
          "metric_type": null,
          "value": null,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "mRS scores at 90 days",
          "population_subgroup": null,
          "comparison": "transdermal GTN vs sham treatment",
          "raw_text": "The pri­mary outcome, a shift in mRS scores at 90 days, revealed no benefit from GTN in either the inten­tion-to-treat, target-disease (confirmed stroke and transient ischemic attack [TIA]), or global analyses."
        }
      ],
      "metric_count": 1
    },
    "ROSE-TNK": {
      "trial_name": "ROSE-TNK",
      "full_name": null,
      "category": "IVT extended window",
      "sections_referenced": [
        "4.6.3"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "SADQ": {
      "trial_name": "SADQ",
      "full_name": "Stroke Aphasic Depression Questionnaire",
      "category": "Other",
      "sections_referenced": [
        "5.5"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "SATIS": {
      "trial_name": "SaTIS",
      "full_name": null,
      "category": "Antiplatelet therapy",
      "sections_referenced": [
        "4.8"
      ],
      "metrics": [
        {
          "metric_type": "OR",
          "value": 1.18,
          "ci_95_lower": 0.66,
          "ci_95_upper": 2.06,
          "p_value": null,
          "outcome": "rate of HT",
          "population_subgroup": null,
          "comparison": "IV tirofiban vs placebo",
          "raw_text": "The primary outcome was the rate of HT and did not differ between either group (OR, 1.18 [95% CI, 0.66–2.06])"
        },
        {
          "metric_type": "percentage",
          "value": 2.3,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "mortality after 5 months",
          "population_subgroup": null,
          "comparison": "IV tirofiban vs placebo",
          "raw_text": "Mortality after 5 months was significantly lower in patients treated with tirofiban (2.3% versus 8.7%; OR, 4.05 [95% CI, 1.1–14.9])"
        }
      ],
      "metric_count": 2
    },
    "SAVE CHILDS": {
      "trial_name": "Save ChildS",
      "full_name": null,
      "category": "EVT standard window",
      "sections_referenced": [
        "4.7.5"
      ],
      "metrics": [
        {
          "metric_type": "mRS at discharge",
          "value": 3.5,
          "ci_95_lower": 1.0,
          "ci_95_upper": 5.1,
          "p_value": null,
          "outcome": "mRS at discharge",
          "population_subgroup": "children 0 to 6 years of age",
          "comparison": null,
          "raw_text": "the mRS score at discharge was higher in children 0 to 6 years of age (3.5; IQR, 1.0–5.1) than in the whole study cohort including all age groups (mRS, 1.0; IQR, 0.2–2.0)"
        }
      ],
      "metric_count": 1
    },
    "SAVE CHILDS PRO": {
      "trial_name": "Save ChildS Pro",
      "full_name": null,
      "category": "EVT standard window",
      "sections_referenced": [
        "4.7.5"
      ],
      "metrics": [
        {
          "metric_type": "functional outcome",
          "value": null,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "better functional outcomes",
          "population_subgroup": "children with LVO, especially age ≥6 years, presenting <6 hours, PedNIHSS ≥6",
          "comparison": "EVT vs medical management",
          "raw_text": "the large prospective multicenter Save ChildS Pro registry1 has shown that EVT in children with LVO results in better functional outcomes than medical management alone, especially in children ≥6 years, presenting <6 hours after symptom onset, and with a PedNIHSS score ≥6"
        },
        {
          "metric_type": "age threshold",
          "value": 6,
          "unit": "years",
          "outcome": "Minimum age for EVT in recommendations 1 and 2",
          "raw_text": "Age: ≥6 years",
          "source": "footnote"
        },
        {
          "metric_type": "age range",
          "value": [
            28,
            2190
          ],
          "unit": "days",
          "outcome": "Age range for EVT in recommendation 3 (28 days to 6 years)",
          "raw_text": "Age: 28 days to 6 years",
          "source": "footnote"
        },
        {
          "metric_type": "time window",
          "value": 6,
          "unit": "hours",
          "outcome": "Time window for EVT in recommendation 1",
          "raw_text": "within 6 hours from symptom onset",
          "source": "footnote"
        },
        {
          "metric_type": "time window",
          "value": [
            6,
            24
          ],
          "unit": "hours",
          "outcome": "Time window for EVT in recommendation 2",
          "raw_text": "6 to 24 hours from symptom onset",
          "source": "footnote"
        },
        {
          "metric_type": "time window",
          "value": 24,
          "unit": "hours",
          "outcome": "Time window for EVT in recommendation 3",
          "raw_text": "within 24 hours from symptom onset",
          "source": "footnote"
        }
      ],
      "metric_count": 6
    },
    "SELECT2": {
      "trial_name": "SELECT2",
      "full_name": null,
      "category": "EVT large core",
      "sections_referenced": [
        "3.2",
        "4.7.2"
      ],
      "metrics": [
        {
          "metric_type": "NNT",
          "value": 8,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "prevent 1 additional instance of functional dependence",
          "population_subgroup": "large predicted core infarcts, ASPECTS 3 to 5, within 6 hours",
          "comparison": "EVT vs medical management",
          "raw_text": "The NNT to prevent 1 additional instance of functional dependence in these patients was 8."
        },
        {
          "metric_type": "percentage",
          "value": 19.5,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "achieved functional independence",
          "population_subgroup": "large predicted core infarcts, ASPECTS 3 to 5, within 6 hours",
          "comparison": "EVT",
          "raw_text": "In these trials, 19.5% of patients achieved functional independence"
        },
        {
          "metric_type": "percentage",
          "value": 36.5,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "achieved independent ambulation",
          "population_subgroup": "large predicted core infarcts, ASPECTS 3 to 5, within 6 hours",
          "comparison": "EVT",
          "raw_text": "36.5% achieved independent ambulation"
        },
        {
          "metric_type": "percentage",
          "value": 7.5,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "rate of functional independence",
          "population_subgroup": "large predicted core infarcts, ASPECTS 3 to 5, within 6 hours",
          "comparison": "medical management",
          "raw_text": "EVT recipients more than doubled their rate of functional independence compared with patients receiving maximum medical therapy alone (7.5%)"
        },
        {
          "metric_type": "threshold",
          "value": 26,
          "unit": "mL",
          "outcome": "CT hypodensity volume threshold above which EVT shows no benefit",
          "raw_text": "a threshold of >=26 mL of severe CT hypodensity...",
          "source": "footnote"
        },
        {
          "metric_type": "confidence interval",
          "value": 26,
          "unit": "Hounsfield units",
          "outcome": "Lower 99% CI of contralateral thalamic gray matter for severe CT hypodensity",
          "raw_text": "defined as the lower 99% CI of the contralateral thalamic gray matter (≤26 Hounsfield units)",
          "source": "footnote"
        }
      ],
      "metric_count": 6
    },
    "SHEN ET AL": {
      "trial_name": "Shen et al",
      "full_name": null,
      "category": "Other",
      "sections_referenced": [
        "5.5"
      ],
      "metrics": [
        {
          "metric_type": null,
          "value": null,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "effectiveness of rTMS in PSD treatment",
          "population_subgroup": null,
          "comparison": "rTMS vs control",
          "raw_text": "Shen et al showed that repeated transcranial magnetic stimulation (rTMS) was effective in PSD treatment in a meta-analysis of 22 RCTs."
        }
      ],
      "metric_count": 1
    },
    "SHINE": {
      "trial_name": "SHINE",
      "full_name": "Stroke, Hyperglycemia Insulin Network Effort",
      "category": "Glucose management",
      "sections_referenced": [
        "4.5"
      ],
      "metrics": [
        {
          "metric_type": null,
          "value": null,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "functional outcome at 3 months",
          "population_subgroup": null,
          "comparison": "intensive blood glucose control (80-130 mg/dL) vs standard control (80-180 mg/dL)",
          "raw_text": "there was no benefit of intensive blood glucose control on functional outcome at 3 months"
        },
        {
          "metric_type": "percentage",
          "value": null,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "severe hypoglycemia (glucose <40 mg/dL)",
          "population_subgroup": "intensive blood glucose treatment group",
          "comparison": "intensive blood glucose control vs standard control",
          "raw_text": "severe hypoglycemia (glucose <40 mg/dL) occurred only in the intensive blood glucose treatment group"
        }
      ],
      "metric_count": 2
    },
    "SINGLE-INSTITUTION, RETROSPECTIVE, OBSERVATIONAL, COHORT STUDY": {
      "trial_name": "single-institution, retrospective, observational, cohort study",
      "full_name": null,
      "category": "IVT standard window",
      "sections_referenced": [
        "4.6.5"
      ],
      "metrics": [
        {
          "metric_type": "risk",
          "value": "did not change",
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "sICH",
          "population_subgroup": "DOAC-exposed patients",
          "comparison": "before vs after protocol revision to permit IVT among DOAC-exposed patients",
          "raw_text": "a single-institution, retrospective, observational, cohort study9 found that the risk of sICH did not change after an institutional protocol was revised to permit IVT among DOAC-exposed patients"
        }
      ],
      "metric_count": 1
    },
    "SKIP": {
      "trial_name": "SKIP",
      "full_name": "Direct Mechanical Thrombectomy in Acute LVO Stroke",
      "category": "EVT vs combined IVT+EVT",
      "sections_referenced": [
        "2.9"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "SOCRATES": {
      "trial_name": "SOCRATES",
      "full_name": "Acute Stroke or Transient Ischaemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes",
      "category": "Antiplatelet therapy",
      "sections_referenced": [
        "4.8"
      ],
      "metrics": [
        {
          "metric_type": "HR",
          "value": 0.89,
          "ci_95_lower": 0.78,
          "ci_95_upper": 1.01,
          "p_value": 0.07,
          "outcome": "primary composite endpoint of stroke, myocardial infarction, or death within 90 days",
          "population_subgroup": "minor noncardioembolic AIS (NIHSS ≤5) or high-risk TIA (ABCD2 ≥4)",
          "comparison": "ticagrelor vs aspirin",
          "raw_text": "The primary composite endpoint of stroke, myocardial infarction, or death within 90 days occurred in 6.7% of the ticagrelor group versus 7.5% of the aspirin group (HR, 0.89 [95% CI, 0.78–1.01]; P=0.07)."
        },
        {
          "metric_type": "percentage",
          "value": 0.5,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "major bleeding",
          "population_subgroup": "ticagrelor group",
          "comparison": "ticagrelor vs aspirin",
          "raw_text": "Major bleeding (0.5% ticagrelor versus 0.6% aspirin)"
        },
        {
          "metric_type": "percentage",
          "value": 0.2,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "ICH",
          "population_subgroup": "ticagrelor group",
          "comparison": "ticagrelor vs aspirin",
          "raw_text": "ICH (0.2% ticagrelor and 0.3% aspirin)"
        }
      ],
      "metric_count": 3
    },
    "SPORTIF III": {
      "trial_name": "SPORTIF III",
      "full_name": null,
      "category": "Antiplatelet therapy",
      "sections_referenced": [
        "4.8"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "SPORTIF IV": {
      "trial_name": "SPORTIF IV",
      "full_name": null,
      "category": "Antiplatelet therapy",
      "sections_referenced": [
        "4.8"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "SSNAP": {
      "trial_name": "SSNAP",
      "full_name": null,
      "category": "Prehospital/systems of care",
      "sections_referenced": [
        "2.10"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "STOCKBRIDGE ET AL": {
      "trial_name": "Stockbridge et al",
      "full_name": null,
      "category": "Imaging",
      "sections_referenced": [
        "3.1"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "STROKE DOC": {
      "trial_name": "STRokE DOC",
      "full_name": "Stroke Team Remote Evaluation Using a Digital Observation Camera",
      "category": "Prehospital/systems of care",
      "sections_referenced": [
        "2.8"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "STROKE DOC IN ARIZONA": {
      "trial_name": "STRokE DOC in Arizona",
      "full_name": null,
      "category": "Prehospital/systems of care",
      "sections_referenced": [
        "2.8"
      ],
      "metrics": [
        {
          "metric_type": "percentage",
          "value": 95.4,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "agreement with central reads by a blinded adjudicating committee with respect to identification of radiological contraindications to thrombolysis and overall reports",
          "population_subgroup": null,
          "comparison": "CT scan interpretations by hub vascular neurologists vs central reads",
          "raw_text": "CT scan interpretations by hub vascular neurologists showed very high agreement (95.4%) with central reads by a blinded adjudicating committee with respect to identification of radiological contraindications to thrombolysis and overall reports"
        }
      ],
      "metric_count": 1
    },
    "STROKE DOC INITIAL MAYO CLINIC EXPERIENCE (AZ TIME)": {
      "trial_name": "STRokE DOC Initial Mayo Clinic Experience (AZ TIME)",
      "full_name": null,
      "category": "Prehospital/systems of care",
      "sections_referenced": [
        "2.8"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "STROKE UNIT TRIALISTS’ COLLABORATION": {
      "trial_name": "Stroke Unit Trialists’ Collaboration",
      "full_name": null,
      "category": "Rehabilitation",
      "sections_referenced": [
        "5.1"
      ],
      "metrics": [
        {
          "metric_type": "percentages",
          "value": null,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "survival, independence, and residence at home at end of follow-up",
          "population_subgroup": null,
          "comparison": "organized inpatient care vs alternative service",
          "raw_text": "patients with stroke cared for within an organized inpatient care unit were more likely to survive, be independent, and reside at home at the end of scheduled follow-up (median, 1 year)"
        }
      ],
      "metric_count": 1
    },
    "STROKE-INF": {
      "trial_name": "STROKE-INF",
      "full_name": "Antibiotics to Prevent Infection in Stroke",
      "category": "Complications management",
      "sections_referenced": [
        "5.6"
      ],
      "metrics": [
        {
          "metric_type": "adjusted OR",
          "value": 1.21,
          "ci_95_lower": 0.71,
          "ci_95_upper": 2.08,
          "p_value": 0.489,
          "outcome": "incidence of the primary endpoint of poststroke pneumonia",
          "population_subgroup": null,
          "comparison": "prophylactic antibiotics vs standard care",
          "raw_text": "prophylactic antibiotics did not affect the incidence of the primary endpoint of poststroke pneumonia (adjusted OR, 1.21 [95% CI, 0.71–2.08]; P=0.489)"
        },
        {
          "metric_type": "adjusted OR",
          "value": 0.87,
          "ci_95_lower": 0.6,
          "ci_95_upper": 1.24,
          "p_value": 0.448,
          "outcome": "mRS score of 0 to 2 at 90 days",
          "population_subgroup": null,
          "comparison": "prophylactic antibiotics vs standard care",
          "raw_text": "or the secondary endpoint of mRS score of 0 to 2 at 90 days (adjusted OR, 0.87 [95% CI, 0.6–1.24]; P=0.448)"
        }
      ],
      "metric_count": 2
    },
    "SWEDISH NATIONAL REGISTRY": {
      "trial_name": "Swedish national registry",
      "full_name": null,
      "category": "Other",
      "sections_referenced": [
        "4.12"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "SWIFT DIRECT": {
      "trial_name": "SWIFT DIRECT",
      "full_name": "Solitaire With the Intention For Thrombectomy Plus Intravenous t-PA Versus DIRECT Solitaire Stent-Retriever Thrombectomy in Acute Anterior Circulation Stroke",
      "category": "EVT vs combined IVT+EVT",
      "sections_referenced": [
        "2.9"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "SWIFT PRIME": {
      "trial_name": "SWIFT PRIME",
      "full_name": "Solitaire With the Intention For Thrombectomy as PRIMary Endovascular Treatment",
      "category": "EVT standard window",
      "sections_referenced": [
        "2.9",
        "3.2",
        "4.3",
        "4.7.1"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "SYSTEMATIC REVIEW AND META-ANALYSIS OF 11 STUDIES": {
      "trial_name": "systematic review and meta-analysis of 11 studies",
      "full_name": null,
      "category": "Antiplatelet therapy",
      "sections_referenced": [
        "4.8"
      ],
      "metrics": [
        {
          "metric_type": "RR",
          "value": 0.63,
          "ci_95_lower": 0.43,
          "ci_95_upper": 0.94,
          "p_value": 0.02,
          "outcome": "ischemic stroke risk",
          "population_subgroup": null,
          "comparison": "anticoagulation vs antiplatelet",
          "raw_text": "anticoagulation was associated with a lower ischemic stroke risk (risk ratio, 0.63 [95% CI, 0.43–0.94]; P=0.02; I2=0%)"
        },
        {
          "metric_type": "RR",
          "value": 2.25,
          "ci_95_lower": 1.07,
          "ci_95_upper": 4.72,
          "p_value": 0.03,
          "outcome": "major bleeding risk",
          "population_subgroup": null,
          "comparison": "anticoagulation vs antiplatelet",
          "raw_text": "higher major bleeding risk (risk ratio, 2.25 [95% CI, 1.07–4.72]; P=0.03, I2=0%)"
        }
      ],
      "metric_count": 2
    },
    "TARDIS": {
      "trial_name": "TARDIS",
      "full_name": null,
      "category": "Antiplatelet therapy",
      "sections_referenced": [
        "4.8"
      ],
      "metrics": [
        {
          "metric_type": "percentage",
          "value": 6,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "recurrent stroke or TIA",
          "population_subgroup": "triple therapy group",
          "comparison": "triple antiplatelet therapy vs standard antiplatelet therapy",
          "raw_text": "The incidence and severity of recurrent stroke or TIA did not differ between the triple therapy and guideline therapy groups (6% versus 7%; adjusted cOR, 0.90 [95% CI, 0.67–1.20]; P=0.47)"
        },
        {
          "metric_type": "cOR",
          "value": 2.54,
          "ci_95_lower": 2.05,
          "ci_95_upper": 3.16,
          "p_value": "<0.0001",
          "outcome": "more bleeding and increased severity of bleeding",
          "population_subgroup": null,
          "comparison": "triple antiplatelet therapy vs standard antiplatelet therapy",
          "raw_text": "triple antiplatelet therapy was associated with more bleeding and increased severity of bleeding (adjusted cOR, 2.54 [95% CI, 2.05–3.16]; P<0.0001)"
        }
      ],
      "metric_count": 2
    },
    "TASTE": {
      "trial_name": "TASTE",
      "full_name": null,
      "category": "IVT alternative agents",
      "sections_referenced": [
        "4.6.2"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "TEMPO-2": {
      "trial_name": "TEMPO-2",
      "full_name": null,
      "category": "IVT standard window",
      "sections_referenced": [
        "4.6.1"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "TENCRAOS": {
      "trial_name": "TenCRAOS",
      "full_name": "TENecteplase in Central Retinal Artery Occlusion Study",
      "category": "IVT standard window",
      "sections_referenced": [
        "4.6.5"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "TENSION": {
      "trial_name": "TENSION",
      "full_name": null,
      "category": "EVT large core",
      "sections_referenced": [
        "4.7.2"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "TESLA": {
      "trial_name": "TESLA",
      "full_name": "Thrombectomy for Emergent Salvage of Large Anterior Circulation Ischemic Stroke",
      "category": "EVT large core",
      "sections_referenced": [
        "4.3",
        "4.7.2"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "THALES": {
      "trial_name": "THALES",
      "full_name": "The Acute Stroke or Transient Ischaemic Attack Treated with Ticagrelor and Aspirin for Prevention of Stroke and Death",
      "category": "Antiplatelet therapy",
      "sections_referenced": [
        "4.8"
      ],
      "metrics": [
        {
          "metric_type": "HR",
          "value": 0.83,
          "ci_95_lower": 0.71,
          "ci_95_upper": 0.96,
          "p_value": "0.02",
          "outcome": "composite of stroke or death within 30 days",
          "population_subgroup": null,
          "comparison": "DAPT (ticagrelor plus aspirin) vs aspirin alone",
          "raw_text": "DAPT with ticagrelor plus aspirin was associated with a decrease in the primary outcome of composite of stroke or death within 30 days (5.5% versus 6.6%; HR, 0.83 [95% CI, 0.71–0.96]; P=0.02)"
        },
        {
          "metric_type": "percentage",
          "value": 0.5,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": "0.001",
          "outcome": "severe bleeding",
          "population_subgroup": null,
          "comparison": "DAPT (ticagrelor plus aspirin) vs aspirin alone",
          "raw_text": "was also associated with increased risk of severe bleeding (0.5% versus 0.1%; P=0.001)"
        }
      ],
      "metric_count": 2
    },
    "THAWS": {
      "trial_name": "THAWS",
      "full_name": "Thrombolysis for Acute Wake-Up and Unclear-Onset Strokes with Alteplase at 0.6 mg/kg",
      "category": "IVT extended window",
      "sections_referenced": [
        "3.2",
        "4.6.3"
      ],
      "metrics": [
        {
          "metric_type": "percentage",
          "value": 47.1,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "clinical outcome benefit",
          "population_subgroup": null,
          "comparison": "alteplase vs control",
          "raw_text": "no clinical outcome benefit in the alteplase group (32/68 [47.1%]) could be demonstrated over the control group (28/58, 48.3% risk ratio [RR], 0.97 [95% CI, 0.68–1.41]; P=0.892)"
        },
        {
          "metric_type": "RR",
          "value": 0.97,
          "ci_95_lower": 0.68,
          "ci_95_upper": 1.41,
          "p_value": 0.892,
          "outcome": "clinical outcome benefit",
          "population_subgroup": null,
          "comparison": "alteplase vs control",
          "raw_text": "risk ratio [RR], 0.97 [95% CI, 0.68–1.41]; P=0.892"
        }
      ],
      "metric_count": 2
    },
    "THEIA": {
      "trial_name": "THEIA",
      "full_name": "THrombolysis [Alteplase] in Patients With acutE Central retInal Artery Occlusion",
      "category": "IVT standard window",
      "sections_referenced": [
        "4.6.5"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "THRACE": {
      "trial_name": "THRACE",
      "full_name": "THRombectomie des Artères CErebrales",
      "category": "EVT standard window",
      "sections_referenced": [
        "3.2",
        "4.3",
        "4.7.4"
      ],
      "metrics": [
        {
          "metric_type": "RR",
          "value": 1.82,
          "ci_95_lower": 0.55,
          "ci_95_upper": 6.07,
          "p_value": null,
          "outcome": "benefit for EVT in tandem occlusion",
          "population_subgroup": "tandem occlusion",
          "comparison": "EVT vs medical management",
          "raw_text": "in THRACE, 24 of 196 patients (risk ratio, 1.82 [95% CI, 0.55–6.07])"
        },
        {
          "metric_type": "RR",
          "value": 1.34,
          "ci_95_lower": 0.87,
          "ci_95_upper": 2.07,
          "p_value": null,
          "outcome": "benefit for EVT in tandem occlusion",
          "population_subgroup": "tandem occlusion",
          "comparison": "EVT vs medical management",
          "raw_text": "(risk ratio, 1.34 [95% CI, 0.87–2.07]) had tandem occlusions that were treated emergently."
        }
      ],
      "metric_count": 2
    },
    "TIMELESS": {
      "trial_name": "TIMELESS",
      "full_name": null,
      "category": "IVT extended window",
      "sections_referenced": [
        "3.2",
        "4.6.3",
        "4.7.1"
      ],
      "metrics": [
        {
          "metric_type": "cOR",
          "value": 1.13,
          "ci_95_lower": 0.82,
          "ci_95_upper": 1.57,
          "p_value": 0.45,
          "outcome": "ordinal mRS (functional outcomes)",
          "population_subgroup": null,
          "comparison": "tenecteplase vs placebo",
          "raw_text": "tenecteplase was not beneficial in improving functional outcomes (ordinal mRS: adjusted cOR, 1.13 [95% CI, 0.82–1.57]; P=0.45)"
        },
        {
          "metric_type": null,
          "value": null,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "good functional outcomes",
          "population_subgroup": "patients undergoing EVT in the 4.5- to 24-hour window and with ischemic penumbra as determined by perfusion imaging",
          "comparison": "tenecteplase vs placebo",
          "raw_text": "tenecteplase did not improve the odds of good functional outcomes compared with placebo in patients undergoing EVT in the 4.5- to 24-hour window and with ischemic penumbra as determined by perfusion imaging"
        }
      ],
      "metric_count": 2
    },
    "TIMING": {
      "trial_name": "TIMING",
      "full_name": "Timing of Oral Anticoagulant Therapy in AIS with Atrial Fibrillation",
      "category": "Anticoagulation",
      "sections_referenced": [
        "4.9"
      ],
      "metrics": [
        {
          "metric_type": "percentage",
          "value": 6.9,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "primary outcome",
          "population_subgroup": "early anticoagulation",
          "comparison": "early anticoagulation vs delayed anticoagulation",
          "raw_text": "The primary outcome occurred in 6.9% of participants with early anticoagulation and 8.7% of participants with delayed anticoagulation"
        },
        {
          "metric_type": "noninferiority",
          "value": null,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "primary outcome",
          "population_subgroup": null,
          "comparison": "early anticoagulation vs delayed anticoagulation",
          "raw_text": "suggesting that early anticoagulation was noninferior to delayed anticoagulation."
        }
      ],
      "metric_count": 2
    },
    "TIPS": {
      "trial_name": "TIPS",
      "full_name": "Thrombolysis in Pediatric Stroke",
      "category": "Prehospital/systems of care",
      "sections_referenced": [
        "2.7",
        "4.6.1"
      ],
      "metrics": [
        {
          "metric_type": "n",
          "value": 26,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "patients included in retrospective analysis",
          "population_subgroup": "pediatric patients aged 28 days to 18 years with PedNIHSS score ≥4",
          "comparison": null,
          "raw_text": "The retrospective analysis of the 26 included patients at least confirms the safety of IV alteplase if administered at a dose of 0.9 mL/kg within 0 to 4.5 hours after symptom onset in pediatric patients aged 28 days to 18 years with a PedNIHSS score ≥4."
        }
      ],
      "metric_count": 1
    },
    "TITAN": {
      "trial_name": "TITAN",
      "full_name": null,
      "category": "EVT standard window",
      "sections_referenced": [
        "4.7.4"
      ],
      "metrics": [
        {
          "metric_type": "percentage",
          "value": 76.7,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "mTICI grade 2b/3 achieved",
          "population_subgroup": null,
          "comparison": null,
          "raw_text": "an mTICI grade 2b/3 was achieved in 76.7% of patients"
        },
        {
          "metric_type": "percentage",
          "value": 52.2,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "90-day mRS 0-2",
          "population_subgroup": null,
          "comparison": null,
          "raw_text": "at 90 days, 52.2% achieved an mRS score of 0 to 2"
        }
      ],
      "metric_count": 2
    },
    "TOAST": {
      "trial_name": "TOAST",
      "full_name": "Trial of Org 10172 in Acute Stroke Treatment",
      "category": "Anticoagulation",
      "sections_referenced": [
        "4.9"
      ],
      "metrics": [
        {
          "metric_type": "percentage",
          "value": 53.8,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": 0.023,
          "outcome": "favorable outcome",
          "population_subgroup": "AIS associated with ipsilateral large artery atherosclerosis",
          "comparison": "danaparoid vs placebo",
          "raw_text": "A favorable outcome was seen in 53.8% of participants treated with danaparoid compared with 38.0% of participants treated with placebo (P=0.023; Fisher exact test)."
        }
      ],
      "metric_count": 1
    },
    "TRACE-2": {
      "trial_name": "TRACE-2",
      "full_name": null,
      "category": "IVT alternative agents",
      "sections_referenced": [
        "4.6.2"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "TRACE-III": {
      "trial_name": "TRACE-III",
      "full_name": null,
      "category": "IVT extended window",
      "sections_referenced": [
        "3.2",
        "4.6.3"
      ],
      "metrics": [
        {
          "metric_type": "percentage",
          "value": 33.0,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "mRS score 0–1 at 90 days",
          "population_subgroup": "tenecteplase group",
          "comparison": "tenecteplase vs placebo",
          "raw_text": "TRACE-3 achieved its primary outcome (mRS score 0–1 at 90 days) in favor of the tenecteplase group (33.0% versus 24.2%; risk ratio, 1.37 [95% CI, 1.04–1.81]; P=0.03)"
        }
      ],
      "metric_count": 1
    },
    "TREND": {
      "trial_name": "TREND",
      "full_name": null,
      "category": "Antiplatelet therapy",
      "sections_referenced": [
        "4.8"
      ],
      "metrics": [
        {
          "metric_type": null,
          "value": null,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "risk of early neurological deterioration",
          "population_subgroup": "noncardioembolic AIS within 24 hours",
          "comparison": "tirofiban vs control",
          "raw_text": "tirofiban decreased the risk of early neurological deterioration, without increasing the risk of sICH or systematic bleeding"
        }
      ],
      "metric_count": 1
    },
    "TRIAGE-STROKE": {
      "trial_name": "TRIAGE-STROKE",
      "full_name": null,
      "category": "Prehospital/systems of care",
      "sections_referenced": [
        "2.4"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "TRUTH": {
      "trial_name": "TRUTH",
      "full_name": null,
      "category": "Blood pressure management",
      "sections_referenced": [
        "4.3"
      ],
      "metrics": [
        {
          "metric_type": null,
          "value": null,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "90-day mRS",
          "population_subgroup": "patients otherwise eligible for IVT",
          "comparison": "BP lowering followed by thrombolysis vs BP non-lowering",
          "raw_text": "The TRUTH RCT evaluated BP lowering followed by thrombolysis versus BP non-lowering among patients otherwise eligible for IVT8 The trial found insufficient evidence of a difference in 90-day mRS with either strategy."
        }
      ],
      "metric_count": 1
    },
    "TWIST": {
      "trial_name": "TWIST",
      "full_name": null,
      "category": "IVT extended window",
      "sections_referenced": [
        "3.2",
        "4.6.3"
      ],
      "metrics": [
        {
          "metric_type": "aOR",
          "value": 1.18,
          "ci_95_lower": 0.88,
          "ci_95_upper": 1.58,
          "p_value": 0.27,
          "outcome": "better functional outcome (mRS at 90 days)",
          "population_subgroup": null,
          "comparison": "tenecteplase vs no tenecteplase",
          "raw_text": "aOR, 1.18 [95% CI, 0.88–1.58]; P=0.27"
        }
      ],
      "metric_count": 1
    },
    "UK NATIONAL REGISTRY": {
      "trial_name": "UK national registry",
      "full_name": null,
      "category": "Other",
      "sections_referenced": [
        "4.12"
      ],
      "metrics": [],
      "metric_count": 0
    },
    "URICO-ICTUS": {
      "trial_name": "URICO-ICTUS",
      "full_name": null,
      "category": "Neuroprotective Agents",
      "sections_referenced": [
        "4.11"
      ],
      "metrics": [
        {
          "metric_type": "median mRS",
          "value": null,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "median mRS scores",
          "population_subgroup": null,
          "comparison": "uric acid vs placebo",
          "raw_text": "median mRS scores were lower in the treatment group"
        }
      ],
      "metric_count": 1
    },
    "WAKE-UP": {
      "trial_name": "WAKE-UP",
      "full_name": "Efficacy and Safety of MRI-Based Thrombolysis in Wake-Up Stroke",
      "category": "IVT extended window",
      "sections_referenced": [
        "3.2",
        "4.6.1",
        "4.6.3"
      ],
      "metrics": [
        {
          "metric_type": "percentage",
          "value": 21.4,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "patients with at least 1 CMB on baseline imaging",
          "population_subgroup": null,
          "comparison": null,
          "raw_text": "in a secondary analysis of the WAKE-UP trial in which all enrolled patients had MRI before receiving IVT or placebo, 21.4% of patients had at least 1 CMB on baseline imaging"
        },
        {
          "metric_type": "percentage",
          "value": 3.5,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": null,
          "outcome": "patients with ≥5 CMBs",
          "population_subgroup": null,
          "comparison": null,
          "raw_text": "only 3.5% had ≥5 CMBs"
        },
        {
          "metric_type": "OR",
          "value": 2.32,
          "ci_95_lower": 0.99,
          "ci_95_upper": 5.43,
          "p_value": 0.052,
          "outcome": "risk of sICH",
          "population_subgroup": "patients with CMBs",
          "comparison": "CMBs present vs CMBs absent",
          "raw_text": "The presence of CMBs was associated with a nonsignificant increased risk of sICH (11.2% versus 4.2%; OR, 2.32 [95% CI, 0.99–5.43]; P=0.052)"
        },
        {
          "metric_type": "percentage",
          "value": 53.3,
          "ci_95_lower": null,
          "ci_95_upper": null,
          "p_value": 0.02,
          "outcome": "mRS 0-1 at 90 days",
          "population_subgroup": null,
          "comparison": "IV alteplase vs placebo",
          "raw_text": "The primary endpoint of an mRS score of 0 to 1 at 90 days was achieved in 53.3% of the IV alteplase group versus 41.8% of the placebo group (P=0.02)."
        },
        {
          "metric_type": "threshold",
          "value": 0.33,
          "unit": "fraction of MCA territory",
          "outcome": "MRI-DWI lesion smaller than one-third of the MCA territory",
          "raw_text": "MRI-DWI lesion smaller than one-third of the MCA territory",
          "source": "footnote"
        },
        {
          "metric_type": "threshold",
          "value": 4.5,
          "unit": "hours",
          "outcome": "IVT administered within 4.5 hours of stroke symptom recognition",
          "raw_text": "IVT administered within 4.5 hours of stroke symptom recognition",
          "source": "footnote"
        },
        {
          "metric_type": "time window",
          "value": 9,
          "unit": "hours",
          "outcome": "within 9 hours from midpoint of sleep (wake-up stroke)",
          "raw_text": "within 9 hours from midpoint of sleep (wake-up stroke)",
          "source": "footnote"
        }
      ],
      "metric_count": 7
    },
    "WARSS": {
      "trial_name": "WARSS",
      "full_name": null,
      "category": "Antiplatelet therapy",
      "sections_referenced": [
        "4.8"
      ],
      "metrics": [
        {
          "metric_type": "HR",
          "value": 1.13,
          "ci_95_lower": 0.92,
          "ci_95_upper": 1.38,
          "p_value": null,
          "outcome": "2-year recurrent ischemic stroke or death",
          "population_subgroup": "cryptogenic stroke (noncardioembolic, no high-grade carotid stenosis)",
          "comparison": "warfarin vs aspirin",
          "raw_text": "no difference in the primary endpoint (2-year recurrent ischemic stroke or death) between the groups (17.8% warfarin versus 16% aspirin; HR, 1.13 [95% CI, 0.92–1.38])"
        }
      ],
      "metric_count": 1
    },
    "ZHAO": {
      "trial_name": "ZHAO",
      "full_name": null,
      "category": "Other",
      "sections_referenced": [
        "6.3"
      ],
      "metrics": [],
      "metric_count": 0
    }
  }
}